Diabetic Microvascular Disease: An Endocrine Society Scientific Statement

Eugene J. Barrett, Zhenqi Liu, Mogher Khamaisi, George L. King, Ronald Klein, Barbara E. Klein, Timothy M. Hughes, Suzanne Craft, Barry I. Freedman, Donald W. Bowden, Aaron I. Vinik, and Carolina M. Casellini

Affiliations: Division of Endocrinology (E.J.B., Z.L.), Department of Medicine, University of Virginia, Charlottesville, Virginia; Section of Vascular Cell Biology (M.K., G.L.K.), Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; Roena B. Kulynych Center for Memory and Cognition Research and Sticht Center on Aging (T.M.H., S.C.), Wake Forest School of Medicine, Winston-Salem, North Carolina; Divisions of Nephrology and Endocrinology (B.I.F., D.W.B.), Department of Internal Medicine, Centers for Diabetes Research and Center for Human Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, North Carolina; EVMS Strelitz Diabetes Center (A.I.V., C.M.C.), Eastern Virginia Medical Center, Norfolk, Virginia

Short Title: Diabetic Microvascular Disease

Key Terms: ACACB, acetyl-CoA carboxylase beta; ACCORD, Action to Control Cardiovascular Risk in Diabetes; ACE, angiotensin converting enzyme; ACEi, ACE inhibitor; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation; AD, Alzheimer’s disease; AGE, advanced glycation end product; ALA, α-lipoic acid; Ang I, angiotensin I; Ang II, angiotensin II; APC, activated protein C; AR, aldose reductase; ARB, angiotensin II receptor blocker; ARI, aldose reductase inhibitor; AT1, angiotensin type 1 receptor; ATP, adenosine triphosphate; Aβ, amyloid β; BBB, blood-brain barrier; BK, bradykinin; CA, carbonic anhydrase; BK2R, bradykinin 1 receptor; BK2R, bradykinin 2 receptor; BM, basement membrane; C1-INH, C1-inhibitor; CBF, cerebral blood flow; CHEPS, contact heat evoked potential simulators; CKD, chronic kidney disease; CMB, cerebral microbleeds; CMI, cerebral microinfarcts; CNDP1, carnosinase 1; CNS, central nervous system; CVD, cardiovascular disease; DAG, diacylglycerol; DCCT, Diabetes Control and Complications Trial; DN, diabetic nephropathy; DPN, diabetic peripheral neuropathy; DR, diabetic retinopathy; DSPN, distal symmetric polyneuropathy; DTI, diffusion tensor imaging; ECM, extracellular matrix; EDIC, Epidemiology of Diabetes Interventions and Complications; eGFR, estimated glomerular filtration rate; eNOS, endothelial nitric oxide synthase; EPCs, endothelial progenitor cells; EPVS, enlarged perivascular spaces; ER, endoplasmic reticulum; ESKD, end-stage kidney disease; ET-1, endothelin 1; FA, fatty acid; FDG-PET, fludeoxyglucose F18 ligand-positron emission tomography; FRMD3, FERM domain containing 3; FLT-1, fms-like tyrosine kinase 1; VEGFR-1, vascular endothelial growth factor receptor 1; fMRI, functional MRI; GCLC, glutamyl cysteine ligase; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide 1; GSH, glutathione; GWAS, genome-wide association studies; HbA1c, hemoglobin A1c; IAPP, islet amyloid polypeptide; iNOS, inducible nitric oxide synthase; KEAP-1, Kelch like-ECH-associated protein 1; KKS, kallikrein-kinin system; LDL, low-density lipoprotein; MAPK, mitogen-activated protein kinase; MTI, magnetization transfer imaging; NADPH,
nicotinamide adenine dinucleotide phosphate; NHANES, National Health and Nutrition Examination Survey; NO, nitric oxide; NOS, nitric oxide synthase; Nrf2, NF-E2-related factor 2; NTSS-6, neuropathy total symptoms score-6; NVC, nerve conduction velocity; NVC, nerve conduction velocity; PET, positron emission tomography; PK, plasma kallikrein; PKC, protein kinase C; PDGF, platelet-derived growth factor; QOL, quality of life; RAAS, renin-angiotensin aldosterone system; RAGE, receptor for AGE; RAS, renin-angiotensin system; RBF, retinal blood flow; RBX, ruboxistaurin; RCT, randomized controlled trial; ROS, reactive oxygen species; RVP, retinal vascular permeability; SC, Schwann cells; SHP-1, Src homology-2 domain-containing phosphatase-1; SNP, single nucleotide polymorphism; STX, streptozotocin; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TGF-β, transforming growth factor β; VADT, Veterans Affairs Diabetes Trial; VEGF, vascular endothelial growth factor; WESDR, Wisconsin Epidemiologic Study of Diabetic Retinopathy; WMH, white matter hyperintensities

Word Count:

Corresponding Author and Reprint Request:

Any grants or fellowships supporting the writing of the paper:

Disclosure Summary:

Abstract (Word count = 202)
Both type 1 and type 2 diabetes adversely affect the microvasculature in multiple organs. Our understanding of the genesis of this injury and of potential interventions to prevent, limit, or reverse injury/dysfunction is continuously evolving. This statement reviews biochemical/cellular pathways involved in facilitating as well as in abrogating microvascular injury. The statement summarizes the types of injury/dysfunction that occur in the three classical diabetes microvascular target tissues, the eye, the kidney and the peripheral nervous system and also reviews information on the effects of diabetes and insulin resistance on the microvasculature of skin, brain, cardiac and skeletal muscle and adipose tissues. Despite extensive and intensive research, it is disappointing that today microvascular complications of diabetes continue to compromise the quantity and quality of life for patients with diabetes. Hopefully, by understanding and building on current research findings, the future will bring new approaches for prevention and treatments that will be effective for future generations.
## Table of Contents

73 Table of Contents

74 DIABETIC MICROVASCULAR DISEASE: AN ENDOCRINE SOCIETY SCIENTIFIC STATEMENT

75 INTRODUCTION

76 CHAPTER 1. BIOCHEMICAL PATHWAYS OF MICROVASCULAR INJURY

77 Introduction

78 Molecular Mechanisms of Injury

79 The Activation of Protein Kinase C in Vascular Tissues

80 The Polyol Pathway and the Pathogenesis of Diabetic Microvascular Complications

81 Oxidative Stress and the Pathogenesis of Diabetic Microvascular Complications

82 Protein Glycation and Diabetic Microvascular Complications

83 The Renin-Angiotensin System and the Pathogenesis of Diabetic Microvascular Complications

84 Endoplasmic Reticulum Stress and Diabetic Microvascular Complications

85 The Kallikrein-Bradykinin System and the Development of Diabetic Microvascular Complications

86 Insulin: Selective Insulin Resistance on the Vessel Wall in Diabetes

87 Antioxidant Enzymes

88 Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor

89 Transforming Growth Factor Beta-1

90 Vascular Endothelial Growth Factor

91 Activated Protein C

92 Vascular Progenitor Cells

93 Summary

94 CHAPTER 2. RETINAL MICROVASCULAR DISEASE

95 Natural History of Diabetic Retinopathy

96 Pathogenesis

97 Epidemiology

98 Prevalence

99 Incidence

100 Risk Factors

101 Glycemia

102 Hypertension

103 Serum Lipids

104 Other Risk Factors

105 Genetic Factors

106 Comorbidity and Mortality
CHAPTER 3. MICROVASCULAR DISEASE AND THE BRAIN  

Introduction 69

Mechanisms for Microvascular Complications 71
- Hyperinsulinemia and Impaired Insulin Signaling 71
- Hyperglycemia 73
- Oxidative Stress 74
- Advanced Glycation End Products 74
- Summary of Mechanisms 75

Assessment of Brain Complications in Type 2 Diabetes Mellitus 76
- Brain Atrophy 76
- Alterations in Cerebral Blood Flow and Glucose Utilization 78
- Microvascular Ischemia 81
- Non-Ischemic Microvascular Complications 85

Summary and Conclusions 87

CHAPTER 4. THE MICROVASCULTURE IN SKELETAL AND CARDIAC MUSCLE, ADIPOSE, AND SKIN 89

Introduction 89

Skeletal Muscle Microvasculature: Structural and Functional Changes that Accompany Diabetes and Insulin Resistance 89

The Myocardial Microcirculation in Diabetes 94

Microvascular Disease/Dysfunction in the Skin 99

Microvascular Dysfunction/Disease in Adipose Tissue 101

CHAPTER 5. MICROVASCULAR DISEASE IN THE KIDNEY 106

Introduction 106

Epidemiology 106

Clinical Presentation 108
<table>
<thead>
<tr>
<th>Page</th>
<th>Section Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>136</td>
<td>A Genetic Component to Diabetic Kidney Disease Risk</td>
<td>111</td>
</tr>
<tr>
<td>137</td>
<td>The Search for Diabetic Kidney Disease Susceptibility Genes</td>
<td>112</td>
</tr>
<tr>
<td>138</td>
<td>Genetics of Diabetic Kidney Disease Now and in the Future</td>
<td>117</td>
</tr>
<tr>
<td>139</td>
<td>Current Treatment</td>
<td>119</td>
</tr>
<tr>
<td>140</td>
<td>Summary</td>
<td>123</td>
</tr>
<tr>
<td>141</td>
<td>CHAPTER 6. THE MICROVASCULATURE AND DIABETIC NEUROPATHY</td>
<td>125</td>
</tr>
<tr>
<td>142</td>
<td>Introduction</td>
<td>125</td>
</tr>
<tr>
<td>143</td>
<td>Epidemiology</td>
<td>125</td>
</tr>
<tr>
<td>144</td>
<td>Classification of Diabetic Neuropathies</td>
<td>127</td>
</tr>
<tr>
<td>145</td>
<td>Natural History of Diabetic Neuropathies</td>
<td>129</td>
</tr>
<tr>
<td>146</td>
<td>Pathogenesis of Diabetic Neuropathies</td>
<td>130</td>
</tr>
<tr>
<td>147</td>
<td>Clinical Presentation of Diabetic Neuropathies</td>
<td>132</td>
</tr>
<tr>
<td>148</td>
<td>Focal and Multifocal Neuropathies</td>
<td>132</td>
</tr>
<tr>
<td>149</td>
<td>Proximal Motor Neuropathy (Diabetic Amyotrophy) and Chronic Demyelinating Neuropathies</td>
<td>134</td>
</tr>
<tr>
<td>150</td>
<td>Diabetic Truncal Radiculoneuropathy</td>
<td>136</td>
</tr>
<tr>
<td>151</td>
<td>Generalized Symmetric Polyneuropathy</td>
<td>136</td>
</tr>
<tr>
<td>152</td>
<td>Chronic Sensorimotor Neuropathy or Distal Symmetric Polyneuropathy</td>
<td>137</td>
</tr>
<tr>
<td>153</td>
<td>Clinical Manifestations of Small Fiber Neuropathies</td>
<td>137</td>
</tr>
<tr>
<td>154</td>
<td>Clinical Manifestations of Large Fiber Neuropathies</td>
<td>138</td>
</tr>
<tr>
<td>155</td>
<td>Diagnosing Diabetic Peripheral Neuropathy</td>
<td>138</td>
</tr>
<tr>
<td>156</td>
<td>Conditions Mimicking Diabetic Neuropathy</td>
<td>139</td>
</tr>
<tr>
<td>157</td>
<td>Clinical Assessment Tools for Diabetic Neuropathy</td>
<td>140</td>
</tr>
<tr>
<td>158</td>
<td>Objective Diagnosis of Diabetic Neuropathy</td>
<td>140</td>
</tr>
<tr>
<td>159</td>
<td>Nerve Conduction Studies</td>
<td>142</td>
</tr>
<tr>
<td>160</td>
<td>Summary of Diagnosis of Diabetic Polyneuropathies</td>
<td>142</td>
</tr>
<tr>
<td>161</td>
<td>Treatment of Diabetic Polyneuropathies</td>
<td>143</td>
</tr>
<tr>
<td>162</td>
<td>Treatment of Specific Underlying Pathogenic Mechanisms</td>
<td>143</td>
</tr>
<tr>
<td>163</td>
<td>Immune Therapy</td>
<td>150</td>
</tr>
<tr>
<td>164</td>
<td>Summary</td>
<td>150</td>
</tr>
<tr>
<td>165</td>
<td>CHAPTER 7. CONCLUSION</td>
<td>152</td>
</tr>
<tr>
<td>166</td>
<td>CHAPTER 8 FIGURES AND TABLES</td>
<td>ERROR! BOOKMARK NOT DEFINED.</td>
</tr>
<tr>
<td>167</td>
<td>CHAPTER 9. REFERENCES</td>
<td>154</td>
</tr>
</tbody>
</table>
Introduction

The cellular elements of the microvasculature appear to be particularly sensitive to injury from sustained hyperglycemia. This injury, and responses by the body directed towards its repair, cause tissue/organ dysfunction that affects the quality and duration of life for persons with either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Despite the disparate pathogenesis of these two common forms of diabetes, they (along with secondary forms of diabetes resulting from genetic mutations or pharmaceutical or surgical interventions) all share microvascular injury/dysfunction as a chronic outcome. This scientific statement provides an up-to-date overview of the general pathogenesis of microvascular disease in diabetes, as well as its impact on specific tissues. As such, this statement provides readers with a clear understanding of how microvascular injury adversely affects the normal physiologic function of multiple tissues within the body. This statement does not attempt to provide a compendium of all of the organ-specific treatments for limiting microvascular damage that are in use or in development. Nor do we attempt to review/critique the more general systemic approaches to treatment designed to control glycemia, blood pressure, lipids, or oxidative stress.

At the outset, we are reminded that the very diagnosis of diabetes rests on identifying a level of blood glucose that associates with microvascular injury to the eye. In addition, much of the impetus for developing effective glycemic therapy arises from clinical trials that demonstrate that improved glycemic control decreases the incidence and progression of microvascular injury.

The body’s microvasculature is a diffuse target whose properties differ considerably between different tissues and organs. The response of the microvasculature to injury/repair
likewise differs across tissues and organs. For this reason we chose to use an organ-based
organizational structure for this scientific statement. However, while we discuss the
microvascular complications of diabetes in an organ-by-organ basis, we recognize that in the
individual patient all organs are affected simultaneously to a greater or lesser degree (i.e., evident
microvascular dysfunction found in one organ is a sentinel of systemic injury, which may be pre-
clinical).
Chapter 1. Biochemical Pathways of Microvascular Injury

Introduction

Vascular complications are the major cause of morbidity and mortality in diabetic patients. These result from interactions between systemic metabolic abnormalities such as hyperglycemia, dyslipidemia, genetic and epigenetic modulators, and local tissue responses to toxic metabolites. Macrovascular complications involve atherosclerotic/thrombotic obstructions, such as those that occur in coronary, cerebral, and peripheral artery diseases. Classic microvascular pathologies include retinopathy, nephropathy, and neuropathy, but the also affect brain, myocardium, skin, and other tissues. Here, we focus on cellular/molecular mechanisms causing diabetic microvascular pathologies.

Hyperglycemia is the major systemic risk factor for diabetic microvascular complications. The Diabetes Control and Complications Trial (DCCT) in T1DM and the United Kingdom Prospective Diabetes Study (UKPDS) in T2DM clearly demonstrated that intensive blood glucose control delays the onset and retards the progression of diabetic microvascular complications (1,2).

Hyperglycemia alone however is not sufficient to trigger generalized diabetic microvascular pathologies (e.g., only 20-40% of diabetic patients will ultimately develop chronic renal failure), suggesting that as yet unidentified genetic or other endogenous protective factors play important roles (3,4). The Joslin Diabetes Center 50-Year Medalist Study of patients surviving more than 50 years with T1DM has shown that 30-35% are without significant microvascular complications, regardless of their hemoglobin A1c (HbA1c) levels and other
classical risk factors thought to predict diabetic vascular complications (3). These patients may
possess endogenous tissue factors that diminish the adverse microvascular effects of
hyperglycemia.

Research has suggested that multiple biochemical pathways link the adverse effects of
hyperglycemia with vascular complications. Cellular mechanisms include: the activation of the
diacylglycerol (DAG)-protein kinase C (PKC) pathway (5), endoplasmic reticulum stress, Src
homology-2 domain-containing phosphatase-1 (SHP-1), the renin-angiotensin system (RAS),
and the kallikren-bradykinin (BK) system. It is likely that hyperglycemia-induced intra- and
extracellular changes alter signal transduction pathways, thus affecting gene expression and
protein function and causing cellular dysfunction and damage.

**Molecular Mechanisms of Injury**

Research has described multiple abnormalities in cell signaling, gene expression, and the
regulation of cell biology and physiology in diabetes, and it is likely that many of these
abnormalities operate concurrently to cause the various diabetic microvascular complications.
These mechanisms may be active preferentially in some, though probably not all, vascular
tissues or organs, but generally they are associated with the development of complications in
several organs (Figure 1). We will discuss seven mechanistic pathways that appear to be
involved in diabetic microvascular injury, as well as several potentially protective factors. The
emphasis here is on cellular mechanisms; we will cite mechanism-based efforts at clinical
interventions but not analyze them in detail.
Figure 1. Schema of hyperglycemia's induced pathways to microvascular complications
PKC is a family of serine/threonine-related protein kinases that includes multiple isoforms and affects many cellular functions and signal transduction pathways (6). Phosphatidyl serine (PS), calcium, and DAG or phorbol esters (such as phorbol 12-myristate 13-acetate) activate the conventional PKC isoforms PKCα, β1, β2, and γ. PS and DAG, but not calcium, also activate the novel PKC isoforms PKCd, ε, φ, and η. Neither calcium nor DAG activate the atypical PKC isoforms PKCζ and υ/λ. Hyperglycemia, per se, modulates PKC activation. In addition, oxidants (e.g., H2O2 and superoxide) can also activate PKC in a manner unrelated to lipid second messengers (7,8). Many abnormal vascular and cellular processes including endothelial dysfunction; vascular permeability; angiogenesis; cell growth and apoptosis; vessel dilation; basement membrane (BM) thickening; extracellular matrix (ECM) expansion; and altered enzymatic activity of mitogen-activated protein kinase (MAPK), cytosolic phospholipase A2, Na⁺–K⁺–ATPase, and several transcription factors are attributed to the activation of several PKC isoforms. Diabetes increases PKC activity in skeletal muscle and the renal glomeruli, retina, myocardium, and liver. Among the isoforms of PKC, the α, β, and δ isoforms are most consistently implicated in diabetic vascular complications.

DAG levels are elevated chronically in the hyperglycemic, diabetic environment due to increased levels of glycolytic intermediate dihydroxyacetone phosphate. This intermediate is reduced to glycerol-3-phosphate, which subsequently increases de novo synthesis of DAG (9). In diabetes, studies reported that total DAG levels were elevated in the retina (10) and renal
glomeruli (11). However, there is no consistent change in DAG levels in the central nervous system (CNS) or peripheral nerves (12). Cell culture studies have shown that DAG levels increase in a time-dependent manner as glucose levels rise from 5.5 to 22 mmol/L in aortic endothelial cells (13), retinal pericytes (14), smooth muscle cells (9), kidney proximal tubular cells (15), and renal mesangial cells (16). Increased DAG synthesis can also occur from dihydroxyacetone phosphate that accumulates when poly (ADP ribosylation) inhibits glyceraldehyde-3-phosphate dehydrogenase in the presence of high glucose concentrations (17).

Elevated cytosolic glucose levels promote the accumulation of glyceraldehyde-3-phosphate, which can increase DAG and activate PKC (18). In an experimental model of diabetes, large doses of thiamine and thiamine monophosphate derivative (benfotiamine) appear to decrease the formation of DAG and mitigate PKC activation (19).

**Protein Kinase C Activation and the Development of Diabetic Nephropathy**

Experiments in diabetic rodents support a role for PKC in the pathogenesis of diabetic nephropathy (DN). PKCα, β, and δ isoforms are activated in renal glomeruli isolated from streptozotocin (STZ)-induced diabetic rats (20) and mice, and 50% of the increase in PKC activity in renal glomeruli is prevented in PKCβ knockout mice (21). PKCα activation can upregulate vascular endothelial growth factor (VEGF) expression through nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (22). PKCα knockout mice are protected against BM proteoglycan losses induced by VEGF (23). In wild type mice, diabetes increases NADPH oxidase activity and induces the expression of endothelin 1 (ET-1), VEGF, transforming growth factor β (TGFβ), connective tissue growth factor, and collagen types IV and VI. These changes
are partly prevented in PKCβ knockout mice (21). Mesangial expansion and albuminuria in mice with STZ-induced diabetes are reduced in both PKCβ (21) and PKCδ (24) knockout versus wild type mice.

General PKC isoform inhibitors can interact with other kinases and can have significant toxic side effects. The PKCβ inhibitor ruboxistaurin (RBX) is a bisindolylmaleimide class agent that selectively inhibits PKCβ1 and PKCβ2 (25). Rottlerin (mallotoxin), has higher affinity for PKCδ but also inhibits other isoforms of PKC (26) and other non-PKC kinases, such as MAPKs, protein kinase A, and glycogen synthase kinase-3 (27). Orally administered RBX reversed glomerular hyperfiltration and reduced urinary albumin excretion in diabetic rodents without a change in DAG content (28). In addition, glomerular TGFβ1 expression, mesangial expansion, glomerulo-sclerosis, tubule-interstitial fibrosis, and renal function all improved (28). In Ren-2 diabetic rats, RBX attenuated macrophage recruitment, tubulointerstitial injury associated with TGFβ activation, and increases in PKC-induced osteopontin expression in tubular epithelial cells of the renal cortex (29).

Remarkably, PKCε may have effects on DN that are opposite to the effects of PKCα, β, and δ. One study showed that knockout of PKCε upregulated renal TGF-β1 and its downstream signaling and increased the expression of fibronectin and collagen type IV, which caused glomerular and tubulointerstitial fibrosis and the development of albuminuria (30). These changes were further aggravated by diabetes (30). Therefore, PKCε may act as a protective factor by reducing kidney damage.
Supporting the relevance of these findings to human DN, one study associated polymorphisms of the PKCβ gene with accelerated kidney disease in Japanese T2DM subjects (31), and another study associated polymorphisms in the PKCβ-1 gene with end-stage kidney disease (ESKD) in Chinese patients with T2DM (32). However, efforts to treat DN by inhibiting PKC activation with RBX have generally been disappointing, as illustrated by a secondary analysis of three DN trials (33), which showed no differences in kidney outcomes with RBX treatment.

Protein Kinase C Activation and the Development of Diabetic Retinopathy

The early stage of diabetic retinopathy (DR) is characterized by the loss of pericytes in capillaries of the retina is followed by weakness in the capillary wall, microaneurysm formation and fluid leakage, and increased adhesion of leukocytes and monocytes to the endothelium (34). Hyperglycemia activates PKCα, β, δ, and ε (18) in retinal tissues and alters ET-1 and VEGF activity and nitric oxide (NO) levels in endothelial cells, as well as levels of platelet-derived growth factor (PDGF), reactive oxygen species (ROS), and nuclear factor κB in pericytes (35). Administering RBX to diabetic rats can reduce retinal PKC activation and normalize retinal blood flow (RBF) (36,37). In vessels isolated from diabetic animals, NO-dependent acetylcholine-induced vessel relaxation is delayed (38), and the PKC agonist phorbol-12-myristate-13-acetate impaired vascular relaxation in otherwise normal arteries (39).

The mechanism for reduced RBF mediated by PKCβ involves the upregulation of ET-1 synthesis in the retina of diabetic rats (40). RBX treatment can block this induction of retinal ET-
VEGF, through signaling involving PKCβ (41), helps mediate diabetic macular edema to increase the phosphorylation of occludin, a component of tight junctions, leading to increased vascular permeability (42) and kallikrein activation (43). Hyperglycemia may also increase endothelial cell permeability via PKCα activation (44).

Recently researchers have clarified PKC’s actions on vascular cell proliferation and death. Both PKCβ and PKCδ isoforms are translocated to the membrane fraction in total retinal lysates of diabetic mice, but the consequences of PKCβ, δ, and ε isoform activation are very different. PKCδ induces cell apoptosis (14), whereas PKCβ enhances cell growth (45).

Accordingly, the elevation of membranous PKCδ levels in diabetes correlated with the appearance of retinal pericyte apoptosis in vitro and acellular capillaries in vivo. In vivo studies reported that the induction of PKCδ in the retinal capillaries of diabetic mice led to PDGF resistance; this was not true with PKCδ knockout mice. Hyperglycemia, through PKCδ action, promotes two distinct important pathways: (a) increasing ROS production and NF-κB activity, and (b) decreasing the survival-signaling pathway of PDGF by upregulating SHP-1 expression. These findings suggest a pivotal role for PKCδ in regulating pericyte apoptosis and the formation of cellular capillaries (14).

In animal studies, inhibiting PKCβ ameliorated the decline of RBF typically associated with DR and decreased diabetes-induced vascular leakage (36). Similarly, the stimulus for neovascularization is suppressed in animals with reduced PKCβ levels (45,46). More recently, Nakamura showed that subcutaneous RBX treatment reduced retinal neovascularization (induced
in neonatal mice) by returning the retina to normoxia (21% O2) after exposure to hyperoxia (75% O2). In addition, Nakamura reported that the RBX anti-angiogenic effects were due, in part, to suppressed phosphorylation of ERK1/2 and Akt (47).

In phase II clinical trials (PKC-Diabetic Retinopathy Study and PKC-Diabetic Macular Edema Study) (48) RBX failed to alter the primary outcome (loss of visual acuity). However, there was a significant reduction in the secondary endpoint—the progression of diabetic macular edema. A much larger clinical trial (PKC-Diabetic Retinopathy Study 2) that administered a single daily dose (again using the loss of visual acuity, as the primary endpoint) (49) reported that RBX treatment significantly prevented the loss of visual acuity for diabetic patients with moderate vision loss and decreased the onset of diabetic macular edema (50). These results suggest that PKC activation, especially of the β isoform, could participate in the development of non-proliferative DR. However, RBX did not delay the progression of vascular DR. This suggests that inhibiting the PKCβ isoform alone is not adequate to stop the metabolic changes that drive the progression of proliferative DR.

Protein Kinase C and the Development of Diabetic Peripheral Neuropathy
Neuropathy is one of the most distressing complications of diabetes and involves the entire peripheral nervous system (51). Healthy nerves receive a rich supply of blood from the vasa nervorum (52). Hyperglycemia can damage neuronal cells by impairing vasodilation and increasing capillary BM thickening and endothelial hyperplasia, which diminishes oxygen tension (52,53). Additionally, hyperglycemia reduces Na⁺K⁺ ATPase activity, which is essential
for maintaining normal nerve membrane resting potential, as well as providing neurotrophic support (54).

The contribution of PKC activation to diabetic peripheral neuropathy (DPN) is still unclear. Hyperglycemia does not increase DAG content in nerve cells, nor is there any consensus as to whether it increases, decreases, or has any effect on PKC activity (55). One study reported that high glucose concentrations in neurons can decrease phosphatidylinositol, thereby decreasing DAG levels and actually decreasing PKC activity. This diminished activity reduces the phosphorylation of Na⁺K⁺ ATPase, leading to a decrease in nerve conduction and regeneration. Immunochemical analysis demonstrated the presence of PKCα, β1, β2, γ, δ, and -ε isoforms in nerves (56). A previous study that directly measured sciatic nerve tissues in STZ diabetic rats also reported a reduction of PKC activity (57). However, these results contrast with recent studies showing that treating diabetic animals with nonselective PKC isoform inhibitors, as well as selective PKCβ inhibitors, improved neural function (58). Some animal studies have reported that PKCβ inhibitor treatments improved both nerve conduction as well as neuronal blood flow (59). Indeed, Cameron et al. showed that low-dose RBX treatments improve motor nerve conduction velocity, normalize nerve blood flow, and restore Na⁺K⁺ ATPase activity in diabetic rats (60). In humans, 1 year of RBX treatment did not significantly affect vibration detection threshold and Neuropathy Total Symptoms Score-6 (NTSS-6), but may have benefitted a subgroup of patients with less severe symptomatic DPN (61,62). More recently, Boyd et al. reported that RBX produced significant improvements in large fiber measures, quality of life (QOL), and NTSS-6 in diabetic patents (63).
In summary, there is substantial evidence that PKCβ mediates some of the micropathologies in the early stages of microvascular complications. However, it is also clear that the effective prevention or treatment of these microvascular complications may involve inhibiting multiple PKC isoforms, including α, β, and δ.

The Polyol Pathway and the Pathogenesis of Diabetic Microvascular Complications

Increased cellular glucose uptake elevates glucose flux through multiple pathways, including the polyol pathway (also known as the sorbitol pathway). Aldose reductase (AR), the first enzyme of this pathway, has a Km between 5-10mM of glucose, which allows it to be active only when intracellular glucose is elevated. This pathway consumes NADPH in the AR reaction and reduces NAD+ in the sorbitol reductase reaction (64). A hyperactive polyol pathway may deplete cytosolic NADPH, which is necessary to maintain the primary intracellular antioxidant (glutathione) in its reduced state. In mice, deleting AR(-/-) reduced retinal neovascularization and capillary permeability. Furthermore, expression levels of VEGF, p-Erk, p-Akt, and p-IκB were significantly reduced in AR(-/-) retina (65). In diabetic mice induced to have retinal ischemia by transient middle cerebral artery occlusion, AR(-/-)db/db mice had significantly less retinal swelling than the db/db diabetic controls; this correlated with a reduced expression of the water channel aquaporin 4 (66). Similarly, AR deficiency in the renal glomeruli protects the mice from the diabetes-induced ECM accumulation and collagen IV overproduction. Furthermore, AR deficiency completely or partially prevented diabetes-induced activation of renal cortical PKC, TGF-β1 and glomerular hypertrophy. Loss of AR resulted in a reduction of urinary albumin excretion in the diabetic AR(-/-) mice (67), and mice were protected from the reduction of motor
and sensory nerve conduction velocities (NCVs) seen in diabetic AR(+/+) mice. Sorbitol levels in the sciatic nerves of diabetic AR(+/+) mice were increased significantly, whereas sorbitol levels in the diabetic AR(-/-) mice were significantly lower. In addition, the study reported signs of oxidative stress, such as increased activation of c-Jun NH(2)-terminal kinase, depletion of reduced glutathione, increased superoxide formation, and DNA damage in the sciatic nerves of diabetic AR(+/+) mice but not in the diabetic AR(-/-) mice, indicating that the diabetic AR(-/-) mice were protected from oxidative stress in the sciatic nerve (68). Polymorphisms in the promoter gene region of AR are associated with susceptibility to neuropathy, retinopathy, or nephropathy, and these associations have been replicated in patients with either T1DM or T2DM, as well as across several ethnic groups (69).

Animal studies using AR inhibitors (ARI) showed promise with regard to an effect on DN or DR, but clinical trials since the 1980s have generally not confirmed such effects in patients with diabetes, except in Japan, where ARI treatments are approved for DN.

**Oxidative Stress and the Pathogenesis of Diabetic Microvascular Complications**

The production of superoxide and other ROS in vascular cells may play an important role in the pathogenesis of vascular diseases in general and particularly in the diabetic state. A major source of superoxide in vascular cells is the NOX family of NADPH oxidases that favors NADH as a substrate (70). The elevation of oxidants and signaling enzymes, like PKC, can induce NOX 1, 2, 4 and 5 in endothelial and contractile vascular cells (70). The expression and activity of NOX are increased in the vascular tissue of rodents with T1DM (71) and T2DM (72). An
increase in the NADH/NAD\textsuperscript{+} ratio may activate NOX. In diabetes this may be caused by an increased flux through the polyol pathway (see above) or through the activation of poly (ADP-ribose) polymerase (73) or PKC (74). In animal models, Baicalein, a NOX inhibitor, reduced vascular hyperpermeability and improved retinal endothelial cell barrier dysfunction (75). However, the role of NOX isoforms in the pathogenesis of kidney disease (KD) in diabetes is unclear. For example, NOX2 deficiency did not protect NOX2 knockout mice against DN, despite a reduction in macrophage infiltration (76). Administering apocynin, a NOX inhibitor, corrected the vascular conductance deficits and reversed the reduction of sciatic nerve motor conduction velocity and sensory saphenous nerve blood flow induced by diabetes (77).

Mitochondria are another important source of ROS. The elevated intracellular glucose concentration in diabetes can yield excessive mitochondrial reducing equivalents, thus increasing the proton gradient. This inhibits the transfer of electrons from reduced coenzyme Q (ubiquinone) to complex III of the electron transport chain (64). As a result, these electrons are transferred to molecular oxygen, which results in superoxide production.

By promoting DNA strand breaks, oxidative stress can activate poly(ADP-ribose) polymerase, which can activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\textsuperscript{κ}B) and cause endothelial dysfunction (73). Oxidative stress can also inhibit the proteasomal degradation of homeo-domain-interacting protein kinase 2, which promotes kidney fibrosis through the activation of p53, TGF-\textsuperscript{β}, and Wnt (78).
When cultured rat mesangial cells are incubated with high glucose, adding an inhibitor of the tyrosine kinase c-Src (which is activated by oxidative stress) reduces type IV collagen accumulation (79). Similarly, in STZ-induced diabetic mice, inhibiting c-Src in vivo reduced albuminuria, glomerular collagen accumulation, and podocyte loss (79). Podocyte injury, a major contributor to the genesis of diabetic glomerulopathy, may, in part, result from excess ROS generation. Khasim et al. reported that the antioxidant plant extract silymarin reduced the high glucose-induced apoptosis of cultured mouse podocytes; in type I diabetic mice it reduces glomerular podocyte apoptosis and albuminuria (80). Another study reported that in T2DM patients with macroalbuminuria, silymarin treatment reduces the urinary excretion of albumin and suggested it as a treatment for preventing the progression of DN (81).

ROS overproduction can also cause major retinal metabolic abnormalities associated with the development of DR. NF-E2-related factor 2 (Nrf2), a redox sensitive factor, provides cellular defenses against the cytotoxic ROS. In stress conditions, Nrf2 dissociates from its cytosolic inhibitor, Kelch like-ECH-associated protein 1 (Keap1), and moves to the nucleus to regulate the transcription of multiple (>30) antioxidant genes including the catalytic subunit of glutamyl cysteine ligase (GCLC), a rate-limiting enzyme for reduced glutathione (GSH) biosynthesis (see section on antioxidant enzymes). Diabetes increased retinal Nrf2 and its binding to Keap1, but decreased DNA-binding activity of Nrf2l, as well as its binding to the promoter region of GCLC. A study reported similar impairments in Nrf2-Keap1-GCLC in endothelial cells exposed to high glucose and in the retina from donors with DR (82).
So far, large clinical trials using antioxidants have not shown that the vitamins E, C, or \( \alpha \)-lipoic acid have a significant effect on definitive clinical endpoints for preventing or treating DR and other vascular complications (83-85).

Motor and sensory neuron myelination and nerve conduction decline with DPN; however, the mechanisms responsible are poorly understood. Chronic oxidative stress is one potential determinant of demyelination, as lipids and proteins are important structural constituents of myelin and are highly susceptible to oxidation. Using the leptin receptor deficient mouse (db/db) model of DPN and the superoxide dismutase 1 knockout mouse model of \textit{in vivo} oxidative stress, Hamilton reported recently that oxidation mediated protein misfolding, and the aggregation of key myelin proteins may be linked to demyelination and reduced nerve conduction in peripheral neuropathies (86).

Some studies have reported high oxidative status and oxidative stress index together with low serum total antioxidant status in serum from DPN patients (87). In a double-blind placebo-controlled trial of DPN subjects, vitamin E improved electrophysiological parameters of nerve function, including motor NCV and tibial motor nerve distal latency (88). Furthermore, a meta-analysis of 15 randomized controlled trials (RCTs) reported that the antioxidant \( \alpha \)-lipoic acid (ALA), significantly improved both nerve conduction velocity and positive neuropathic symptoms (89). Despite this, it is clear that we will need better antioxidants if they are to significantly delay the progression of diabetic microvascular pathologies.
Protein Glycation and Diabetic Microvascular Complications

Sugars, such as pentosidine, carboxymethyllysine, methylglyoxal and pyraline, can cause AGE formation (90). AGE formation can occur via a non-enzymatic reaction between glucose and protein through the Amadori product (1-amino-1-deoxyfructose adducts to lysine). However, faster reactions take place between proteins and intra-cellularly formed dicarbonyls, including 3-deoxyglucosone, glyoxal, and methylglyoxal, which result in the crosslinking of proteins. Due to their long turnover rate, structural extracellular proteins (such as collagen) accumulate more AGE modification. AGEs are probably present in all tissues of diabetic and/or ageing patients.

AGE modification of ECM proteins and signaling molecules may alter their function. In addition, AGE-modified extracellular proteins may bind to receptors, the most well-characterized being the receptor for AGE (RAGE) (91). Most cells express RAGE, including endothelial cells, mononuclear phagocytes, smooth muscle cells, pericytes, mesangial cells, podocytes, and neurons, and RAGE may play a role in the regulation of these cells in homeostasis and/or their dysfunction in the development of diabetic complications (92). Binding to RAGE on the endothelial cell surface can stimulate NOX and increase ROS, p21 RAS, and MAPK. The AGE-RAGE interaction may also stimulate signaling via p38 MAPK and Rac/Cdc, although its exact mechanism is unclear, since RAGE is not an enzyme. A key target of RAGE signaling in the endothelium is NF-κB, which is translocated to the nucleus where it increases the transcription of a number of different proteins, including ET-1, ICAM-1, E-selectin, and tissue factor (93). The ability of RAGE signaling to cause diabetic complications has been reported in transgenic mice overexpressing both inducible inducible NO synthase (iNOS) targeted to β cells (providing a
model for T1DM) and RAGE in all cells. These double transgenic mice develop accelerated
glomerular lesions (94), which an AGE inhibitor prevents (94). Conversely, a soluble RAGE
prevents the development of increased vascular permeability and atherosclerosis in experimental
diabetes (95). Furthermore, RAGE fusion protein inhibitor administered to STZ-diabetic rats had
beneficial effects on early DR or DN (96). Clinical trials are ongoing for small molecule
antagonists of RAGE (97). Researchers have used other approaches to inhibit tissue
accumulation of AGE in diabetes, including AGE formation inhibitors, such as aminoguanidine,
ALT 946, and pyridoxamine, or putative cross-link breakers, such as ALT 711 (98).

Interestingly, not all AGEs or their actions affect vascular cells adversely. Several recent
studies have reported inverse correlations of carboxymethyl-lysine and fructose-lysine with
vascular complications (4).

The Renin-Angiotensin System and the Pathogenesis of Diabetic
Microvascular Complications

A large number of clinical trials have clearly shown that angiotensin converting enzyme
(ACE) inhibitors, angiotensin type-1 receptor blockers, or the combination may delay the onset
of renal disease or progression to renal failure (99). However, an analysis of renal biopsies from
T1DM patients treated with these drugs did not report improved glomerular pathology,
indicating that RAS inhibition may only delay the progression of functional impairment in DN
(100). The kidney produces angiotensin I (Ang I) and angiotensin II (Ang II) locally, and part of
the renoprotective effect of ACE inhibition (in addition to lowering systemic blood pressure) is a
decrease of glomerular capillary pressure. Ang II actions may also lead to kidney damage
through the induction of local factors, including ECM protein synthesis via TGFβ and inflammatory cytokines (101). Ang II receptors mediate angiotensin action, including the activation of RAF kinase/MAP kinase and multiple inflammatory cytokines such as TNFα, interleukin 6, and others (102). Furthermore, RAS blockade may improve or delay the development of DR and macular edema in diabetic patients (103) and DR in normotensive, normal albuminuric T1DM patients (104). This suggests their beneficial effects may be more than just the reduction of blood pressure. In animal models of diabetes, the renin inhibitor aliskiren provided similar or greater protection than ACE inhibition alone to decrease non-proliferative DR and proliferative neoangiogenesis in oxygen-induced retinopathy. In transgenic TGR(mRen-2)27 rats, which overexpress mouse renin in extra-renal tissues, aliskiren treatment reduced retinal acellular capillaries and leucostasis and normalized retinal VEGF expression (105).

Endoplasmic Reticulum Stress and Diabetic Microvascular Complications

The endoplasmic reticulum (ER) plays an important role in Ca^{2+} and redox homeostasis, lipid biosynthesis, and protein folding. Increases in protein synthesis, protein misfolding, or perturbations in Ca^{2+} and redox balance can disturb ER function causing ER stress. This triggers a coordinated program (the unfolded protein response) that reduces translation and increases protein-folding capacity to restore ER homeostasis. With chronic, unresolved ER stress, the unfolded protein response can initiate signaling that promotes apoptosis. Unfolded protein response genes are upregulated in kidney tissue from patients with diabetes, and ER stress may be a mediator of DN. Mice with STZ-induced diabetes and knockout of C/EBP homologous
protein are protected from DN (106). In the retina of rats with STZ-induced diabetes, ER stress is also involved in the upregulation of inflammatory genes and VEGF and increased vascular permeability (107). These and other findings have prompted the development of therapeutics to reduce ER stress. These include synthetic chaperones to promote protein folding, as well as inhibitors of CCAAT/enhancer-binding protein homologous protein and other molecules that interfere with protein folding (107).

Several studies have also implicated ER dysfunction in the pathogenesis of DPN. In cultured Schwann cells (SC), knockout of anti-apoptotic protein ORP150 promoted high glucose-induced SC apoptosis, whereas knockout of C/EBP homologous protein protected SC from apoptosis (108). In rat models of high-fat STZ-diabetes, knockout of ORP150 induced DPN in early diabetes and exacerbated DPN after prolonged diabetes, whereas knockout of the pro-apoptotic protein C/EBP homologous protein ameliorated DPN in rats with prolonged diabetes.

The Kallikrein-Bradykinin System and the Development of Diabetic Microvascular Complications

Plasma kallikrein (PK) is a serine protease with well characterized effects in innate inflammation and the intrinsic coagulation cascade (109). The majority of PK physiological actions are attributed to the cleavage of factor XII and high-molecular-weight kininogen. The conversion of factor XII to factor XIIa leads to the activation of factor XI and the intrinsic coagulation cascade, which results in fibrin production and thrombus stabilization. Kininogen cleavage releases the nonapeptide bradykinin (BK), which is the ligand for the G protein coupled BK2 receptor (BK2R). Subsequent BK cleavage by carboxypeptidases generates des-Arg9-BK,
which binds and activates the BK1 receptor (BK1R). The activation of BK2R by BK and BK1R by des-Arg9-BK are associated with nearly all the effects the plasma kallikrein-kinin system (KKS) has on inflammation, vascular function, blood pressure regulation, and nociceptive responses (110). Plasma KKS is also associated with a variety of coagulation, vascular, and metabolic abnormalities in diabetes. However, most studies have examined the physiological effects of the KKS using BK receptor-targeted approaches.

The Kallikrein-Kinin System and Diabetic Retinopathy

Experimental studies have demonstrated that KKS activation can: result in biological effects that also occur in DR (i.e., increased vascular permeability and edema); promote changes in vascular diameter and hemodynamics; and effect inflammation, angiogenesis, and neuronal functions.

Retinal Vascular Permeability and Blood Flow

Activating the KKS by injecting C1 esterase inhibitor into the vitreous increases retinal vascular permeability (RVP); the co-injection of C1-inhibitor (C1-INH) (a neutralizing antibody against PK) and a small molecule PK inhibitor (1-benzyl-1\(^H\)-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide) inhibited this response (111). Intravitreal PK’s effect is greater in diabetic rats, compared with non-diabetic rats, suggesting that diabetes enhances the retinal responses to intraocular KKS activation (111). Systemic administration of ASP-440 decreased RVP both in diabetic rats and in rats subjected to Ang II-induced hypertension (111,112). Intravitreal BK injection increased RVP in both diabetic and non-diabetic rats, whereas only diabetic rats demonstrated a RVP response to des-Arg9-BK (112,113). A BK1R antagonist
reduced RVP in STZ-induced diabetic rats (113,114). These data suggest that activating KKS in
the circulation, and/or locally in the retina and vitreous, can increase RVP via both BK1R and
BK2R mediation, and that diabetes increases actions mediated via BK1R.

KKS can also regulate retinal vessel diameters and hemodynamics. Intravitreal or
intravenous BK injections acutely increased retinal vessel diameters and blood flow in adult cats
(115), and rats (116), respectively. Des-Arg9-BK increased vessel diameters in the retinal vessels
of diabetic rats but not in the retinal vessels of non-diabetic controls (117). These effects of
BK1R and BK2R on retinal vessel dilation are dependent on NO and prostaglandin in vascular
endothelial cells. BK1R blockade reduces the retinal expression of potential inflammatory
mediators (including iNOS and COX-2), and NG-nitro-L-arginine methyl ester, indomethacin,
and the BK2R antagonist Hoe140 inhibited in vitro BK-induced vasodilation responses
(117,118). BK and Des-Arg9-BK increase intracellular free calcium by coupling Ga q/11 or Ga
i/o through the BK2R or BK1R, respectively (119,120). The increased Ca ^2+ can stimulate
phospholipase A2 to liberate arachidonic acid from membrane phospholipids, which can increase
prostacyclin (121) and increase nitric oxide synthase (NOS) phosphorylation via Ca 2+ -
calmodulin-dependent activation. Whereas under inflammatory conditions, BK1R stimulation
results in a much higher and prolonged NO production via Ga(i) activation of the MAP kinase
pathway, leading to iNOS activation (120,122). eNOS and iNOS activation can independently
and additively increase NO production (120,123). BK also activates the Src kinases and the
subsequent vascular endothelial cadherin phosphorylation, leading to the quick and reversible
opening of endothelial cell junctions and plasma leakage (124).
Targeting the KKS could occur at multiple levels, including: the inhibition of the contact system, selective inhibition of PK activity, and blockade of BK receptors. PK inhibitors include endogenous inhibitors, engineered proteins, and small molecules. C1-INH is a primary physiological inhibitor of PK, factor Xla, factor XIIa, C1r, and C1s proteases. Both plasma-derived and recombinant forms of C1-INH are effective treatments for hereditary angioedema (125). Intravitreal injection of exogenous C1-INH reduced retinal vascular hyperpermeability induced by diabetes and by intravitreal carbonic anhydrase-1 in rats (111). Although C1-INH is detected in the vitreous, it is unknown whether intravitreal concentrations of this endogenous serpin protease inhibitor are sufficient to inhibit PK. Exogenously administered C1-INH into the vitreous may provide an opportunity to inhibit the KKS, as well as other proteases in the complement and intrinsic coagulation cascades. Selective PK inhibition could provide increased efficacy in targeting the inflammatory effects of the plasma KKS while preserving the potential beneficial effects of the tissue KKS.

The generation of BK peptides that activate B1 and BK2Rs (which are expressed in a variety of ocular cell types and tissues) in large part mediates the effects of the KKS. Since both PK- and tissue kallikrein mediated pathways activate BK receptors, the antagonism of these receptors blocks the effects of both KKSs. Although both BK1Rs and BK2Rs can induce RVP, BK1R appears to increase plasma extravasation in DR. The selective peptide BK1R antagonist, R-954, reduced vascular permeability in a variety of tissues from STZ-induced diabetic rats, including the retina (114). Treating STZ-induced diabetic rats with R-954 for 5 days at the end of
the 4- and 12-week periods of diabetes, reduced NO, kallikrein activity, and capillary permeability, while retinal Na⁺,K⁺-ATPase activity increased (126). Treating diabetic rats with FOV-2304, a nonpeptide BK1R antagonist administered via eye drops, reduced RVP and normalized the retinal mRNA expression of inflammatory mediators (127). Pouliot et al. have reported that one eye drop of the nonpeptide BK1R antagonist LF22-0542 reversed retinal plasma extravasation and RVP in the diabetic retina. These reports indicated that both local and systemic administrations of BK1R antagonists are effective in ameliorating retinal vascular abnormalities in diabetic rodents, which are similar to findings from studies using PK inhibitors (128).

**Protection Factors**

Clinical observational studies in patients with long-duration diabetes (e.g., the Joslin’s Medalist Study) tell us that in addition to metabolic toxic factors, there may be equally important protective factors that spare the function and survival of cells involved in microvascular disease beyond the effect of glycemic control (3,4). The finding that over half of diabetic patients with microalbuminuria have regression of this marker over 6 years of follow-up (129) also supports the possibility that endogenous protective factors are common in the general population. Researchers have only recently suggested that some factors with well-established functions were protective (Figure 2).
Figure 2. Interplay of hyperglycemia’s toxic mechanisms and tissues endogenous protective properties.
Insulin: Selective Insulin Resistance on the Vessel Wall in Diabetes

Insulin receptors are present on vascular cells and cells recruited to the vascular wall; these include endothelial cells, vascular smooth muscle cells, pericytes, macrophages, and all the glomerular cells. Insulin signal transduction in these cells occurs primarily by the activation of the IRS1/2 and PI3 Kinase/Akt pathways, which have been shown to phosphorylate eNOS, induce the expression of VEGF and heme oxygenase-1, and decrease that of VCAM-1. Insulin also activates the Src/MAPK pathway to induce the expression of ET-1 and the migration and proliferation of vascular contractile cells (130). In diabetes or insulin resistance, hyperglycemia or free fatty acids (FAs) activate PKCα, β, or δ to phosphorylate IRS2 and p85/PI3K and selectively inhibit the p-Akt pathway in the vessel wall with the loss of insulin’s anti-inflammatory and anti-oxidative effects (130), while insulin activation of the MAP kinase pathway persists. In the kidney, podocytes are critically important for maintaining the integrity of the glomerular filtration barrier and preventing albuminuria. Insulin receptor signaling has a surprisingly profound effect on podocyte survival. Mice with targeted knockout of the podocyte insulin receptor (131) after 5 weeks of age developed albuminuria, effacement of podocyte foot processes, and increased apoptosis, together with increased deposition of BM components. Some of these glomerular pathologies were similar to those observed in DN. Some animals also developed shrunken kidneys with scar tissue, similar to the macroscopic appearance of kidneys in late-stage DN, accompanied by mild worsening of kidney function. This is notable because kidney function is not affected by STZ-induced diabetes (the most commonly studied rodent model of diabetes), despite albuminuria and histopathological changes. One explanation for the
importance of insulin action on podocytes is that insulin increases the expression of VEGF in
several cell types, including podocytes (132). Insulin upregulates VEGF expression, mostly via
the IRS/Akt pathway, which may act as a survival factor for podocytes and endothelial and
mesangial cells. Recently, Hale et al. reported that insulin directly increased VEGF-A mRNA
levels and protein production in conditionally immortalized wild-type human and murine
podocytes. Furthermore, when podocytes were rendered insulin resistant in vitro (using stable
short hairpin RNA knockdown of the insulin receptor) or in vivo (using transgenic podocyte-
specific insulin receptor knockout mice), podocyte VEGF-A production was impaired (132).
Insulin could also prevent apoptosis by other mechanisms, including inhibiting pro-apoptotic
molecule caspase-9 (133), inhibiting transcription factor FoxO (134), or upregulating the
antioxidant activity of heme oxygenase-1 (18).

Researchers have also described the selective (IRS1/pI3K/Akt pathway) impairment of
insulin action in the glomeruli of diabetic animals and patients, which may contribute to DN
development. The IRS/PI3K/Akt pathway mediates many of insulin’s protective effects,
including the upregulation of eNOS (135,136) and heme oxygenase-1 (18). In contrast, the
Ras/MAPK pathway mediates the induction of ET-1 (137). With diabetes or insulin resistance,
elevated concentrations of glucose and free FAs can activate PKC and selectively inhibit insulin
signaling through the PI3K pathway (138). Certain threonine/serine residues on IRS2 and on the
p85 regulatory subunit of PI3K are substrates for PKC, and phosphorylation of these sites
inhibits insulin-stimulated PI3K pathway signaling (139,140). Hyperinsulinemia in T2DM may
promote vascular disease through the induction of ET-1 (141) or other factors induced by MAPK signaling.

**Antioxidant Enzymes**

While extensive evidence from cell- and animal-based studies supports the role of oxidative stress in the development of vascular complications, nearly all clinical trials using antioxidants have failed to show efficacy with clinically significant vascular endpoints.

Nevertheless, tissue-specific endogenous anti-oxidant enzymes are likely important to neutralize the increased levels of oxidants seen with hyperglycemia. This idea has stimulated clinical trials using bardoxolone methyl, a synthetic triterpenoid that (142) activates Nrf2. This nuclear factor upregulates a gene program of molecules with antioxidant activity called phase 2 genes, which includes heme oxygenase 1 and enzymes in the GSH biosynthesis pathway. Keap1, a repressor that binds Nrf2 in the cytoplasm and promotes Nrf2 proteasomal degradation, inhibits Nrf2 translocation to the nucleus. Bardoxolone methyl interacts with cysteine residues on Keap1, preventing Nrf2 repression and allowing phase-2 gene transcription. Results from a trial of bardoxolone methyl in patients with advanced chronic kidney disease (CKD) showed an improvement in GFR up to 1 year after start of treatment (143). However, proteinuria was increased and researchers stopped phase-III trials due to safety issues. Researchers also reported that Nrf2 has a protective role in the retina against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. In Nrf2 (+/+) mice, ischemia-reperfusion injury resulted in leukocyte infiltration of the retina and vitreous and increases in retinal levels of superoxide and proinflammatory mediators. These changes were greatly accentuated in Nrf2 (-/-) mice (144).
Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor

PDGF expressed by retinal endothelial cells plays a role both in vascular cell survival and proliferative retinopathy (145). During sprouting angiogenesis, endothelial tip cells produce PDGF, which acts through PDGF receptor-β expressed by pericytes. This signal recruits pericytes to develop blood vessels. Pericytes, in turn, can support endothelial cell survival and inhibit its proliferation. This is demonstrated by findings in PDGF knockout mouse embryos, which show pericyte loss and endothelial cell proliferation (146). Mice with heterozygous deletion of the PDGF gene not only have an increased frequency of acellular capillaries (particularly after diabetes induction), but also an increased tendency for retinal neovascularization during ischemic retinopathy (147). As described above, we have reported that hyperglycemia can inhibit the survival effects of PDGF by upregulating SHP-1, which causes dephosphorylation of the PDGF receptor in pericytes and possibly also in podocytes (14).

High glucose concentrations and diabetes can activate SHP-1, a tyrosine phosphatase, in microvessels, including the retina and renal glomeruli. This leads to the dephosphorylation and deactivation of specific growth factor receptors critical for the survival of pericytes in the retina and podocytes in the kidney (14). One study reported that SHP-1 regulates AGE-related endothelial cell injury in vitro, (148). In the retina of diabetic rodents, SHP-1 activation can desensitize pericytes to PDGF and cause pericyte apoptosis, an initiating step in the development of DR (14). In the renal glomeruli, the upregulation of SHP-1 expression can impair VEGF survival signaling and increase podocyte apoptosis and endothelial dysfunction (24). The
upregulation of SHP-1 expression in diabetes depends on the activation of PKCδ and p38MAPKα transcription (14,24), which is prevented in PKCδ knockout mice. These mice are protected from the apoptosis of retinal pericytes, mesangial expansion, and albuminuria (14,24). Therefore, inhibiting SHP-1 is a potential novel approach to preserving survival signaling in vascular cells.

Transforming Growth Factor Beta-1

TGFβ1 is a major inducer of profibrotic responses in diabetic kidneys. Diabetes increases the expression of TGFβ in blood vessels in many vascular beds, and one study suggests that it is a causative factor for the development of fibrosis in the kidney and other tissues (149). An earlier study has shown that treating C57BLKS/J db/db mice with neutralizing monoclonal TGF-β1 antibody decreases plasma TGF-β1, mesangial matrix expansion, and kidney mRNA levels of collagen IV and fibronectin (150). In addition, this therapy prevented a loss of renal function but had no effect on the elevated albuminuria in db/db mice. More recently, investigators have used an inhibitor of TGF-β receptor kinase activity, GW788388, to treat C57BLKS/J db/db mice (151). This therapy reduced glomerular collagen staining and kidney mRNA levels of plasminogen activator inhibitor 1 and collagen (I and III) but did not alter albuminuria (151).

However, numerous studies have reported that TGF-β has potent anti-inflammatory effects on macrophages and is a negative regulator of T cell and B cell activation. Therefore, it may have protective actions due to an anti-inflammatory effect, and its elevation is a reaction to the inflammatory stress of diabetes. Thus, it is likely that the overexpression of TGF-β in many
tissues by diabetes could be an endogenous response to the inflammatory actions of hyperglycemia in vascular cells. These paradoxical roles of TGF-β are a challenge for using it as a drug target.

**Vascular Endothelial Growth Factor**

VEGF expression changes paradoxically with diabetes, it increases in the retina and renal glomeruli, but it decreases in the myocardium, peripheral limbs, and nerves correlating with the extent of angiogenesis. VEGF neutralization is already a treatment for proliferative DR and macular edema, and one study suggests it as a therapy for DN (152). However, the increased levels of VEGF in both tissues are likely an appropriate response to hypoxia, which results from loss of capillary function. It has been a longstanding concern that neutralizing VEGF could counteract survival signaling in retinal neurons. Interestingly, injecting low doses of VEGF accelerated the restoration of the physiological capillary bed and prevented pre-retinal neovascularization in a mouse model of proliferative retinopathy (153).

The highest expression level of VEGF in the kidney is in renal podocytes, and some of the most insightful work describing a role for VEGF as a survival factor comes from studies of renal podocytes. The conditional deletion of VEGF in podocytes resulted in a complete lack of endothelial and mesangial cells in mature glomeruli and death within the first day of life (154). This finding strongly supports a role for VEGF in the maintenance of glomerular endothelial cells. Heterozygous knockout of VEGF in podocytes of mice resulted in proteinuria and ESKD in young adults (154) and was preceded by the disappearance of endothelial cell fenestrations, increases in necrosis, the effacement of podocyte foot processes, and a dramatic loss of
mesangial cells (154). Inducing STZ diabetes in these mice exacerbated glomerular cell apoptosis, glomerulosclerosis, and proteinuria compared with non-diabetic controls (155).

However, other studies reported that increased podocyte VEGF (156) expression worsens DN characterized by glomerulosclerosis, microaneurysms, mesangiolysis, glomerular BM thickening, podocyte effacement, and massive proteinuria associated with hyperfiltration (156).

VEGF also has neuroprotective effects. Primary dorsal root ganglion cultures lacking VEGF-B or VEGF receptor-1 (FLT-1) exhibited increased neuronal stress and are more susceptible to paclitaxel-induced cell death, and mice lacking VEGF-B or a functional FLT-1 develop more retrograde degeneration of sensory neurons. Conversely, adding VEGF-B (186) to dorsal root ganglia cultures antagonizes neuronal stress, maintained the mitochondrial membrane potential, and stimulated neuronal survival. Mice overexpressing VEGF-B (186) or FLT-1 selectively in neurons were protected against distal neuropathy, whereas exogenous VEGF-B (186), either delivered by gene transfer or as a recombinant factor, was protective by directly affecting sensory neurons and not the surrounding vasculature (157). Identifying the pro-survival mechanisms in stressed neuronal cells revealed that protein kinase A functioned concurrently with the VEGF receptor-2 pathway to signal the activation of the extracellular signal-regulated protein kinases (ERK1/2) as protection against caspase-3/7 activation and subsequent cell death (158).

**Activated Protein C**

Activated protein C (APC) is an anticoagulant factor that acts as a survival factor for renal glomerular cells (159). Thrombomodulin, a procoagulant factor that activates protein C, is
highly expressed in glomeruli of mice but downregulated in diabetes (159). Diabetic mice with a loss-of-function thrombomodulin gene mutation had more albuminuria and more severe glomerular pathology than diabetic wild-type mice, whereas diabetic mice with a gain-of-function mutation of the protein C gene had less (159). The anticoagulant effects of APC did not account for its protective actions. Rather, APC was shown to counteract the apoptosis of endothelial cells and podocytes through the activation of two of its receptors (159). Therefore, endothelial-derived APC appears to act as a protective factor with local survival effects for both podocytes and endothelial cells in the glomerulus. The underlying mechanism for APC protection from renal dysfunction is still unknown, but Gupta et al. (173) reported that APC-mediated protease: suppressed lipopolysaccharide-induced increases in the vasoactive peptide adrenomedullin, suppressed infiltration of iNOS-positive leukocytes into renal tissue, and activated receptor-1 agonism. The anticoagulant function of APC was responsible for suppressing lipopolysaccharide-induced stimulation of the proinflammatory mediators ACE-1, IL-6, and IL-18, perhaps accounting for its ability to modulate renal hemodynamics (160).

**Vascular Progenitor Cells**

Bone-marrow-derived cells, including endothelial progenitor cells (EPCs) and myeloid progenitors, may contribute to postnatal angiogenesis (161). EPCs may contribute by incorporating into newly formed blood vessels. However, it is likely the major action of EPCs is to release proangiogenic factors and temporarily associate with neovascular structures. In diabetic patients, both the number and function of EPCs are reduced (162), impairing the ability
of EPCs to repair the vascular endothelium (163). The angiogenic potential of EPCs was also
reduced in diabetic animals (164).

The differentiation of bone marrow-derived EPCs may also play a role (164). eNOS is
necessary to mobilize EPCs from bone marrow, (165). Uncoupling eNOS that favors superoxide
rather than NO production may impair EPC function. Indeed, EPC function improves after eNOS
is inhibited \textit{ex vivo} in EPCs isolated from patients with diabetes (166). Interestingly, neuropathy
in the bone marrow may reduce EPC mobilization. STZ-induced diabetes in rats reduced nerve
terminals in bone marrow, and this correlated with increased EPCs in bone marrow and
decreased EPCs released into the circulatory system. These abnormalities were associated with
an increase in retinal acellular capillaries (167). Transplanting non-diabetic EPCs into diabetic
animals can improve angiogenesis after peripheral ischemic injury (168).

These studies suggest that it may be possible to promote the repair of ischemic tissue in
diabetes by improving the mobilization, differentiation, and function of EPCs or other
progenitors. Recently, researchers have suggested that autologous EPC transplantation could be a
potential therapy for DN. However, safety concerns regarding possible unwanted proliferation or
differentiation of the transplanted stem cells might limit such treatment. An alternative approach
is to stimulate endogenous bone-marrow-derived EPC recruitment into ischemic lesions by
administering stem cell mobilization agents or chemokines (169). Administering AMD3100, an
EPC mobilization agent, increased the local expression levels of vasculogenesis-associated
factors and the number of newly formed endothelial cells in the sciatic nerve, which restored the
sciatic vasa nervorum (169).
Circulating EPCs are markedly reduced in CKD patients (170), and EPCs have been shown to improve renal function, attenuate the pro-inflammatory response associated with renal injury, and improve damaged tubules and renal vascular segments during kidney injury while providing enhanced neoangiogenesis (171). An intact and healthy EPC niche, residing in the bone marrow but also found locally in renal vascular beds, such as in the area of the adventitia layer of vessels, may be able to support normal vascular function, including maintenance and possible replacement of the endothelium (172).

Emerging studies in animal models suggest that EPCs help revascularize ischemic and injured retinas. Thus, EPCs could be a potential therapy for ischemic retinopathies in humans, which are a leading cause of blindness (173). In non-proliferative DR, EPCs may be less effective, as they don’t recruit other EPCs and repair the acellular capillaries. In proliferative DR, the EPCs take on a pro-inflammatory phenotype and recruit too many EPCs, leading to pathological neovascularization.

For the last 10 years, many groups have focused on understanding the basic mechanism responsible for the diabetes-associated defect in EPC function. Correcting this defect may allow diabetic patients to use their own EPCs to repair injured retinal and systemic vasculature. Specifically in the retina, correction of this dysfunction may prevent early and intermediate stages of vasodegeneration (thus enhancing vessel repair), reverse ischemia, and prevent the progression to the late stages of DR. However, these findings on the changes of EPCs and their correlation to various complications in diabetes have been inconsistent. Clearly, we need more
studies to clarify changes in diabetes and the role EPCs play before patients can use them therapeutically (173).

Summary

Hyperglycemia initiates its adverse effects by increasing its metabolites in vascular cells, which can cause specific changes in vascular functions, such as those mediated by PKC or ROS activation. However, increases in glucose metabolism can also generate non-diabetic specific toxic products such as oxidants, AGE, and methylglyoxal, which accelerate the specific toxic actions of hyperglycemia and cause microvascular pathologies. The specific needs of various tissues (such as the retina, glomeruli, and the peripheral neuron), the importance of the various functions that are changed by hyperglycemia, and the protective responses generated by each tissue all modulate specific pathologic manifestations. Thus, treatment to prevent and delay the progression of diabetic microvascular complications depends on: a) the elimination of hyperglycemia, b) the inhibition of the major mechanisms that hyperglycemia activates to induce vascular dysfunction, c) the neutralization of accelerants such as inflammation and oxidative stress, and d) the activation of tissue-specific protective factors.
Chapter 2. Retinal Microvascular Disease

Introduction

DR and DN are considered the quintessential microvascular complications of diabetes. These complications are frequent and may result in severe visual impairment and renal failure and are associated with poor QOL. Plasma glucose and HgA1c concentration thresholds for the diagnosis of diabetes have been established based upon the correlation of these chemical indices to microvascular changes in the retina as observed on fundus photography. We review here the natural history, pathogenesis, epidemiology as well as the impact of risk factors and co-morbidities on DR development and progression, and brief discuss clinical management.

Natural History of Diabetic Retinopathy

A number of subclinical changes in the physiology of the retinal vessels (retinal microaneurysms and blot hemorrhages that can be detected by ophthalmoscopy) are known to occur in persons with diabetes prior to the appearance of the first clinical signs (174). They include disruption of the blood-retinal barrier and increased RBF, likely due to disturbances in autoregulation. Clinicians do not routinely measure this. Another early change is widening of the retinal venules. In one study, in the absence of any other clinical signs of DR, a widening of the retinal venules by 10 μm over a 4-year period was associated with a 26% increase in the risk of incident DR over the next 6 years (174). These data suggest that measuring venular diameter
may provide an even earlier clinically measurable stage of DR than retinal microaneurysms and blot hemorrhages.

Retinal microaneurysms are small outpouchings of the retinal capillaries. Retinal blot hemorrhages often follow but may appear prior to microaneurysms. Both lesions are not pathognomonic of diabetes, as they may appear in 2-11% of persons aged 40 years or older without diabetes and are often associated with hypertension (175).

After the appearance of retinal microaneurysms and/or blot hemorrhages, retinopathy may progress with the appearance of other non-proliferative retinal abnormalities, such as: retinal hard exudates (lipid deposits in the retina resulting from lipoprotein leakage from the retinal microvasculature), cotton wool spots (small localized infarctions of the nerve fiber layer of the retina [also called soft exudates]), intraretinal microvascular abnormalities (collateral dilated capillary channels in areas of retinal ischemia), and venous beading (irregular dilation of retinal veins associated with significant retinal ischemia). Retinopathy may further progress to the proliferative stage, characterized by the development of new retinal blood vessels and fibrous tissue at the optic disc or near venules elsewhere in the retina. These new retinal blood vessels may bleed, resulting in pre-retinal and vitreous hemorrhage, and the fibro-vascular tissue can cause traction on the macula, resulting in loss of vision. While the progression of proliferative disease in untreated eyes is the usual course, spontaneous regression of the new retinal vessels may occur at any stage. Macular edema (thickening of the retina in the macular area) may also develop and regress without treatment. While clinicians can identify the source and extent of the leakage in the macula by fluorescein angiography, they now usually confirm the retinal thickness
and response to treatment in eyes with macular edema by spectral domain optical coherence tomography (176). Visual loss may result from macular edema or proliferative retinopathy.

While retinopathy is believed to result from the effects of hyperglycemia, hypertension, and high lipid levels on the retinal microvasculature (see the section on epidemiology), there is also growing evidence of concurrent early neurodegenerative changes of the retinal neuronal cells (e.g., retinal ganglion and Mueller cells, cones), which (in whole) we generally refer to as the neurovascular unit (177). The neurodegenerative changes are associated with impaired control of the metabolism of neurotransmitter glutamate, apoptosis in the ganglion cells and inner nuclear layer cells, and the activation of microglial cells, resulting in localized inflammation (177-179). These neuronal changes result in a loss of synaptic activity and loss of dendrites. Levels of brain-derived neurotrophic factor are also reduced (180,181). These neuronal changes are postulated to contribute to the development of retinopathy by impairing autoregulation and vascular integrity in persons with T2DM (182,183). Retinal flicker responses, a neurologic function, are impaired before the onset of retinopathy in people with T1DM (182,184). Neuropathy may involve nerves in the cornea and pupil in addition to the retinal neuron. Retinal neurodegenerative changes may manifest clinically as a decreased ability to discriminate blue from yellow color, decreases in dark adaptation with decreases in the electroretinograph a-wave and b-wave amplitudes, changes in the oscillatory potentials generated by inner retinal neurons, and changes in contrast sensitivity (185). We have a poor understanding of the temporal and causative relationships between the neuropathic and retinopathic changes.
The pathogenesis of DR is complex (see chapter 1). A number of possible mechanisms appear to contribute (177,186-188) (Figure 3). Hyperglycemia is an important initiator of the disease process. Studies have shown that hyperglycemia induces biochemical, physiological, rheological, hormonal, and other changes that are involved in the pathogenesis of DR (Figure 3). These abnormalities are associated with the development of a number of anatomic changes in the diabetic retina, which include pericyte loss, endothelial cell abnormalities, acellular capillaries, increased BM thickness, and retinal pigment epithelial abnormalities.

It is likely that the initiation and progression of DR is due to a complex relationship among a number of these factors and pathways, which vary at different stages in the natural history of DR and also vary from individual to individual.
Figure 3. Conceptual diagram showing the effect of hyperglycemia on different mechanisms hypothesized to be involved in the pathogenesis of DR.
Epidemiology

Prevalence

Epidemiologic population-based studies have provided important descriptive information on the prevalence, incidence, and progression of DR, as well as information on modifiable and potentially intervenable risk factors such as glycosylated hemoglobin, blood pressure, and lipid levels. The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) provided data on the prevalence and severity of DR by duration of diabetes (Figure 4) and the 4-year incidence and progression of DR by age, sex, and duration of diabetes in younger-onset persons with T1DM and older-onset persons with T2DM (189-192). In the WESDR, the prevalence of DR in patients with T1DM was 17% versus 98% in those with less than 5 years diabetes duration versus those with 15 or more years, respectively; proliferative retinopathy was absent in those with shorter duration of diabetes, but present in 48% in those with 15 or more years of diabetes. For persons with older-onset T2DM, the prevalence of any retinopathy was 28% versus 78% and proliferative retinopathy 2% versus 16% for those with diabetes for less than 5 years versus 15 or more years, respectively. The WESDR cohort is 99% white. Data indicate a higher prevalence of retinopathy in Mexican Americans and blacks with T2DM compared to whites (Table 1), although the data reflect prevalence estimates from a different time period (192,193).
### Table 1. Prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy in United States individuals age 40 and older

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Crude Prevalence of DR</th>
<th>Diabetes Population</th>
<th>U.S. Population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N*</td>
<td>N†</td>
<td>Weighted Size, (in thousands)‡</td>
</tr>
<tr>
<td>Total</td>
<td>1,006</td>
<td>324</td>
<td>4,202</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-64</td>
<td>575</td>
<td>189</td>
<td>2,588</td>
</tr>
<tr>
<td>≥65</td>
<td>431</td>
<td>135</td>
<td>1,613</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>504</td>
<td>173</td>
<td>2,257</td>
</tr>
<tr>
<td>Female</td>
<td>502</td>
<td>151</td>
<td>1,944</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic white</td>
<td>396</td>
<td>107</td>
<td>2,507</td>
</tr>
<tr>
<td>Non-Hispanic black</td>
<td>306</td>
<td>119</td>
<td>1,006</td>
</tr>
<tr>
<td>Mexican American</td>
<td>197</td>
<td>70</td>
<td>401</td>
</tr>
<tr>
<td>Other</td>
<td>107</td>
<td>28</td>
<td>286</td>
</tr>
<tr>
<td>Crude Prevalence of Vision-Threatening DR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1,006</td>
<td>62</td>
<td>655</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-64</td>
<td>575</td>
<td>36</td>
<td>376</td>
</tr>
<tr>
<td>≥65</td>
<td>431</td>
<td>26</td>
<td>278</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>504</td>
<td>24</td>
<td>298</td>
</tr>
<tr>
<td>Female</td>
<td>502</td>
<td>38</td>
<td>356</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic white</td>
<td>396</td>
<td>13</td>
<td>304</td>
</tr>
<tr>
<td>Non-Hispanic black</td>
<td>306</td>
<td>28</td>
<td>241</td>
</tr>
<tr>
<td>Mexican American</td>
<td>197</td>
<td>16</td>
<td>85</td>
</tr>
<tr>
<td>Other</td>
<td>107</td>
<td>5</td>
<td>22</td>
</tr>
</tbody>
</table>

DR, diabetes retinopathy; NHANES, National Health and Nutrition Examination Surveys; U.S., United States; N, number; CI, confidence interval.

*Number of participants with diabetes in NHANES 2005-2008. †Number of participants with diabetes who had DR or vision-threatening DR in NHANES 2005-2008.

‡Weighted total number of U.S. adult population who had DR or vision-threatening DR. §Estimate is considered unreliable because relative standard error is greater than 30%.
Data obtained from the National Health and Nutrition Examination Surveys, 2005-2008 (194)
Incidence

The duration of diabetes is associated with the incidence and progression of retinopathy in those with younger-onset T1DM. In the WESDR, half of the people with fewer than 5 years of diabetes at baseline and no retinopathy (n=317) went on to develop retinopathy 4 years later (191). For those with more than 5 but fewer than 15 years of diabetes at baseline, there were too few persons with no retinopathy at baseline to reliably calculate incidence by duration of diabetes; however, the longer the duration of diabetes, the greater the incidence of progression over the following 4 years (191). Within duration-specific groups, the incidence of retinopathy, proliferative retinopathy, and macular edema were higher in Mexican Americans with T2DM than in whites (195).

Risk Factors

Glycemia

The WESDR (Figure 5), DCCT, and the Epidemiology of Diabetes Interventions and Complications (EDIC) studies confirmed the role of glycemic control as a critical risk factor preceding the development of retinopathy.

Figure 5. Test of trend p<0.001 for both groups
and progression of DR in persons with T1DM. The UKPDS (196), and the Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Eye studies made the same conclusion regarding persons with T2DM (197-200). One can see a decline in the levels of A1c when examining the trends over more than 30 years of follow-up of the group with T1DM in the WESDR (Table 2) (197).
Table 2. Mean glycosylated hemoglobin A1c levels (%) at each examination in the Wisconsin Epidemiologic Study of Diabetic Retinopathy, 1980-2013

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycosylated hemoglobin A1c, %*</td>
<td>10.1</td>
<td>9.4</td>
<td>9.3</td>
<td>8.9</td>
<td>7.6</td>
<td>7.6</td>
</tr>
</tbody>
</table>

*Values are mean ± SD.
Figure 4. Prevalence of any retinopathy and proliferative retinopathy in persons with:
A. T1DM diagnosed at age <30 years
B. T2DM diagnosed at age ≥30 years, taking and not taking insulin, by duration of diabetes
in the Wisconsin Epidemiologic Study of Diabetic Retinopathy

A.

B.
ACCORD-Eye was a sub-study of the ACCORD trial, an RCT comparing the effects of intensive glycemic control (target A1c below 6.0%) to standard glycemic control (target A1c between 7.0% and 7.9%) that further randomized blood pressure and lipid medication for high levels of each. The aim of this sub study was to examine the effects of the primary and secondary randomizations on the progression of DR in persons with T2DM. In a relatively short period (4 years), the study found a lower risk of DR progression (7.3%) in those in the intensive glycemia treatment group versus those in the standard therapy (10.4%) (adjusted odds ratio 0.67; 95% CI: 0.51-0.87; P=0.003) (190).

The ACCORD intensive glycemic strategy was prematurely stopped because of a statistically significant 22% increase in overall mortality in the intensive glycemic group (197) of the larger study. The early closure of the glycemic phase of the trial diminished the power to observe a protective effect for the severe microvascular endpoints, such as proliferative DR and clinically significant macular edema, which usually evolve over a longer period. In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, intensive blood glucose control did not have any effect on any of the retinopathy and vascular outcomes in patients with T2DM (197).

The results of the UKPDS, ACCORD, ADVANCE, and the Veterans Affairs Diabetes Trial (VADT) (201) (an RCT of intensive glycemic control in people with T2DM) have advanced the way we think about managing hyperglycemia in people with T2DM. Intensive therapy to a target goal of A1c level of 7.0% is the suggested American Diabetes Association guidelines to reduce the risk of visual loss from DR in persons with diabetes. It is likely that
clinicians helping people with T2DM manage glycemia have used this guideline, as the National Health and Nutrition Examination Survey (NHANES) reported that the number of people with T2DM taking three or more hypoglycemic drugs increased from 1999 to 2006 (202). This has been accompanied by a decrease in mean A1c from 7.8% to 7.2% from 1996-1997 and an increase in the percentage (from 40% in 1996-1997 to 54% in 2004-2006) of persons aged 40 years or older with T2DM that had A1c levels below 7% (202). Data from the ACCORD and ADVANCE trials and VADT suggest the need to tailor intensive treatment to the individual, especially in patients with long-standing T2DM who have or who are at risk of developing cardiovascular disease (CVD). The findings from these studies may lead to a reduction in the number of persons with T2DM meeting the American Diabetes Association guidelines of having an A1c of less than 7%.

**Hypertension**

Uncontrolled hypertension in persons with both T1DM and T2DM is associated with both DR (203) and DN (204). Data suggests that its effect on blood flow damages the retinal capillary endothelial cells, resulting in the development and progression of DR (205).

The UKPDS was designed to test whether lowering blood pressure is beneficial in reducing macrovascular and microvascular complications associated with T2DM (206). The study assigned hypertensive participants (defined at the time of the start of the trial in the 1980s as having a mean blood pressure reading of 160/94 mmHg) to tight blood pressure control (aiming for <150/<85 mmHg) and initial captopril or atenolol treatment (adding other agents as needed) or to less-tight blood pressure control (aiming for <180/<105 mmHg). Tight blood pressure
control resulted in a 35% reduction in retinal photocoagulation compared to the less-tight control group. After 7.5 years of follow-up, there was a 34% reduction in the rate of retinopathy progression and a 47% reduction in the deterioration of visual acuity. Atenolol and captopril were equally effective in reducing the risk of developing these microvascular complications, suggesting that blood pressure reduction was more important than the type of medication used to reduce it. The effects of blood pressure control were independent of the effects of glycemic control. These findings support the recommendations for blood pressure control in patients with T2DM as a means of preventing visual loss from DR. Two years after completing the trial, follow-up of the UKPDS cohort showed that the reduction in blood pressure was not sustained in the group that received tight blood pressure control (207). This was associated with loss of reductions in relative risk present during the trial for diabetes-related end points, such as death, microvascular disease, and stroke in the group receiving tight blood pressure control, as compared to the group receiving less-tight blood pressure control.

In the ACCORD study, hypertensive persons with T2DM were randomized to intensive blood pressure treatment targeted to lowering the systolic blood pressure to below 120mmHg or to standard treatment targeted to maintaining systolic blood pressure below 140mmHg (208). The average systolic blood pressure was 119 mmHg in the intensive group and 133 mmHg in the standard group. Despite this 14 mmHg difference, intensive blood pressure control was not associated with decreased progression of DR, nor was it associated with a reduction in the hazard of developing moderate loss of vision (208). There were no statistically significant interactions with glycemic or lipid control.
Other RCTs have targeted specific types of antihypertensive agents such as renin angiotensin system blockade. The EURODIAB Controlled Trial of Lisinopril in Insulin Dependent Diabetes Mellitus reported a borderline beneficial effect of renin angiotensin system blockade on the progression of DR in patients with T1DM, independent of blood pressure (209). The Renin-angiotensin System Study showed that the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II receptor blocker (ARB) losartan were both associated with a reduced progression of retinopathy compared to those not randomized to blood pressure medications, but these agents were not associated with the progression of nephropathy in subjects with T1DM (100). However, the Diabetic Retinopathy Candesartan-Prevent and -Protect trials reported that candesartan cilexetil did not result in a statistically significant reduction in the progression of DR in persons with T2DM (P=0.0508) or in the incidence or progression in those with T1DM (210,211). Neither the ACCORD nor the ADVANCE study found that lowering blood pressure in those with mild hypertension or in those already normotensive was of benefit in preventing the incidence and progression of DR.

Together, these data suggest that lowering blood pressure in those who have poorly controlled hypertension provides the greatest benefit in preventing the progression of retinopathy, as shown in the UKPDS. The type of antihypertensive medication used was less important, however the renin angiotensin system blockade had the greatest efficacy in those with T1DM at moderate risk of DR progression. Aggressive blood pressure control below 120 mmHg was not indicated in persons with T2DM with mild or no hypertension. The American Diabetes Association recommends that people with hypertension should be treated to a systolic blood
pressure goal of <140 mmHg and that patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure (212).

**Serum Lipids**

Epidemiological studies have associated serum total and low-density lipoprotein (LDL) cholesterol and triglycerides with the severity of DR and diabetic macular edema (213-216). In the Early Treatment Diabetic Retinopathy Study, persons with higher levels of serum triglycerides, LDL cholesterol, and very LDL cholesterol at baseline had a 50% increased risk of developing hard exudates in the macula and decreased visual acuity and a 23% increased risk of developing proliferative DR (208). In the DCCT/EDIC study, those with higher serum total cholesterol, LDL cholesterol, and triglycerides (4th vs. 1st quartile range) had a 2- to 3-fold increase in the odds of developing macular edema (217).

Pilot studies to examine the efficacy of statin therapy in preventing or reducing the severity of macular edema have suggested a possible short-term benefit (218-220). In the Fenofibrate Intervention and Event Lowering in Diabetes Study, fenofibrate was shown to reduce the need for laser treatment for DR in persons with T2DM (HR 0.69 95% CI: 0.56,0.84, p=.0002), although the effect was not clearly due to lowering of plasma lipid concentrations (221). Fenofibrate in the context of simvastatin use in the ACCORD-Eye study was associated with a significant decrease in the 3-step or greater group (6.5% in the fenofibrate group vs. 10.2% in the placebo group [HR 0.60 95% CI: 0.42–0.87, P<0.006]). There was no effect on moderate vision loss. A recent study, which used the HealthCore Integrated Research DatabaseSM containing administrative claims data for more than 35 million Americans, examined
microvascular complications of diabetes, (e.g., DR and DN). The incidence of microvascular complications of diabetes was lower in patients who attained their goal of lower serum LDL cholesterol, higher serum high-density lipoprotein cholesterol, and lower serum triglycerides compared with those who did not (222). In summary, accumulating evidence suggests that lipid lowering may have a role in limiting the development and progression of DR and macular edema, but the pathways leading to this protective effect are still unclear.

Other Risk Factors

There is evidence, mostly from clinical studies, that AGEs and oxidative stress are associated with complications of diabetes. AGEs result from the long-term exposure of proteins and lipids to hyperglycemia, with nonenzymatic glycation of these molecules. AGEs have been identified in renal lesions of persons with nephropathy as well as in atherosclerotic streaks in large blood vessels in persons with diabetes (223-226). The accumulation of AGEs in people with diabetes is thought to lead to retinopathy, nephropathy, neuropathy, CVD, and cognitive dysfunction by directly damaging the tissue. AGEs may also lead to increased oxidative stress, endothelial dysfunction, inflammation, thrombosis, and fibrinolysis, and they adversely affect the RAS. All of these processes are hypothesized to be pathogenetic mechanisms for these complications (93,224,227-230). Some, but not all, clinical studies have associated serum AGEs with diabetic complications, independent of A1c levels.

The body normally generates oxidizing compounds as an important component of the inflammation and tissue repair processes (231,232). It represents part of the normal defense mechanism against invading microorganisms and malignant cells and occurs during tissue
healing and remodeling. The retina exists in a highly oxidizing environment and is thought to be especially vulnerable to oxidative stress. Animal studies have shown a beneficial effect of antioxidants (e.g., nicanartine, vitamin E, and lipoic acid) on retinopathy lesions in diabetic animals, suggesting that oxidative stress may be involved in the pathogenesis of DR (233-235).

Data from some studies have led researchers to hypothesize that oxidative stress in persons with diabetes is involved in the pathogenesis of not only DR, but also DN, myocardial infarction, and cognitive dysfunction (236-242). Oxidative stress in those with diabetes has been attributed to hyperglycemia with an increase in ROS through glucose auto-oxidation, nonenzymatic protein glycation, decreased antioxidant status, and reduced ROS removal (243).

### Genetic Factors

Studies have reported familial clustering of DR and this is compatible with the notion that genetic factors may contribute to developing DR (244,245). It is possible that similarities in retinopathy severity within families are related to how genes affect glycemia and blood pressure (246,247). Control of these factors may influence the apparent effect of genes on retinopathy. Also, because retinal microaneurysms and blot hemorrhages are not specific to diabetes, their presence (in the absence of signs of more severe retinopathy) may lead to misclassification, resulting in inconsistent associations of candidate genes with early stages of DR compared to more severe stages of DR (248).

DR has been associated with mitochondrial genes (69,249), an AR gene (69,250), endothelial NO synthase (251), paraoxonase (an enzyme that prevents oxidation of LDL cholesterol) (252), TNF-beta NcoI gene (253), epsilon4 allele of the apolipoprotein E gene (254),
intercellular adhesion molecule-1 (255), alpha2beta1 integrin gene (involved with platelet function) (256), and cytokine VEGF genes, but subsequent studies have not consistently replicated these associations (257,258). Two recent studies, one a meta-analysis (259) and one from separate studies in France and Denmark (260), failed to find definitive evidence of the effects of genes associated with serum levels of VEGF on DR.

**Comorbidity and Mortality**

In the WESDR, the risk of developing systemic complications (e.g., myocardial infarction, stroke, lower extremity amputation, DN) was higher in those with proliferative DR compared to those with no or minimal retinopathy at baseline (Table 3) (261).
Table 3. The relative risk for the prevalence and 4-year incidence of myocardial infarction, stroke, and amputation of lower extremities associated with presence of proliferative diabetic retinopathy, adjusted for age in the Wisconsin Epidemiologic Study of Diabetic Retinopathy

<table>
<thead>
<tr>
<th></th>
<th>Myocardial Infarction</th>
<th>Stroke</th>
<th>Amputation of Lower Extremity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>RR (95% CI)</td>
<td>RR (95% CI)</td>
</tr>
<tr>
<td>T1DM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence</td>
<td>3.5 (1.5-7.9)</td>
<td>2.6 (0.7-9.7)</td>
<td>7.1 (2.6-19.7)</td>
</tr>
<tr>
<td>Incidence</td>
<td>4.5 (1.3-15.4)</td>
<td>1.6 (0.4-5.7)</td>
<td>6.0 (2.1-16.9)</td>
</tr>
<tr>
<td>T2DM, taking insulin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence</td>
<td>0.8 (0.4-1.4)</td>
<td>1.2 (0.6-2.4)</td>
<td>4.2 (2.3-7.9)</td>
</tr>
<tr>
<td>Incidence</td>
<td>1.2 (0.5-3.4)</td>
<td>2.9 (1.2-6.8)</td>
<td>3.4 (0.9-13.2)</td>
</tr>
<tr>
<td>T2DM, not taking insulin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence</td>
<td>0.3 (0.0-2.4)</td>
<td>2.9 (0.9-9.4)</td>
<td>5.2 (0.6-45.0)</td>
</tr>
<tr>
<td>Incidence</td>
<td>1.5 (0.2-12.5)</td>
<td>6.0 (1.1-32.6)</td>
<td>7.0 (0.8-64.4)</td>
</tr>
</tbody>
</table>

CI, confidence interval; RR, relative risk; WESDR, Wisconsin Epidemiologic Study of Diabetic Retinopathy; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus

Source: Table 9 from Klein R et al. (261)
In those with T1DM, while adjusting for age and sex, DR severity was associated with all-cause and ischemic heart disease mortality. In persons with T2DM, DR severity was associated with all-cause and ischemic heart disease mortality, as well as with stroke (262). After adjusting for systemic factors, these associations remained only for all-cause and stroke mortality in persons with T2DM. These findings suggest that severe DR is an indicator for increased risk of death, and may identify individuals who should be under care for CVD. Other studies have reported this finding (263-265). The higher risk of CVD in persons with more severe DR may be partially due to the association of severe retinopathy with CVD risk factors such as hyperglycemia, hypertension, platelet aggregation, and chronic renal disease.

**Prevention of Incidence or Progression of Diabetic Retinopathy**

The primary method currently used to prevent or retard the progression of DR is the judicious use of hypoglycemic agents. However, there is evidence that other treatments may also be protective. As noted above, studies have reported that angiotensin-converting enzyme inhibitors targeting the RAS (100,206,209), as well as fenofibrate (208,221), reduce the risk of progression of DR in those who are normotensive, independent of changes in blood pressure and the lowering of uncontrolled blood pressure (regardless of the antihypertensive medication used). However, RCTs of inhibitors of AR, PKC, and metalloproteinases have not shown efficacy in preventing the incidence and progression of DR in persons with diabetes (266).

**Current Treatment for Severe Diabetic Retinopathy**

Standard treatment for proliferative DR is still panretinal photocoagulation (267); for diabetic macular edema it is focal laser treatment (268). RCTs have shown the efficacy of
intravitreally administered VEGF inhibitors (269) and steroids in treating proliferative diabetic retinopathy and diabetic macular edema (270). However, steroid injections are associated with increased risk of high intraocular pressure (271), glaucoma (272), and cataract surgery (273). There are times when retinopathy is so severe that vitrectomy is needed to attempt to maintain or restore vision after the non-resolution of a vitreous hemorrhage and to decrease the risk of tractional retinal detachment (274). Such treatment, while not without its own risks, has been found (on average) to be successful in maintaining visual function (275) and is still the best alternative for late-stage proliferative disease.

Summary

While there is strong evidence of the efficacy of intensive glycemic and blood pressure control in persons with diabetes, and therapeutic guidelines for these treatments exist, recent findings from clinical trials suggest the each person be treated individually, balancing micro- and macrovascular risk against the risk of hypoglycemia and CVD mortality. The ACCORD trial clearly taught us that there’s no single recipe for glycemic management of CVD risk in T2DM. The old principles still hold: treat each patient as an individual and first do no harm (276).
Chapter 3. Microvascular Disease and the Brain

Introduction

Cognitive impairment is a common complication in T2DM (277). Compared to the general population, the risk of dementia is 1.5-2.5 times greater for adults with T2DM (278-280). Recent data suggest that microvascular pathologies play an important role in the associations among T2DM, Alzheimer’s disease (AD), and vascular subtypes of dementia, but little is known about the microvascular mechanisms underlying these associations. There is increased interest in illuminating these mechanisms in order to tailor and implement intervention strategies aimed at preventing dementia, AD, and cognitive decline in T2DM as well as in aging populations with T2DM risk factors.

Much work has focused on T2DM-related microvascular complications in peripheral organs systems, including the retina, kidney, and peripheral nerves. Although the brain is seldom discussed as a site of microvascular complications in T2DM, diabetes-associated vascular risk factors predispose individuals to both macro- and microvascular complications in the central nervous system (see table 4). In particular, T2DM is an established risk factor for cerebral small vessel disease, as well as thrombo-embolic stroke (281). Cerebrovascular damage in the form of small vessel disease is likely to be a major factor in the association between T2DM and dementia and could explain the increased risk of vascular dementia. Furthermore, data from experimental studies also suggest that metabolic disturbances associated with T2DM may accelerate the development of AD-type pathologies (282,283).
<table>
<thead>
<tr>
<th>Peripheral Microvascular Complication</th>
<th>Shared Microvascular Mechanisms</th>
<th>Brain Outcomes</th>
<th>WMH</th>
<th>Infarcts</th>
<th>CMBs</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinopathy</td>
<td>Arteriovenous nicking</td>
<td>Brain Atrophy</td>
<td>Cooper et al., 2006 (699)</td>
<td>Qiu et al., 2008 (700)</td>
<td>Qiu et al., 2008 (700)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Microhemorrhages</td>
<td></td>
<td>Cooper et al., 2006 (699)</td>
<td>Qiu et al., 2008 (700)</td>
<td>Qiu et al., 2008 (700)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Venular dilation</td>
<td>Ikram et al., 2006 (702)</td>
<td>Cooper et al., 2006; Ikram et al., 2006 (699,702)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nephropathy</td>
<td>Hypertension</td>
<td>Reviewed Beuchet et al., 2013 (703)</td>
<td>Verhaaren et al., 2013; King et al., 2013 (704,705)</td>
<td>Reviewed Loitfelder et al., 2012 (706)</td>
<td>Reviewed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Creatinine</td>
<td>Rajagopalan et al., 2013 (707)</td>
<td>Reviewed</td>
<td>Vogels et al., 2012 (708)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cystatin C</td>
<td>Rajagopalan et al., 2013 (707)</td>
<td>(709)</td>
<td></td>
<td>Unexplored</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glomerular filtration rate</td>
<td>Reviewed</td>
<td>Vogels et al., 2012 (708)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Islet amyloid polypeptide</td>
<td>Jackson et al., 2013 (299)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuropathy</td>
<td>Hyperglycemia</td>
<td>Manschot et al., 2007; Launer et al., 2011; Ursache et al., 2012 (336,342,712)</td>
<td>Manschot et al., 2007 (712)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AGES, RAGE</td>
<td>Hudson et al., 2011 (713)</td>
<td></td>
<td>Hudson et al., 2011 (713)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vitamin B12 deficiency</td>
<td>Tangney et al., 2011 (714)</td>
<td>Feng et al., 2013; de Lau et al., 2009; Tangney et al., 2011 (714-716)</td>
<td>Kealey et al., 2002 (717)</td>
<td>Tangney et al., 2011 (714)</td>
<td>Sm200</td>
</tr>
</tbody>
</table>

Abbreviations: WMH = white matter hyperintensities, CMBs = cerebral microbleeds; AGE = advanced glycation end product; RAGE = receptor for advanced glycation end product

*Unexplored common features in humans include: pericytes loss, microvascular reactivity, AGES, ROS, etc.
Mechanisms for Microvascular Complications

Hyperinsulinemia and Impaired Insulin Signaling

Insulin is known to have multiple functions in the CNS (284). While there is some controversy regarding whether insulin is synthesized in the adult brain, circulating insulin in the blood stream is readily transported across the blood-brain barrier (BBB) by a saturable, receptor mediated process (285-287). Hyperinsulinemia and insulin resistance may downregulate insulin transport across the BBB, leading to reduced insulin levels in the CNS (288). In select brain circuits (such as the hippocampus), insulin-containing neurons, insulin receptors, and glucose transporter isoforms 4 and 8 are co-localized (289), providing an infrastructure for insulin-stimulated glucose uptake into neurons to support cognitive function. In addition, other insulin-related mechanisms have also been implicated in normal hippocampal functioning (290). Insulin receptors are located in the synapses of both astrocytes and neurons where insulin signaling contributes to synaptogenesis and synaptic remodeling (290). Insulin also modulates CNS levels of neurotransmitters such as acetylcholine and norepinephrine that influence cognitive function (291,292). Given the multifactorial role of insulin in the brain, maintaining proper insulin homeostasis and insulin receptor activity may be essential for proper brain function and memory (289).

Chronic hyperinsulinemia is a key factor early in the process leading to insulin resistance and T2DM and may potentially mediate the relationships between T2DM and proinflammatory states, microvascular disease, and AD pathology. While anti-inflammatory effects are observed
with low doses of insulin, long-term hyperinsulinemia may exacerbate the inflammatory
response and increase markers of oxidative stress (293).

Intravenous infusions of insulin to levels associated with insulin resistance increased the
levels of F2-isoprostanes and cytokines in cerebrospinal fluid (294). Hyperinsulinemia may also
potentiate AD pathology (e.g., amyloid β [Aβ] plaques) by causing increased production but
reduced extracellular degradation of Aβ, impaired insulin signaling, oxidative stress,
inflammatory mechanisms, and coupling of neuronal components by AGEs (295). The amyloid
precursor protein produces Aβ (a peptide of 36–43 amino acids). While best known as a main
component of amyloid plaques in association with AD (e.g., Aβ42), there is evidence that Aβ is a
highly multifunctional peptide with significant non-pathological activity, including protecting
against metal-induced ROS, modifying cholesterol transport, and potentially acting as a
transcription factor (296). Hyperinsulinemia, at levels associated with insulin resistance, can
elevate inflammatory markers and Aβ42 in the periphery and the CNS, which may increase the
risk of AD (284). Interestingly, AD pathology may have direct effects on insulin receptors and
their signaling. Aβ regulates brain insulin signaling through the binding of soluble Aβ to the
insulin receptor and disrupts insulin signaling (297), suggesting interactions between T2DM,
and AD pathology.

Aβ aggregation also occurs outside the CNS and often is associated with increased cell
death (298). Aβ deposits also occur from the aggregation of the polypeptide hormone islet
amyloid polypeptide (IAPP). IAPP aggregates into Aβ deposits and may induce the depletion of
islet β-cells in T2DM (298). Aβ deposits are the most typical morphological islet lesion in
T2DM. A recent study reported mixed IAPP and Aβ deposits in the brains of patients with T2DM and vascular dementia or AD (299). The study found IAPP oligomers and plaques in the temporal lobe gray matter, blood vessels, and perivascular spaces in T2DM patients but not controls. The study also detected IAPP deposition in blood vessels and brain parenchyma of patients with late onset AD without clinically apparent T2DM.

**Hyperglycemia**

In many prediabetic adults, the degree of insulin resistance increases as insulin secretion by pancreatic cells declines, resulting in hyperglycemia of sufficient magnitude to warrant a T2DM diagnosis. Extracellular and intracellular hyperglycemia are two general pathophysiologic mechanisms by which hyperglycemia leads to irreversible tissue damage, even in prediabetic states (300). Chronic hyperglycemia (both cellular and extracellular) leads to glycation end product formation (discussed below). This may have particular effects on the endothelial cell where intercellular glucose appears to be a significant driver of microvascular dysfunction (see Chapter 1). It also contributes to heart disease, microvascular complications, intracellular hyperglycemia, and may increase the risk of developing dementia. Among participants without T2DM (random glucose <120 mg/dl), higher normal plasma glucose levels are associated with an increased risk of incident dementia (301); individuals with T2DM also had a similar relationship at glucose levels above 170 mg/dl (301). High glucose levels may contribute to an increased risk of dementia through several potential mechanisms, including acute and chronic hyperglycemia and insulin resistance (302) and increased microvascular disease of the CNS (303-306).
Extracellular hyperglycemia can lead to intracellular hyperglycemia through the increased flux of glucose freely across the cell membrane of many cell types. Excess intracellular glucose not used for energy will enter the polyol pathway, leading to decreased levels of NADPH (300). NADPH plays a central role in the production of NO and GSH. NO is an important vasodilator; therefore, reductions in NADPH may limit NO production with direct pathologic effects on vasodilation throughout the body, particularly in the kidneys and brain. NADPH also prevents ROS from accumulating and damaging cells, and thus reductions in NADPH can also increase oxidative stress (307).

**Oxidative Stress**

Oxidative stress in the cerebral parenchyma and blood vessels plays a critical role in the processes associated with cerebrovascular dysfunction, with NADPH oxidase being a major source of ROS (308-310). ROS can alter vascular regulation through processes involving the formation of peroxynitrite from the reaction between NO and superoxide radical. Oxidative stress and ROS resulting from mitochondrial dysfunction have, consequently, been strongly implicated in brain aging, AD, and vascular dementia (307,311). Overall, several factors related to hyperglycemia may contribute to a chronic hypoperfusive state leading to microscopic tissue damage and regional specific syndromes (312).

**Advanced Glycation End Products**

Another direct result of high circulating levels of unbound glucose is the formation of AGEs. AGEs accumulate with age in the human brain, and may be one possible mechanism linking T2DM to cognitive impairment (313). One study found AGEs in hallmark
neuropathologic features (e.g., neurofibrillary tangles and Aβ plaques) in patients with AD (314). Older adults with cerebrovascular disease have higher AGEs in cortical neurons and cerebral vessels, which are related to the severity of cognitive impairment (315). RAGE likely plays an important role in the brain with respect to inflammation (316) and AD pathology. RAGE is expressed in astrocytes, microglia, and neurons, as well as being highly expressed in the endothelial cells within the brain (317). RAGE expression in the endothelium has important consequences for vascular inflammation and BBB integrity (318). BBB integrity is an essential factor in Aβ equilibrium in the brain, which is regulated through the LDL receptor related protein 1 and RAGE. The RAGE protein mediates the influx, and the LDL receptor related protein 1 mediates the efflux of amyloid protein through the BBB (317). Patients with T2DM not only produce endogenous AGEs at a higher rate, but they have an upregulation of RAGE expression in the brain (319). Increased RAGE expression in the T2DM brain might create an imbalance between the rates of influx and efflux of Aβ through the BBB, promoting uptake of Aβ into the brain and subsequent deposition of Aβ plaques (320).

**Summary of Mechanisms**

The characteristic metabolic deregulation of T2DM promotes changes in insulin signaling, glucose uptake, ROS formation, and inflammation in the microvasculature that affect BBB integrity. In the brain, hyperinsulinemia promotes insulin resistance and reduced insulin signaling, which is essential to glucose uptake, amyloid regulation, and vascular function. T2DM-associated hyperglycemia leads to the formation of proinflammatory AGEs, which increase RAGE expression in the endothelium and brain. RAGE expression is thought to play a
crucial role in BBB integrity through regulating inflammation and the flux of Aβ across the BBB. These factors likely play important roles in the development of microvascular brain complications and AD pathology seen in T2DM. Considerable progress has been made in imaging microvascular complications and Aβ pathology in living humans, which has enabled a better characterization of microvascular disease in the brain.

**Assessment of Brain Complications in Type 2 Diabetes Mellitus**

Neuroimaging is currently the best way to examine the effects of microvascular disease and other brain abnormalities on the human brain *in vivo*. Neuroimaging techniques aimed at studying microstructural cerebral small vessel disease are the most common. More recent advances enable the imaging and quantification of microstructural abnormalities of the brain, as well as functional abnormalities, including regional cerebral blood flow and functional activation. Recently, concerted efforts to standardize the study of small vessel disease resulted in a position paper from the Standards for Reporting Vascular Changes on nEuroimaging (321). This paper sets the groundwork for the systematic evaluation of brain structure and function necessary for research using *in vivo* brain imaging.

**Brain Atrophy**

Longitudinal observational cohorts of brain aging in the general population have shown that brain volume declines across the age range (322). After adolescence, the total brain volume tends to slowly decrease with age, until the 5th to 6th decade of life when volume loss accelerates (323,324). The average rate of decline is estimated to between 0-4%/year (324,325). It is generally accepted that atrophy is not consistent across brain regions and tissue...
compartments (324,326,327). Brain atrophy is thought to be a result of both macrovascular and microvascular abnormalities in the brain.

T2DM is associated with greater total brain atrophy (328,329), with possible preferential gray matter volume loss in cerebrum (329), putamen (329), medial temporal (330-332) and frontal (331,333) regions. The longitudinal decline in total cerebral brain volume is associated with increasing age, T2DM, hypertension, current smoking, and evidence of cerebral small vessel disease (334). Cerebellar atrophy shares similar risk factors with longitudinal cerebral atrophy, including T2DM, higher serum glucose, and evidence of cerebral small vessel disease (334), but appears to be unrelated to hypertension and smoking or heavy drinking (325,334).

While cerebral and cerebellar volumes do not entirely overlap, T2DM is the strongest common factor related to smaller volumes in both parts of the brain (334). T2DM is associated with enlargement of the ventricles and higher white matter hyperintensities (WMHs) (335); individuals with T2DM also had greater longitudinal changes in these measures over 4 years of follow-up, resulting in smaller brain volumes and increases in WMHs and ventricle enlargement (335).

Recently, studies have directly assessed the relationship between insulin sensitivity and regional brain volume differences. Higher basal insulin resistance, assessed by the homeostatic assessment of insulin resistance, was associated less gray matter in hippocampus and prefrontal regions of the brain among adolescents and young adults without T2DM (336). In cohorts of late middle-aged adults, homeostatic assessment of insulin resistance was associated with progressive atrophy in regions affected by early AD (337) and with worse cognitive performance (338). In
longitudinal studies, higher fasting insulin showed small but significant correlations with gray
matter atrophy in orbitofrontal cortex and hippocampus (339). Some studies, however, have not
found a relationship between insulin resistance and hippocampus volume in late middle-aged
(340) or elderly (341) adults.

The pathological basis for this T2DM-associated global and regional brain atrophy still
needs to be resolved. It is likely that T2DM-associated factors including glucose homeostasis and
insulin resistance play central roles. Yet, the results from the ACCORD-Memory in Diabetes
clinical trials provide an important caveat when considering the effect of glucose control on brain
structure (342). They showed that intensive glycemic control targeting HbA1c to less than 6.0%,
compared to standard strategy targeting HbA1c to 7.0-7.9%, resulted in slightly greater total
brain volume, but did not enhance cognition. Intensive therapy was also associated with
abnormal white matter and increased mortality in the intensive therapy arm. The findings from
the ACCORD-Memory in Diabetes trial thus do not support intensive therapy to reduce the
adverse effects of T2DM on the brain (342). However, these relationships are likely to be
mediated by more detailed evidence of cerebrovascular disease and brain integrity. Atrophy is a
relatively crude tool when used to assess microvascular complications in the brain.

### Alterations in Cerebral Blood Flow and Glucose Utilization

Clinicians can measure changes in innate brain function relating to cerebrovascular
function and glucose utilization by positron emission tomography (PET) using the
fludeoxyglucose F18 ligand (FDG-PET) and by MRI through measures of cerebral blood flow
(CBF) and functional connectivity known as functional MRI (fMRI) (Figure 6). FDG-PET
provides insight into regional glucose metabolism in the brain and changes in regional CBF.

Figure 6. Neuroimaging measures related to cerebral small vessel disease and concomitant pathologies

<table>
<thead>
<tr>
<th>MRI</th>
<th>Recent Small Subcortical Infarct</th>
<th>White Matter Hyperintensity</th>
<th>Lacunar Infarct</th>
<th>Perivascular Space</th>
<th>Cerebral Microbleed</th>
<th>Regional Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Best identified on DWI</td>
<td>Located in white matter</td>
<td>Usually have hyperintense rim</td>
<td>Most linear without hyperintense rim</td>
<td>Detected on GRE seq., round or ovoid, blooming</td>
<td>Quant ASL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PET</th>
<th>Glucose Utilization</th>
<th>Amyloid Deposition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FDG-PET</td>
<td>Amyloid-PET</td>
</tr>
</tbody>
</table>

PET: positron emission tomography; GRE, gradient echo sequences; DWI, diffusion weighted imaging; FDG, frontotemporal dementia

Changes in CBF and glucose utilization on FDG-PET are thought to reflect synaptic dysfunction among regional brain networks. AD is characterized by a pattern of reduced CBF and cerebral glucose hypometabolism. Reductions in FDG-PET are associated with increased AD risk and can be observed years before dementia onset (343,344). Reductions in FDG-PET and CBF are also present in T2DM. Among individuals with prediabetes and T2DM, greater insulin resistance was associated with an AD-like pattern of reduced cerebral glucose metabolic rate in frontal,
parietotemporal, and cingulate regions of the brain (345). Among cognitively normal individuals with a family history of AD, higher fasting glucose levels were significantly associated with lower cerebral glucose metabolic rate in areas differentially affected by AD (346). FDG-PET imaging studies suggest that hypometabolism of glucose in the brains of individuals with T2DM and those who go on to develop AD may be a product of a generalized metabolic dysregulation of glucose. A recent study showed that impaired glucose tolerance measured in mid-life was associated with longitudinal changes in regional CBF as measured by (15)O-water PET scans (347).

Although MRI-defined total CBF is associated with cognitive functioning, there appears to be no relative differences in total CBF between T2DM patients and controls (348). T2DM-related alterations in CBF may be regionally specific (349). In T2DM, total CBF is associated with impaired cognition and total brain volume in cross-sectional analyses, but does not appear to predict changes in cognition or brain volumes over time (350). Similar patterns have been reported with resting state fMRIs for insulin-resistant adults (351). Individuals with T2DM have reduced functional connectivity in brain networks related to AD compared with control subjects, which was associated with insulin resistance in selected brain regions, even when there were no observed between-group differences in brain structure or cognition. Taken together, PET and MRI studies of CBF suggest early alterations occur throughout the brain in areas affected by AD, and these reductions in CBF co-localize with areas of reduced glucose utilization in the brain.
**Microvascular Ischemia**

Ischemia due to microvascular disease manifests itself in several ways in T2DM, including WMHs, subtle alterations in white matter integrity, and lacunar or micro-infarction (figure 6). White matter abnormalities are frequently detected as hyperintense regions on T2-weighted MRIs of the brain in an age-dependent fashion, especially in adults older than 60 years (352), and may be associated with increased relative risk of stroke and the presence of retinal microvascular abnormalities (352). Studies of WMH in T2DM show no consistent association. Discrepancies from early studies were attributed to methodological issues, including the use of crude visual rating scales (353). Studies using semi-quantitative rating scales find more consistent relationships between WMH and T2DM, as well as HbA1c and diabetes duration (354). However, while some more recent studies using quantitative techniques to quantify WMH volume show greater WMH volumes in T2DM compared to controls (355), others do not (329). Diabetes duration, HbA1c and insulin levels, blood pressure, and the presence of infarcts have all been linked to WMH severity (354,356).

WMH can be considered a downstream event of microscopic white matter abnormalities that exist before they can be visualized on T2-weighted MRI (357,358). MRI can quantify white matter integrity in several ways. White matter swelling related to fluid influx can be visualized by magnetization transfer imaging (MTI). MTI is a quantitative MRI technique that detects subtle tissue differences that occur with brain aging, beyond the accumulation of WMH and brain atrophy. MTI correlates with macromolecular attenuation, and therefore is believed to largely reflect myelin content. Hypertension and T2DM are associated with abnormalities in
MTI within the brain (359). Diffusion tensor imaging (DTI) is another form of MRI used to assess the microstructural integrity of the brain. DTI measures the diffusion (movement) of water molecules within each voxel. For example, water molecules restricted by dense membranes move less than unrestricted molecules. DTI is used to assess neuronal density in the gray matter. DTI enables the tractography of white matter tracts, which cannot be resolved using traditional MRI techniques. Furthermore, DTI enables the quantification of white matter integrity within the tracts in axonal and radial directions. Fractional anisotropy is a composite of the axonal and radial diffusivity of water molecules perpendicular to (radial) and along (axonal) the individual white matter tract. In simple terms, proper integrity of white matter tracts should result in high axonal diffusivity and high FAs along the tract. Axonal breaks and rarefication of the surrounding myelin result in lower diffusion of water molecules in the axonal plane and more diffusion in the radial plane, resulting in lower FAs. Several studies using DTI show WM integrity may be compromised in children with T1DM (360,361) and adults with T2DM (329,362,363). T2DM is associated with lower FAs in the total white matter, greater bilateral mean diffusivity for the hippocampus and dorostral prefrontal cortex, and greater lateralized mean diffusivity for the posterior cingulate and right putamen (329). Studies reporting differences in white matter microstructure between controls and T2DM patients do not report significant differences in WMH derived by conventional MRI scans. The associations between T2DM and lower FAs along select white matter tracts extends to other T2DM-related conditions including metabolic syndrome (364) and depression (365).
Lacunar infarction is another form of microvascular brain disease that produces a round or ovoid, subcortical, fluid-filled cavity (visible by brain computed tomography, or MRI [signal similar to cerebrospinal fluid]) that is between 3-15 mm in diameter, consistent with a previous acute small subcortical infarct or hemorrhage in the territory of one perforating arteriole (321). It is estimated that lacunar infarcts account for 25% of all ischemic strokes, with an annual incidence of approximately 15 per 100,000 people (366). A meta-analysis of studies with brain MRI in patients with T2DM showed that there was a significant association between T2DM and lacunar infarcts. Compared to the general population, the odds of having lacunar infarction is 1.3 times higher among individuals with T2DM and 2.2 times higher for those with concomitant vascular disease (328). T2DM modifies the risk of short-term mortality and stroke recurrence among individuals with lacunar infarction. In patients with recent lacunar stroke, T2DM independently predicted ischemic stroke recurrence (367) and short-term and 5-year mortality (366).

Recent data suggests that T2DM may be more likely to contribute to the formation of small lacunes (368). Researchers have hypothesized that small lacunes (≤7 mm) have probable lipohyalinotic etiology, and that larger lacunes (8-20 mm) result from microatheroma. The presence of lacunes ≤7 mm was significantly associated with age, black ethnicity, hypertension, ever-smoking, T2DM, and HbA1c. The same risk factors predicted infarcts with lacunes <3 mm. Interestingly, lacunes 8-20 mm in size, had a risk factor profile more indicative of atherosclerosis that was not associated with T2DM. Taken together, factors related to T2DM, such as HbA1c, may be more likely to contribute to the formation of smaller lacunes (even those <3 mm) than
the formation of larger lacunes. Further research focused on cardiometabolic risk factors contributing to lacunar infarction size will elucidate the mechanisms that atherosclerosis and T2DM share.

Even smaller, cerebral microinfarcts (CMIs) are attracting increasing attention in microvascular brain research. They are considered to be the single most widespread form of brain infarction and thus a major component of the causal pathway between microvascular disease and cognitive dysfunction (369,370). Autopsies reveal CMIs in around 43% of patients with AD, 62% of patients with vascular dementia, and 24% of non-demented elderly subjects (350). CMIs are typically defined as sharply delineated microscopic ischemic lesions accompanied by cellular death or tissue necrosis, often associated with gliosis and cavitation (371). CMIs can occur in both the white matter and subcortical regions of the brain, presumably more so in watershed areas (350). Because of their small sizes (ranging from 50 μm to a few mm), CMIs escape detection by regular clinical MRI protocols. The introduction of high-field-strength 7.0 Tesla MRI, with its high-resolution imaging and isotropic voxel sizes in the submillimeter range, permits clinicians to see CMIs in vivo (372).

In autopsy studies, CMIs were associated with increased measures of neuroinflammation, such as an elevated interleukin-6 concentration in the cortex. Of specific interest, in subjects with both T2DM and dementia, researchers observed different patterns between individuals who have or have not received medical diabetic therapy. Treated diabetic patients with dementia had the highest number of CMIs in the striatum, thalamus, and deep white matter (373). The association
between cerebral injury and diabetes treatment in T2DM patients with dementia could have etiologic or therapeutic implications.

**Non-Ischemic Microvascular Complications**

Microvascular injury can also manifest as non-ischemic pathology, such as cerebral microbleeds (CMBs), enlarged perivascular spaces, evidence of BBB breakdown, and cerebral amyloid deposition. Human studies on aging and neurodegeneration currently utilize ever-developing technology for measuring these lesions.

CMBs are visible in MRIs (374) (figure 6). CMBs commonly occur in patients with stroke, as well as in the general elderly population. The prevalence of CMBs in community-dwelling older adults is as high as 11.1-23.5% (375,376). The presence of CMBs predicts the development of new CMBs (377). Some controversy remains as to whether T2DM predisposes individuals to CMBs (378). However, results from a meta-analysis showed that both T2DM and hypertension were associated with having more than a 2-fold increase in the odds of having CMBs (379). CMBs appear to co-localize with Aβ deposits in brain tissue samples from non-demented older adults, suggesting a shared etiology (380). PET imaging that uses amyloid specific ligands (e.g., PiB-PET) has opened new avenues to study amyloid deposits in the brain in vivo. One small study measured amyloid PET in AD patients with and without T2DM and found that the amyloid accumulation in AD patients was greater than in controls, but did not differ by T2DM status (381). A recent study using PiB-PET in a convenience sample of older adults found no association between serial measures of glucose intolerance and insulin resistance and in vivo brain β-amyloid burden (382).
Enlarged perivascular spaces (EPVS) (also called Virchow-Robin spaces) are visible on T2-weighted MRIs and thought to represent the ex-vacuo dilatation that’s secondary to cerebral tissue shrinkage after demyelination and axonal loss (383,384) (figure 6). Once thought to be a normal phenomenon of aging, more recent studies show EPVS are associated with atherosclerosis (385), dementia, and with other markers of microvascular disease (386,387). EPVS are found in young patients with T1DM (388) and have yet to be examined in T2DM. EPVS may be indicative of perivascular cells (pericytes and vascular smooth muscle cells), which are important regulators of vascular formation, stabilization, remodeling, and function (389). Pericytes are integral components of the BBB and have a dramatic impact on microvascular integrity. They surround capillaries, contain contractile proteins, and are thought to regulate blood flow (390) and permeability (391). Notably, a loss of brain pericytes and resulting BBB breakdown have been shown to impair CNS function through leakage and by depositing several potentially vasculotoxic and neurotoxic blood-derived macromolecules, including fibrin, thrombin, plasmin, and hemoglobin-derived hemosiderin, which causes accumulation of iron and ROS (392). Research suggests that the loss of pericytes in the brain parallels pericyte loss in DR, leading to the breakdown of the BBB (393). There are currently no neuroimaging techniques that enable us to see pericytes directly. Developing novel neuroimaging techniques, such as PET ligands specific for pericytes, may elucidate the in vivo role of pericyte loss in neurodegeneration and diabetes.

The cerebral microvascular endothelial cells, capillary BM, astrocyte endfeet, and pericytes are the structural components that comprise the BBB. The BBB regulates the normal
neuronal and glial cell environment (394) by regulating the passage of circulating elements from blood into the brain. We are becoming increasingly more aware of changes in BBB integrity associated with aging and microvascular disease. Permeability of the BBB is an important aspect of microvascular complications in the brain and can be imaged \textit{in vivo} using a MRI with intravenous gadolinium contrast enhancement (395). Post-contrast enhancement of brain parenchyma and increased signal intensity in the cerebrospinal fluid are presumed indicators of increased BBB permeability, and we see these changes in patients with T2DM (396). Post-contrast signal intensity increased more in the diabetic group than controls after administering gadolinium-diethylene triamine pentaacetic acid, particularly in the basal ganglia, an area known to be particularly vulnerable to cerebrovascular disease. The effects of T2DM on the BBB may contribute to increased risk of AD. Constituents of the endothelium, including RAGE, are important risk factors to consider when investigating T2DM-related BBB breakdown. Several novel neuroimaging techniques, including super paramagnetic nanoparticles and PET imaging ligands designed to image the BBB and its disruption, will provide useful tools for investigating BBB breakdown in the future.

\textbf{Summary and Conclusions}

Adults with T2DM have an increased risk of dementia as they age. T2DM and its associated factors predispose individuals to both micro- and macrovascular complications throughout the body and brain. Recent neuroimaging studies show that patients with T2DM go on to develop structural and functional brain abnormalities similar to older adults with dementia. Many of the strongest neuroimaging markers of brain abnormalities seen in T2DM are related to
microvascular disease. Furthermore, individuals who have evidence of metabolic deregulation (hyperglycemia and insulin resistance), but do not have T2DM, show similar structural and functional brain abnormalities to those with frank T2DM. There is evidence that individuals with T2DM-associated microvascular complications in the periphery have an elevated risk of having microvascular complications in the brain. Future research will determine if the putative causal factors resulting in microvascular complications in the body (e.g. insulin resistance, hypertension, oxidative stress, and AGEs) mediate the observed associations between T2DM and brain microvascular abnormalities. Understanding the causes of microvascular disease in the brain associated with T2DM will provide targets for preventing cognitive decline and dementia in patients with T2DM.
Diabetic microvascular disease is usually associated with eye, nerve, and renal injury. However, diabetes is a pervasive microvascular disease with functional consequences in tissues outside of those commonly associated with the disease. In this section we review microvascular changes in skeletal and cardiac muscle, adipose, and skin, highlighting structural and functional changes that result from chronic hyperglycemia and from other factors that accompany diabetes. The retinal, renal, and neural pathology that accompanies diabetes arises in each case from disease/dysfunction of a very small mass of vessels in critical areas. However, for skeletal and cardiac muscle, adipose, and skin, we are dealing with a larger set of microvascular target vessels, which, where dysfunctional, can impact general metabolic function.

Skeletal Muscle Microvasculature: Structural and Functional Changes that Accompany Diabetes and Insulin Resistance

A study using electron microscopic methods to examine pathologic changes in tissues from patients with diabetes reported that the BM of the microvasculature within skeletal muscle was thicker in diabetic than in healthy control subjects (397). The study also suggested that this change might occur early after the onset of diabetes or even precede frank hyperglycemia (397). However, subsequent work suggested that BM thickening correlated well with diabetes duration and glycemic control (398). Some initial confusion may have arisen as a result of different fixation methodologies for preparing tissues for electron microscopy (399), as well as differences related to which muscle group was biopsied (vastus lateralis, gastrocnemius, or neck muscles).
Most experts now agree that the degree and duration of hyperglycemia appear to be important predictors of BM thickness. Research also indicates that despite increased thickness of the BM, the peripheral vasculature in individuals with established diabetes appeared to be more “leaky” compared with non-diabetic controls. Studies most commonly defined “leaky” as the escape of radio-labeled albumin from the systemic circulation. Though these studies used albumin as the tracer, other plasma proteins and lipoproteins also exit plasma at an accelerated rate. In the wall of larger arteries, this leakage from the vasa vasorum may contribute to the increased atherosclerosis that accompanies diabetes.

Over several decades, more has been learned about the composition of the BM and how diabetes affects it. The principal proteins include type 4 collagen, laminin, perlecan, and nidogen/entactin. These proteins include several different isoforms, and the relative abundance and combinations of specific isoforms differ in various vascular beds. There are also a large number of other proteins present in smaller quantities. The biochemical composition of the BM in diabetes suggested that accumulation of glycosylated and cross-linked proteins contributed to the expanded membrane structure and disordered function. The non-enzymatic glycosylation of these proteins (like that of intracellular proteins), as well as cross-linking of the BM structural proteins by reactive carbonyl compounds like methylglyoxal (see chapter 1), can affect endothelial cell/ECM interactions.

The pericyte is another important support component of the muscle microvasculature. As described elsewhere, pericyte loss is an early finding in the genesis of DR. In the kidney, changes in mesangial cell function (the glomerular cognate of the pericyte) contribute to the
glomerular pathology of diabetes. Within skeletal muscle and many other tissues, pericytes and smooth muscle cells line the vessels down to the level of the capillary. Though originally thought to play principally a support and contractile function, it appears more likely that these cells may play a more dynamic role in regulating multiple functional aspects of the microvasculature (407).

For example, pericytes appear to play an important role in angiogenesis within the microvasculature; they also participate in the formation of the BM that envelops the endothelium. Within skeletal muscle, diabetes decreases the density of pericytes (401,408). It is not certain whether this is one of the factors leading to muscle capillary rarefaction that is seen in diabetes (409) as well as in persons with hypertension or with simple obesity (410). It is of interest that insulin resistance is a common trait among these latter disorders and impaired insulin action on muscle vascular elements may underlie this loss of capillary numbers. This has also been nicely demonstrated in animal models of obesity and insulin resistance where decreased NO availability was implicated as potentially causative (411). In addition to changes in skeletal muscle capillary numbers, diabetes is associated with changes in the capillary architecture which affect the perfusion pattern within the muscle (412).

One study reported that muscle-specific VEGF-deficient mice have capillary rarefaction in both skeletal and cardiac muscle, and this is accompanied by decreased insulin action on skeletal muscle glucose uptake during a euglycemic clamp (413). Glucose uptake in response to insulin was normal when these muscles were excised and studied in vitro, suggesting that the capillary rarefaction was responsible for at least a significant fraction of the metabolic insulin resistance observed. Likewise, a second study reported that mice deficient in insulin receptor
substrate 2, specifically in the endothelium, have in vivo metabolic insulin resistance during the euglycemic clamp (414). This appears to be secondary to impaired insulin signaling to activate NO synthase and increase NO production. Interestingly, the study also reported that endothelial cells from control mice placed on a high-fat diet demonstrated decreased IRS-2 protein content, as well as impaired insulin-mediated glucose disposal. The study did not examine microvascular rarefaction. However, it did report that in control mice, insulin increased capillary recruitment (a process by which insulin, exercise, and other factors increase the fraction of capillaries within muscle that are perfused at any point in time); this did not occur in high fat-fed or endothelial cell specific IRS-2 knockout mice.

These last two studies begin to probe the relationship between microvascular perfusion, capillary density, and metabolic function in muscle. Preceding that work, there are several decades of publications indicating a clear relationship between insulin’s metabolic actions in muscle and insulin’s action on the vasculature (both large conduit vessels, resistance vessels, and the microvasculature) that supply skeletal muscle. By the mid-1990s, it was reasonably established that changes in insulin concentration (using the insulin clamp technique) could modify total blood flow to muscle, and that states of insulin resistance [including obesity (415), T1DM (416), and T2DM (417)] blunted this effect. Presumably, this effect was principally mediated by actions on resistance arterioles, which, along with the microvasculature, regulate total blood flow to muscle. With the development of several methods to specifically measure muscle microvascular blood flow (418,419) and the distribution of blood flow within the muscle, it became apparent that insulin also significantly enhanced the recruitment of capillaries that
were relatively less perfused or unperfused within resting skeletal muscle. Both insulin’s effect on resistance arterioles and insulin’s effect on the smaller fourth- or fifth-order arterioles that regulate muscle flow distribution require intact signaling to NO synthase (420,421). Insulin’s microvascular effect (like its effect on resistance arterioles) was impaired in states of insulin resistance (including diabetes) and correlated strongly with insulin’s metabolic effects within skeletal muscle in both experimental animals (422-424) and humans (425-429).

Even very modest exercise recruits capillaries within human skeletal muscle (430) and the effect appears stronger than that of insulin. Furthermore, the effect of exercise persists unabated in insulin-resistant states. The fact that expanding capillary surface enhances insulin (and nutrient) delivery to muscle (67) may, in part, explain the insulin-sensitizing effect of exercise.

Two aspects related to impaired skeletal muscle microvascular insulin action and its metabolic consequences are of particular interest. First, while this impairment is quite evident in individuals with diabetes, it is also apparent in other states of insulin resistance, like metabolic syndrome or simple obesity. As such, this microvascular dysfunction affects even a larger segment of the general population. This is of significant concern, since both obesity alone and metabolic syndrome increase CVD risk (431). Second, clearly different mechanisms are likely involved. Diabetes microvascular injury appears to be provoked (in many tissues) by excess glucose metabolism by the endothelial cell, which results in enhanced glycolytic activity, greater AGE formation, mitochondrial ROS production, and increased PKC activity (64). Since endothelial cell glucose metabolism occurs in an insulin-independent fashion, but is proportional
to the degree of glycemia, it clearly involves a separate mechanism from that seen in normoglycemic insulin-resistant obese or metabolic syndrome subjects. The latter may involve nutrient overload by FAs or other nutrients (432), although the relationship between obesity (or even T2DM) and increases in circulating concentrations of non-esterified FAs is not without controversy (433).

**The Myocardial Microcirculation in Diabetes**

The coronary microvasculature plays a dynamic role in the regulation of coronary blood flow to meet the oxygen and nutrient demands of the myocardium. As the heart's microvascular bed provides endothelial surface area to facilitate the delivery of oxygen, nutrients, and hormones, and the removal of metabolic end products from the myocardium, changes in the cardiac microvascular blood volume and flow could profoundly affect myocardial metabolism, function, and health.

The coronary circulation is composed of the arterial (epicardial coronary arteries down to 200 μm arterioles), microcirculatory (arterioles <200 μm, capillaries, and small venules <200 μm) and the venous (200 μm venules to coronary sinus) compartments with a total blood volume of ~ 12 mL/100 gram cardiac muscle, which is distributed near evenly among these three compartments (434,435). While most of the arterial and venous blood volumes are located on the epicardial surface of the heart, the microvascular compartment is exclusively located within the myocardium and constitutes ~ 90% of the myocardial blood volume (434). Compared with other insulin sensitive tissues (e.g., skeletal muscle and adipose tissue), myocardium has a much larger endothelial surface area (per gram of tissue). Within the myocardium, endothelial cells
outnumber cardiomyocytes by three to one, and each mm² myocardium contains 3,000-4,000 capillaries, which run parallel to cardiomyocytes (435,436). At rest, only ~ 50% of myocardial capillaries are perfused (437). When myocardial oxygen demand increases, myocardial blood flow velocity and/or volume increase to meet demand.

In addition to providing endothelial exchange surface area, the myocardial microvasculature also actively regulates capillary hydrostatic pressure, which is critical for maintaining cellular homeostasis and health (438), resulting in a constant coronary blood flow over a wide range of coronary driving pressures (~ 45 - 120 mmHg) (435). The largest drop in pressure from the mean aortic pressure of ~ 90 mmHg to the capillary hydrostatic pressure of ~ 30 mmHg occurs in the arterioles smaller than 100 µm in diameter. Tone in these vessels responds to autonomic control and to local metabolites (439). Together, the arterioles confer ~ 60% of total myocardial vascular resistance, while capillaries account for ~25% and venules ~15% (435,437,440). Unlike the arterioles that regulate myocardial blood flow, resistance, and volume by vasodilation or vasoconstriction, capillaries, which lack a smooth muscle component, do so via their recruitment or decruitment driven by arteriolar tone (437).

Coronary blood flow is regulated by many physiological factors including catecholamines, adenosine, exercise, insulin, and glucagon-like peptide 1 (GLP-1). Adenosine is a potent vasodilator, which has been widely used clinically to assess coronary blood flow reserve. Exercise is probably the most important and potent physiological stimulus to increase myocardial blood flow. The increase in oxygen demand of the left ventricle during exercise is mainly met by augmenting coronary perfusion via capillary recruitment and the dilatation of
coronary microvessels, as oxygen extraction is nearly maximal at rest (70-80%) (441). Insulin also increases coronary blood flow in humans (442-448), suggesting a vasodilatory action on coronary vasculature. Studies using myocardial contrast echocardiography (a non-invasive technology that employs perfluorocarbon gas containing microbubbles to noninvasively assess \textit{in vivo} perfusion of the cardiac microvasculature) (449-451) have shown that insulin potently increases cardiac microvascular perfusion in healthy humans (427,452,453). This finding extends a prior report that mixed meal feeding significantly increased cardiac microvascular perfusion in healthy but not in T2DM humans (454). The postprandial increase in cardiac microvascular perfusion is likely multifactorial. In addition to stimulating insulin secretion, the mixed meal induces the secretion of incretins, and at least one of these incretins (GLP-1) increases coronary blood flow independent of insulin (455,456). It is very likely that GLP-1 also regulates coronary microvascular perfusion, as studies recently reported that GLP-1 recruits microvasculature and enhances insulin delivery and glucose use in skeletal muscle (457,458). Researchers have yet to define the mechanisms underlying myocardial capillary recruitment, and these mechanisms likely vary based on the particular stimuli. In skeletal muscle, insulin and GLP-1 recruit muscle microvasculature via a NO-dependent mechanism (457,459-461), while exercise-induced muscle microvascular recruitment is largely NO-independent (462). It’s possible that in myocardium both insulin and GLP-1 act via the NO-dependent mechanism, and exercise recruits myocardial capillaries perhaps by increased metabolic responses of the small arterioles.

Patients with diabetes have accelerated coronary artery disease and are prone to develop diabetic cardiomyopathy. Among many possible contributors are microvascular abnormalities. The morphological changes of small vessels seen in diabetic myocardium are extensive,
including peri-arterial fibrosis, arteriolar thickening, focal constrictions, microvascular tortuosity, capillary BM thickening, capillary microaneurysms, and decreased capillary density (463,464). In addition to structural abnormalities, coronary microvascular dysfunction also occurs in diabetes. Indeed, the maximal coronary flow reserve is reduced and endothelium-dependent coronary vasodilation is clearly impaired in diabetes, even in the presence of angiographically normal coronary arteries and normal left ventricular systolic function (465,466). The reduction in myocardial blood flow reserve correlates significantly with average fasting glucose concentrations and HbA1c (467), confirming the importance of glycemic control in the maintenance of cardiac health. In patients with T1DM and normal exercise echocardiography and autonomic nervous function, myocardial blood flow (measured with PET and $[^{15}O]H_2O$) is ~30% lower, and total coronary resistance is 70% higher than normal healthy controls during hyperemia (468).

Endothelial dysfunction and insulin resistance, two core defects associated with diabetes, are both present in the coronary circulation and are likely the major early cause of coronary microvascular dysfunction. Quantitative angiographic analysis of epicardial coronary artery responses to stepwise intracoronary acetylcholine infusion clearly demonstrates impairment in endothelium-dependent dilatation in diabetic patients with no significant coronary atherosclerosis (466). Vasodilation of the coronary microcirculation in response to sympathetic stimulation evoked by the cold pressor test is also impaired in T2DM patients in the absence of significant epicardial coronary artery lesions (469). Though insulin-mediated increases in coronary blood flow are maintained in young patients with T1DM without microvascular complications or autonomic neuropathy (443,445), it is blunted in patients with obesity (470) or
T2DM (444). Raising plasma insulin concentrations by ~ 8-fold by ingesting a mixed meal not only fails to increase cardiac microvascular perfusion, as is seen in healthy humans, but actually induces a paradoxical decrease in many patients with diabetes (454,471). In the acute insulin resistant state induced by systemic lipid infusion, the myocardial microvascular response to insulin is clearly blunted (427). However, pretreatment with salsalate, an anti-inflammatory agent that inhibits the NF-κB pathway, preserves the microvascular response to insulin (453). These findings are consistent with a prior report that free FAs cause endothelial insulin resistance via NFκB activation (472). Another potential contributor to coronary microvascular dysfunction is the increased blood viscosity seen commonly in patients with diabetes. Hypertriglyceridemia, a common feature of insulin resistance and insulin deficiency, increases blood viscosity and decreases coronary blood flow (473).

In patients with fixed stenosis in major coronary arteries due to coronary atherosclerosis, blood supply to the myocardium is limited. Although resting epicardial coronary blood flow remains normal until >85% of the lumen is obstructed, during hyperemia total flow is reduced when the stenosis exceeds 50% (474-476), and both microvascular blood volume and flow velocity are depressed (475,477). Under this circumstance, expansion of the coronary microvascular blood volume could markedly increase the endothelial exchange surface area. The presence of insulin resistance in the coronary microvasculature could further limit the microvascular blood volume and the capability of cardiac muscle to extract oxygen and nutrients and receive signals from circulating anabolic factors. This may explain partly why patients with diabetes tend to develop cardiac complications including cardiomyopathy and heart failure. This
also suggests that the coronary microvascular endothelial dysfunction and insulin resistance
could be important therapeutic targets in reducing cardiac morbidity associated with diabetes.

**Microvascular Disease/Dysfunction in the Skin**

The skin microvasculature plays an important physiologic role in the body’s defenses
against thermal and mechanical injury and pathogen entry by maintaining the health of the
keratinized epithelium of the epidermis, as well as the supporting dermis and subcutaneous
tissues. Diabetes can injure the skin’s microvasculature, which could compromise the skin
barrier and allow trans-cutaneous microbe migration. Pathologically, thickening of the BM and
loss of pericyte coverage for microvessels characterizes injury to the skin’s microvasculature,
similar to responses in other tissues. The vessels leak plasma proteins, and perhaps as a
consequence of this leaking or as a consequence of hyperglycemia, the supporting connective
tissue becomes more cross-linked and “stiff”. Microvascular injury may play a role in the
development of the “limited joint mobility” syndrome (478) that is seen in both T1DM and
T2DM and correlates with the progression of microvascular disease in the eye (479).

Beyond structural changes, there are abundant data regarding vascular dysfunction in the
skin in diabetes (480). The skin (like the retina) is one of the few areas where clinicians can
directly observe and functionally test the microvasculature. A significant body of data exists that
details the changes in microvascular perfusion that occur as a result of diabetes or insulin
resistance or components of metabolic syndrome. Researchers have used various techniques,
including laser Doppler fluxmetry (481-483) and nail-bed capillaroscopy (484,485), to
characterize skin microvasculature in diabetes (485-487), obesity (488), insulin resistance, and
metabolic syndrome (489). With well-established diabetes, the vascular hyperemic response to
skin heating is impaired, as is the response to hypoxemia. There appears to be a clear relationship
between impaired microvascular function and tissue metabolism in the feet of individuals with
diabetes. Tissue oxygen saturation and high-energy phosphate stores are decreased in lower
extremity skin in individuals with diabetes compared to controls, and this appears to be further
aggravated when neuropathy is present (480).

Impaired function of the skin microvasculature is a key component contributing to
delayed/deficient wound healing in diabetes. This applies to both post-surgical healing as well as
spontaneous wound healing, as is seen with diabetic foot ulcers (490,491). For the former,
glycemic control is an important treatment intervention to improve wound healing. For the latter,
which are more chronic wounds, there is a complex interplay between local tissue factors,
infection, blood flow, and friction/pressure related hyperkeratosis, each of which must be
addressed to optimize the likelihood of successful treatment. Interestingly, recent work in
experimental models has suggested that a defect in endothelial progenitor cell proliferation and
subsequent recruitment to sites of injury may be playing a significant role. The generation of
EPCs appears to depend on NO generation by eNOS within the bone marrow compartment, and
diabetes impairs this (492). Beyond that, the recruitment of generated cells to the area of
inflammation is dependent upon local tissue factors, which diabetes also decreases (492).
Adipose tissue possesses an abundant microvasculature, and most adipocytes are within one cell diameter of a capillary. The resting blood flow to adipose tissue is similar to that of resting skeletal muscle (2-4 mL/min/100g), and blood flow to each of these tissues increases following a meal in healthy subjects (493,494). These changes can be blocked by β-blockade but not by α-blockade or NOS inhibition, suggesting an important role for adrenergic regulation. In as much as adipose tissue is a principal repository for dietary fats that circulate in very LDL particles or chylemicrons, post-prandial increases in flow could enhance nutrient delivery and storage. In muscle, meal ingestion increases both total blood flow and capillary recruitment. Similar blood flow and capillary recruitment may likewise occur post-prandially in adipose tissue (495).

Interestingly, basal adipose blood flow is reduced, and postprandial adipose blood flow increases are blunted or absent in obese or T2DM subjects (495,496). Subcutaneous adipose tissue capillary density (capillaries/mm²) is less in obese subjects (497), consistent with capillary rarefaction similar to that seen in skeletal muscle in diabetes, obesity, and hypertension. The larger fat cell size in subcutaneous tissue from obese diabetic subjects may, in part, explain this apparent rarefaction, which correlates well with the degree of insulin resistance measured using the euglycemic clamp method.

Whether diminished adipose vascularity might have metabolic consequences has been a topic of very recent interest. Several groups had reported decreased tissue oxygen tension within adipose tissue from obese rodents (497-499). These groups hypothesized that this decrease
results in an oxidative stress within the tissue, which might contribute to the development of “inflamed” adipose tissues and the resultant release of inflammatory cytokines. This hypothesis has become more controversial with recent data suggesting that in obese humans, subcutaneous adipose tissue oxygen concentration was either minimally lower (497) or higher (493) than is seen in lean, age- and gender-matched control subjects. In the latter study, which also demonstrated decreased vascularity and reduced blood flow, the seemingly paradoxical adipose tissue hyperoxia appeared secondary to decreased mitochondrial activity and tissue energy expenditure. Whether these differences between rodents and humans represent species differences or differences between the methods employed in the human compared to the rodent studies is uncertain. It is clear that the tissue pO2 in obese rodents is substantially lower (~ 20 mmHg) compared to obese humans (40-70 mmHg). The levels of oxygen seen in humans would not be expected to trigger the same transcriptional program as seen in mice (e.g., enhanced expression of mRNA for HIF-1a, Glut-1, etc.).

The recognition of the close relationship between adipose tissue microvasculature and the adipocyte has recently provoked a number of very interesting investigations into the relationships between expanding fat mass and microvascular angiogenesis or involution and how both relate to body metabolic function. Over a decade ago, Folkman and colleagues observed that angiogenesis inhibitors could lead to significant weight loss in Ob/Ob mice. This was particularly intriguing, as the effect occurred using several different types of angiogenesis inhibitors and the animals tolerated the treatment quite well. Withdrawal of the inhibitor allowed rapid regain of the lost weight. The animals treated with the angiogenesis inhibitors demonstrated increased apoptosis
and decreased angiogenic activity in adipose tissue. The treated animals consumed less food than control animals, however this did not entirely explain the weight loss, which was greater in the animals treated with the angiogenesis inhibitors compared to pair-fed controls. More recently, several intriguing studies have shown that adipose tissue endothelium specifically targeted with a pro-apoptotic peptide likewise caused weight loss in mice (500,501). This treatment affected a decrease in food intake without other apparent toxicity. Importantly, it did not affect appetite or body weight in lean control animals (501). The mechanism responsible for this obesity-dependent appetite decrease is unclear. It is intriguing that treating mice with pro-apoptotic peptide, while causing vessel rarefaction in adipose tissue, improved glucose tolerance and insulin resistance (500). Studies targeting adipose angiogenesis did not assess tissue oxygenation, so it is unclear how this work relates to the hypothesis that adipose hypoxia causes a pro-inflammatory state and consequent insulin resistance.

Several other groups have reported finding a significant relationship between the microvasculature and the metabolic function of the adipocyte. When the VEGF gene is over-expressed in the adipocyte using an AP2 directed promoter, there is increased microvasculature development, specifically in adipose tissue (both white and brown) (502). These mice did not become obese when placed on a high-fat diet. They also showed decreased M1 macrophage infiltration of fat, increased thermogenesis, improved glucose tolerance, and maintained greater insulin sensitivity when compared to high-fat fed control mice. The complexity of this relationship is underscored by the observation that inhibiting VEGF-A expression (whole animal) using an inducible repression system also diminished weight gain on a high-fat diet and...
led to a “browning” of white adipose tissue. In addition, VEGF-B expression was increased in these mice as were downstream FA transport proteins regulated by VEGF-B (503). This is particularly interesting in light of the report that knockout of VEGF-B (whole body) prevented the development of insulin resistance in Db/Db mice and improved glucose tolerance (504). In part, these salutary metabolic effects appeared due to decreased FA transport proteins in the endothelium of muscle and heart, which slowed ectopic lipid deposition at these sites.

Studies probing the relationship between VEGF expression and microvascular development have recently been extended to muscle. Bonner and colleagues created a muscle-specific VEGF-A knockout mouse using the Cre/lox method (505). VEGF-A was absent in both cardiac and skeletal muscle, while plasma concentrations were decreased approximately 25%. Accompanying this was nearly a 50% decline in capillary volume in both skeletal and cardiac muscle. Insulin sensitivity (euglycemic clamp) was diminished in the knockout animals due to a decline in insulin-stimulated glucose disposal. However, when muscles were excised and incubated in vitro with insulin and glucose, metabolism appeared normal. This suggests that the decreased the microvascular supply had limited insulin/glucose delivery to the skeletal muscle.

It is interesting to consider that the relationship between the microvasculature within skeletal muscle and adipose may be operating at an entirely different level. This relates to the fact that small arterioles within both skeletal and cardiac muscle have a surrounding envelope of adipocytes, and the volume of this envelope increases with obesity. Nearly a decade ago it was proposed that a local signaling process occurs between peri-vascular adipose tissue and the microvasculature within skeletal muscle (506), and that adipokines released by adipose might
influence muscle nutritive perfusion in a paracrine fashion. Such a process could provide an
important linkage in our understanding of the relationship between adiposity, inflammation, and
vascular dysfunction that is prevalent in diabetes. Increases in perivascular adipose tissue are not
restricted to skeletal muscle. Indeed, several studies have noted an association between
perivascular adipose tissue in the thoracic aorta and both extramural coronary circulation
calcification and CVD prevalence (507,508).

In summary, there is now abundant evidence that microvascular dysfunction/disease is by
no means restricted to the traditional target tissues (*i.e.*, retina, kidney, and peripheral nerve).
Rather, it is a generalized phenomenon affecting multiple tissues throughout the body. This
allows one to appreciate the pleiotropic effects of diabetes on health. In addition, dysfunction of
the microvasculature in tissues like skeletal and cardiac muscle, skin, and adipose also occurs in
settings related to insulin resistance and contributes to both metabolic and other functional
defects in these tissues.
Chapter 5. Microvascular Disease in the Kidney

Introduction

Microvascular renal disease is part of the classical triopathy of diabetes complications. It is a major contributor to the development of end-stage kidney disease (ESKD) in the developed world. In addition to the morbidity/mortality provoked by DN *per se*, it associates strongly with CVD progression and mortality. Here, we review the epidemiology of DN, its pathogenesis, as well as evolving information on genetic factors that either enhance or diminish risk for development or progression of DN in diabetic patients and briefly highlight aspects of current treatment.

Epidemiology

Determining precise incidence and prevalence rates for KD in subjects with diabetes depends on the definition applied. Excessive albuminuria and/or reduced estimated GFRs (eGFRs) in subjects with diabetes is associated with DKD, but also to non-diabetic KD, particularly in those with T2DM who have atypical clinical courses (short disease duration, severe hypertension, rapidly changing kidney function, or absence of DR). Between 2005 and 2010, NHANES data revealed high rates of nephropathy among subjects with diabetes, 19.3% had an eGFR <60 ml/min/1.73m² based on the Chronic Kidney Disease Epidemiology Collaboration formula, 29.9% an elevated urine albumin:creatinine ratio ≥30 mg/g, and 8.6% had both albuminuria and low eGFR (509). Based on these definitions, similar high rates of KD are present in patients with undiagnosed diabetes (510) and 17.7% of patients with pre-diabetes have KD (511). The incidence rate of CKD was significantly higher among those with metabolic
syndrome (but lacking diabetes) in the Atherosclerosis Risk In Communities study, relative to those without metabolic syndrome (512). These studies demonstrate that hyperglycemia can lead to reduced kidney function and albuminuria prior to the onset of frank diabetes.

The incidence rate of diabetes-attributed nephropathy in the U.S. population with diabetes has been stable for the past two decades (510,513). This is concerning, since it occurred despite marked reductions in HbA1c and systemic blood pressures, a more than 10-fold increase in prescription of statins (with a mean 32 mg/dL reduction in LDL-cholesterol), and a nearly 4-fold increase in use of renin-angiotensin aldosterone system (RAAS) inhibitors during this period. Thus, these stable rates of diabetic patients developing DKD will continue to translate into increasing patient numbers with nephropathy due to rising rates of diabetes and obesity. The prevalence of DKD in the U.S. population was estimated at 2.2% between 1988 and 1994 (95% CI: 1.8-2.6%), with significant increases to 2.8% (95% CI: 2.4-3.4%) between 1999 and 2004 and 3.3% (95% CI: 2.8-3.7%) between 2005 and 2008 (p<0.001 for trend) (509). Much of the excess morbidity and mortality in subjects with diabetes appears to relate to the presence of KD (514,515).

The annual incidence rate of ESKD cases attributed to DKD has also been relatively stable at 152 per million population between 2000 and 2010; although dramatic differences occur based on age and ethnicity (509). The gender-adjusted incident rate for diabetes-attributed ESKD in European Americans aged 30-39 years fell by 1% from 2000 to 2010 (to 35.4 cases/million in 2010). In contrast, African Americans, Native Americans, and Asian Americans in this age range saw their incidence rates increase by 69%, 30.1%, and 100% (133.8, 116, and 32.6 million)
during this period, respectively. The rate of incident ESKD attributed to diabetes fell by 3.6% between 2000 and 2010 in European Americans 60 to 69 years old, whereas it rose by 29% in those >70 years. Between 2000 and 2010, the incidence rate of diabetes-attributed ESKD in African Americans, Native Americans, and Hispanic Americans aged 60-69 fell by 17.2%, 40.4%, and 15.7%, respectively.

**Clinical Presentation**

Our understanding of the natural history of DKD has evolved. Although best evaluated in T1DM with a clear date of disease onset, the histologic and clinical courses of DKD appear similar in T1DM and T2DM. In subjects with hyperglycemia, we do not uniformly see the assumed progression from pre-glomerular afferent arteriolar vasodilation to high renal blood flows, elevated intra-glomerular pressures, and intermittent then fixed microalbuminuria with subsequent macroalbuminuria and declining GFR. Approximately 10% of subjects with T1DM will manifest steadily declining eGFR in the absence of heavy proteinuria (516). Albuminuria and loss of kidney function (declining eGFR) are independent processes with different genetic bases (517).

Current levels of albuminuria divide into three categories: normoalbuminuria (urine albumin:creatinine ratio <30 mg/g (often further divided to “high-normal” >15 mg/g [which extends into the previously normal range]); microalbuminuria, 30-300 mg/g; and macroalbuminuria, >300 mg/g, also known as overt proteinuria.
Higher risk for CVD events is associated with higher levels of albuminuria (518,519).

UKPDS (196) participants with T2DM and microalbuminuria had equivalent rates of progressing to macroalbuminuria and death (196). In those with macroalbuminuria, the risk of death far exceeded the risk for developing progressive loss of eGFR or initiating renal replacement therapy. The urine albumin:creatinine ratio can vary by up to 40% on repeat testing, and T1DM patients with effective glycemic, lipid, and blood pressure control frequently experience microalbuminuria remission (513,515), hence an abnormal urine albumin:creatinine ratio result may not be reflective of a risk for progression in DKD.

During prolonged follow-up of T1DM subjects with an initially normal eGFR (>60 ml/min), approximately two-thirds of patients with microalbuminuria and one-third with overt proteinuria demonstrated stable renal function with low risk for subsequent progression to ESKD (520,521). In contrast, one-third of those with microalbuminuria and two-thirds with overt proteinuria had declining kidney function and were at high risk for subsequent ESKD; rates of decline were variable between patients but remained relatively consistent in each individual. Early eGFR slope appears predictive of a future rate of progression in DKD (521). In addition, the relatively frequent failure of ACE inhibitors (ACEi) to halt progression of early T1DM KD was evaluated. Although precise mechanisms are unclear, poor glycemic control and hypercholesterolemia are likely involved (520).

These data suggest independence between the development and progression of pathologic changes in the glomerular and interstitial renal compartments in DKD. The glomerulus appears primarily responsible for proteinuria; whereas interstitial changes better predict subsequent
declines in kidney function, as in other forms of nephropathy. In a study of RAAS-blocking agents in the primary prevention of DKD, glomerular mesangial fractional volumes (and other glomerular parameters) were not appreciably different in normoalbuminuric T1DM patients after 5 years of treatment with an ACEi, ARB, or placebo (100). Additionally, interstitial changes were not different between these treatment groups, suggesting that RAAS blockers are not suitable for the primary prevention of DKD, despite lowering systemic blood pressures.

Although many patients with progressive DKD and falling eGFR have proteinuria, urine albumin:creatinine ratios better predict CVD events and CVD mortality, relative to the progression of KD (196). Damage to the systemic vasculature, including in the glomerulus, relates to endothelial dysfunction from hyperglycemia and likely contributes to albumin leakage into the urine. This may not reflect diabetic glomerular changes, but contributes to the high rates of CVD and death. Once on renal replacement therapy, death rates from CVD remain high in subjects with DKD. Adjusted 5-year survival on dialysis was 32% in subjects with DKD through December 2010 (509).

Non-DN is frequently present and often misdiagnosed as DKD in proteinuric patients with T2DM and brief diabetes durations who have severe hypertension or rapid loss of eGFR. Several studies report 50% or more of proteinuric patients with T2DM undergoing renal biopsy had non-diabetic CKD (407,522,523). IgA nephropathy frequently co-exists with DKD in Asian and American Indian populations, as well (524). These factors contribute to errors in calculating the true incidence and prevalence of DKD and hamper treatment trials in DKD by including cases with non-DKD. This is further supported by the identification of two coding nephropathy
risk variants in the apolipoprotein L1 (APOL1) gene that contribute to African-ancestry populations having the majority of non-diabetic CKD cases.

APOL1 is strongly associated with a spectrum of proteinuric KDs related to focal segmental glomerulosclerosis, including HIV-associated nephropathy and focal global glomerulosclerosis, which was erroneously attributed to hypertension in African Americans (525-532). The APOL1 family of non-diabetic KDs accounts for up to 40% of ESKD in African Americans. T2DM and focal segmental glomerulosclerosis are common in African ancestry populations and frequently co-exist. It is difficult to accurately determine the cause of nephropathy in those with proteinuria and T2DM without a kidney biopsy, a procedure not commonly performed in patients with longstanding diabetes. APOL1 genotyping may provide a non-invasive tool for identifying CKD that is unrelated to diabetes in individuals of African ancestry (533). As discussed below, partitioning for APOL1 in African Americans with clinically diagnosed DKD replicated the FERM domain containing 3 gene (FRMD3) association with DKD, an effect not possible prior to accounting for APOL1 (533-535).

A Genetic Component to Diabetic Kidney Disease Risk

In addition to lifestyle and environment, genetic heritage is widely accepted as a contributor to the complex phenotype of DKD. An improved understanding of the genetic contributors to DKD has the potential to play a significant role in early prediction, prevention, and efforts to halt disease progression. For example, if genetic predictions using a combination of genetic variants that are proven to predict higher DKD risk (i.e., a genetic risk score) could identify patients at high risk for DKD, these individuals could undergo active surveillance (with
early initiation of anti-hypertensive, blood sugar, and lipid lowering treatment) when diabetes is initially diagnosed. The potential of this form of “personalized medicine” for patients with diabetes has not yet been translated into practice. There is little doubt that genetic variations contribute to DKD risk, supported by a wide range of studies in both T1DM and T2DM in multiple ethnicities. As outlined above, ethnic disparities in DKD prevalence suggest that the different natural histories of human populations have resulted in genetic architectures that confer different DKD risks. Familial clustering and aggregation of DKD has been documented for discrete definitions of DKD (i.e., ESKD in T1DM-affected European Americans and Europeans) (536-538) and in diverse T2DM populations, such as African Americans (539,540), European Americans (539), Canadians (541), Native Americans (542), Europeans (543), East Asians, (544) Brazilians (545), and South Asians (546). In addition, familial aggregation in the form of heritability of quantitative measures of renal function (e.g., urinary protein excretion and eGFR) have been widely reported (547-549), and segregation analyses in European American (550) and Pima (551) diabetes families suggest that genetics significantly influence variations in urinary protein excretion.

The Search for Diabetic Kidney Disease Susceptibility Genes

The broad acceptance that DKD has a significant genetic component has motivated increasingly sophisticated efforts to identify specific genetic polymorphisms associated with DKD. A widely used approach is the comparison of allele frequencies between DKD cases and non-DKD controls, with KD defined as a dichotomous trait (either affected or unaffected). The simplest approach has been candidate gene analysis, which entails the assessment of genetic...
variations in one or more genes with plausible physiological links to DKD. Candidate gene studies continue to be reported in large numbers and in diverse ethnicities. These studies are frequently based on small numbers of cases and controls and often on small numbers of genetic polymorphisms. Thus, they have limited power and do not comprehensively test the gene in question. Such studies, however, can contribute to larger, better-powered meta-analysis efforts. Meta-analyses, while better powered, also have limitations, such as focusing on a limited number of genetic variants and including diverse study samples that were not collected in a uniform fashion.

Two large meta-analyses have evaluated the angiotensin 1-converting ACE insertion-deletion polymorphism in diverse samples of T1DM and T2DM cases and control subjects (552,553). These studies concluded that the ACE D allele was associated with DN risk with odds ratios in the range of 1.1-1.3, an effect similar to many common variant associations with complex diseases. Mooyaart et al. (554) combined bioinformatic and meta-analysis methods to evaluate evidence for genetic associations with DKD. They reported that out of 671 genetic association studies investigating DKD, researchers identified 34 replicated genetic variants; 21 of these remained significantly associated with DKD in a random-effects meta-analysis. Genetic variants in the PKCβ1 gene (PRKCB1) were associated with T2DM KD in a carefully performed candidate gene study from Hong Kong, with replication (555). However, results of these studies have not yet been translated into practice. This may prove difficult, given the variations between the many studies of T1DM KD and T2DM KD and variations in samples sizes and ethnic
Early studies using classical family-based linkage analysis showed great promise. Vardali et al. performed a genome linkage scan in Turkish kindreds with multiple DKD-affected individuals (557). They observed a major linkage peak on chromosome 18 (logarithm of odds score 6.6, i.e., odds of $10^{6.6}:1$ for linkage), revealing evidence for a novel DKD gene. Analysis of this locus in the Pima Indian population provided some evidence of confirmation (558). The carnosinase 1 gene (CNDP1) was ultimately implicated as the likely cause of DKD on 18q (559). CNDP1 is expressed in the brain and kidney, and carnosine is a scavenger of oxygen free radicals and may inhibit the formation of advanced glycosylation end-products. A polymorphic trinucleotide repeat in exon 2 of CNDP1 coding for a leucine repeat in the leader peptide of the carnosinase-1 precursor was associated with DKD. There are additional studies in both T1DM and T2DM from multiple ethnic groups that include several study designs (family-based and case-control). The CNDP1 association was replicated in European Americans with T2DM KD (560), but an analysis of European Americans only nominally associated CNDP1 with T1DM KD (561). Studies have extended the evaluation of CNDP1 to test other genetic variations in the region, including the neighboring CNDP2 gene. McDonough et al. (562) performed a detailed resequencing and analysis of variants in the CNDP1 and CNDP2 genes in European Americans and African Americans. DKD protection was not observed in African Americans, suggesting that the protection afforded by the CNDP1 was masked by additional CNDP1 and CNDP2 risk origins. For example, many genes associate with DKD failed to replicate when tested in European-derived samples with T1DM KD (556).
haplotypes, defined by specific combinations of single nucleotide polymorphisms (SNPs).

Analysis of this locus continues to be of interest (563,564).

There are a number of other family-based linkage studies that include, in some cases, complementary association analyses (565,566). The Family Investigation of Nephropathy and Diabetes study (567) included 11 United States (U.S.) clinical centers and nearly 10,000 European Americans, African Americans, Mexican Americans, and American Indians with T2DM KD. Initial analyses targeted both quantitative albuminuria and GFR (568,569) and DKD (570). In spite of these efforts, the significance and impact of family-based linkage studies remains unclear to human geneticists, with only a few examples of linkage studies leading to the identification of genes underlying complex traits such as DKD. Even in successful cases, such as CNDP1, the overall clinical implications remain uncertain.

Smaller and less comprehensive efforts are now transitioning to larger, better-powered studies with more comprehensive genetic analyses in DKD, including genome-wide association studies (GWAS). In many cases, this new generation of studies has multiple collaborating research groups. For example, McKnight et al. (571) initiated a new level of rigor in study design in their analysis of the Warren 3/UK Genetics of Kidneys in Diabetes Study Group cohort of T1DM patients, with replication testing and meta-analysis of samples from the Finnish Diabetic Nephropathy Study. In total, McKnight et al. evaluated more than 3,400 samples with moderate evidence for association (allelic p-value 0.006, OR 1.27).
Initial GWAS in Japanese and Pima Indians suggested an association between T2DM KD susceptibility and the Engulfment and Cell Motility 1 gene and the plasmacytoma variant translocation gene, respectively (572,573).

Recent extensions of the earlier GWAS work reported results for two genes, A carboxylase beta (ACACB) and FRMD3. A report by Maeda et al. (574) identified SNPs in the acetyl-coenzyme ACACB gene associated with proteinuria in T2DM and these explorations have been extended to multiple ethnic populations, with an associated SNP being consistently more frequent in DKD cases compared to controls (575). Additional in vitro functional analysis further supports a role for ACACB (574), and Murea et al. have proposed that genes involved in lipid metabolism, such as ACACB, could influence DKD (576). Similarly, Pezzolesi et al. (534) performed a GWAS for T1DM KD in Genetics of Kidneys in Diabetes sample and carried out a replication analysis in DCCT and EDIC participants. Noteworthy was the identification of association between DKD and the FRMD3 gene. Importantly, follow-up analyses in multiple populations, including both T1DM and T2DM KD cases, have also reported evidence for the association of FRMD3 with DKD (533,577). A recent mechanistic study proposed a pathway by which FRMD3 variants could influence the risk of DKD based on transcriptional regulation of bone morphogenetic protein pathway genes (578).

A new generation of larger and better-powered GWAS in increasingly large sample sizes is now appearing. One of these is an African American T2DM-ESKD study encompassing over 5,800 African Americans (535), and another is an analysis of high density GWAS data from the Family Investigation of Nephropathy and Diabetes consortium with multi-ethnic samples.
Although McDonough et al. (535) detected no genome-wide significant associations with T2DM-ESKD (p≤5x10^{-8}), multiple variants in RNF185, LIMK2, SFI1, APOL3, and MYH9 demonstrated strong evidence of association with all-cause ESKD, including advanced KD attributed to diabetes and non-diabetic etiologies. Strikingly, the majority of these associations were based on the contribution of protection from nephropathy, rather than risk. Sandholm et al. recently performed an analysis of T1DM KD in the Genetics of Nephropathy: an International Effort cohort, which was a combination of subjects from the United Kingdom-Republic of Ireland, Finnish Diabetic Nephropathy Study, and Genetics of Kidneys in Diabetes cohorts, including over 6,500 European DNA samples (579). The analysis revealed several variants with strong evidence of association with T1DM KD in the AFF3 (AF4/FMR2 family, member 3) gene (p=1.26x10^{-8}, OR=1.26) and an intergenic SNP on chromosome 15q26 (p=2.0x10^{-9}, OR=1.80). An important addition to this study was functional data suggesting that AFF3 is involved in renal tubule fibrosis through the TGF-β1 pathway. The strongest genetic association with DKD in the Genetics of Nephropathy: an International Effort study was observed using T1DM-ESKD as the phenotype. With these encouraging new results from GWAS studies, optimism should be guarded; replication in other large studies remains necessary.

**Genetics of Diabetic Kidney Disease Now and in the Future**

The search for genes associated with common and complex diseases has been driven by technical developments such as the GWAS method. Even with continuing innovations, researchers have made limited progress in both T1DM KD and T2DM KD in all ethnic groups. Given that DKD is a common disorder with high public health impact, it is surprising that the
sample sizes for contemporary studies of DKD are small and powered only to detect major

 genetic effects. In the future, researchers and funding agencies should consider expanding

 available study populations to enhance the power for gene detection.

 Several research questions remain. Despite shared chronic hyperglycemia, it is uncertain

 whether shared genetic contributors in DKD exist for T1DM and T2DM. Evidence to date is not

 compelling. While there are several studies of DKD in T1DM and T2DM that have identified

 genes, such as *CNDP1, ACACB, FRMD3*, and *ELMO1*, that are shared across populations

 (572,580-582), the results are not compelling. It is also unclear whether DKD genes will

 translate their impact across ethnic differences within human populations. It is striking that

 mutations in the *APOL1* gene are powerfully associated (OR 7.3-29) (525,532) with non-DKD

 forms of severe nephropathy in African Americans; yet, these *APOL1* risk variants are virtually

 absent in European-derived populations (525,583). The discovery of *APOL1* is also in striking

 contrast to the apparent heterogeneous genetic architecture of DKD. While we do not have a

 complete picture of DKD, there is clearly no genetic contributor to DKD remotely as powerful as

 *APOL1* is in non-DKD. In sum, the goal of creating genetic risk scores (*i.e.*, combinations of

 genetic variants that will aid in the prediction of DKD risk) remains a work in progress.

 This does not mean that creating genetic tools for DKD that have clinical value will be

 beyond reach. As outlined above, the cornerstone of genetic research to date has been the GWAS

 method, which is limited to common variations and frequently captures information primarily

 from non-coding variants in the genome. New technical innovations have facilitated the creation

 of large and growing databases of coding variants (both low-frequency and rare) through next-
generation sequencing of complete sets of exons from individual DNAs (exome sequencing).

Researchers are actively making use of these resources to test for the impact of low-frequency
coding variants on DKD, and efforts are underway to perform exome sequencing in DNAs from
DKD-affected individuals. For example, the T2DM-Genes consortium sponsored exome
sequencing for more than 1,000 of the DKD cases and controls from the African American
T2DM-ESKD GWAS (535). Equally, epigenetic mechanisms, such as post-translational
methylation or demethylation and histone acetylation to alter the expression of genes, represents
an attractive potential mechanism by which the hyperglycemic environment could mediate renal
failure (83). Initial reports on epigenetic studies are now appearing (584). These many paths of
investigation will undoubtedly reveal new insights into the genetic contributors to DKD in the
near future.

Current Treatment

Therapies to prevent or slow the development of DKD are multi-factorial and include
lowering blood sugar levels with medications, diet, and exercise, as well as treating hypertension
and hyperlipidemia. As previously discussed, an early decline in the eGFR slope best correlated
with subsequent risk of ESKD (520,521). Maintaining eGFR remains the primary focus for
preventing advanced DKD and slowing the progression to ESKD. Intensive glycemic control in
patients with T1DM and T2DM prevents or delays the development of microvascular
complications and reduces the rate of development of overt proteinuria. However, limited data
exists on whether improving glycemic control prevents low eGFR and diabetic ESKD. Reducing
albuminuria through improved glycemic control and other treatments is expected to lower CVD
event rates but requires evaluation regarding how it effects the rate of eGFR loss. It is expected that reducing early-stage DKD, particularly overt proteinuria, will translate into fewer cases of diabetic ESKD in the future (585).

Improving glycemic control remains the mainstay of preventing and delaying DKD and other microvascular complications, as has been shown in longitudinal studies of T1DM and T2DM. The DCCT and subsequent EDIC trial (586) demonstrated that intensive glucose control in T1DM delayed development and progression of microalbuminuria (587,588). The UKPDS reached similar conclusions in patients with T2DM, with prolonged effects of improving glycemic control (metabolic memory), potentially linked to epigenetic factors (199,589). The more recent ADVANCE trial, ACCORD trial, and VADT extended this finding, all demonstrating significant reductions in microalbuminuria and overt proteinuria with intensive glycemic control (197,201,590). Improving blood sugar control in subjects with the more advanced stages of DKD will likely reduce the rate of eGFR loss, as has been shown in UKPDS and EDIC-DCCT (199,586). However, this may be less effective in halting the progression to ESKD, once critical reductions in nephron mass develop. Based on these studies, and considering risks of hypoglycemia, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines recommend a target HbA1c of approximately 7% (and not treating to below 7%) to prevent or delay progression of diabetic microvascular complications, including DKD. A target HbA1c >7% is recommended in those with co-morbidities or limited life expectancy and at risk for hypoglycemia (585).
It is important to appreciate that kidney function can impact the metabolism and safety of several blood-sugar-lowering medications. National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines suggest avoiding first-generation sulfonylureas when eGFR is <60 ml/min/1.73 m². Instead, the guidelines prefer second-generation glipizide to reduce the risk of prolonged hypoglycemia (585). Caution is urged when initiating meglitinides when eGFR is <30 ml/min/1.73 m². FDA guidelines recommend avoiding metformin when eGFR is <30 ml/min/1.73 m² and avoid starting metformin when eGFR is <45 ml/min/1.73 m². Clinicians should closely follow people on metformin whose GFR is between 30-45 ml/min/1.73 m² and assess them for risk factors for adverse effects of metformin. Japanese and British guidelines also suggest withdrawal when eGFR is <30 ml/min/1.73 m². Data suggest additional dose adjustments (or avoidance) of diabetes medications in patients with advanced nephropathy for alpha-glucosidase inhibitors, DPP4-inhibitors, SGLT-2 inhibitors, incretin mimetics, and IAPP analogues (585).

Lowering systemic blood pressures with anti-hypertensive medications and dietary modification slows the development and progression of DKD, although patients likely need to maintain lower blood pressures to sustain this benefit (589,591). The Joint National Commission 7 recommends RAAS blocking agents; however, these agents appear to be most effective at slowing DKD in patients with high levels of proteinuria (592). Although RAAS blockers often slow DKD progression, they do not reliably halt the progression to ESKD. Cessation of RAAS blockers may eventually become necessary in patients with stage-4 and stage-5 CKD because of the excessive lowering of eGFR due to reversible hemodynamic effects and hyperkalemia.
Studies attempting greater RAAS blockade by combining two agents (ACEi and ARBs) carry greater risks for adverse events and hyperkalemia and should be avoided (593,594).

It was disappointing that RAAS blockers proved to be ineffective for primary prevention of the earliest renal histologic lesions of DKD (100). In a longitudinal kidney biopsy trial, patients receiving an ARB ultimately had higher levels of albuminuria than those on placebo (however, both ACEi and ARBs reduced DR, relative to placebo). Although RAAS blockers are first-line therapies for hypertension in subjects with diabetes, they are not likely to markedly reduce the subsequent development of DKD. National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines do not recommend the routine use of RAAS blocking agents in normotensive normoalbuminuric subjects with diabetes, although ACEi and ARBs are recommended in normotensive diabetic patients with a urine albumin:creatinine ratio >30 mg/g who are believed to be at risk for future DKD (585).

Anecdotal evidence suggests that statin therapy for hyperlipidemia may slow nephropathy progression in DKD; however, RCTs with statistically significant results are lacking (595). Statins often reduce CVD rates in patients with and at risk for DKD; however, trials using statins to lower LDL-cholesterol have not demonstrated reduced mortality in patients with diabetes and ESKD on hemodialysis (596,597). Difficulties controlling blood sugars, and the fact that RAAS inhibition was ineffective at primary prevention, led to studies testing novel medications for DKD, including inhibitors of advanced glycation end-product formation and agents to reduce oxidative stress and inflammation. To date, these agents have not proven safe and effective for renal protection (142,598).
Since glycemic control remains the mainstay for preventing DKD and slowing progression, it is critical to appreciate the effect that advanced stages of DKD have on the accuracy of tests employed to assess glycemic control, especially the HbA1c. Since hemoglobin resides in red blood cells, HbA1c assesses glycemic control over the preceding 120 days (the life span of a normal red blood cell). In the late stages of DKD and ESKD, red blood cell survival drops, and clinicians often prescribe medications to treat anemia (erythropoietin). For given degrees of glycemic control, HbA1c levels are markedly reduced in patients with eGFR <30 ml/min/1.73 m² or those on peritoneal dialysis or hemodialysis, relative to subjects with normal kidney function (599,600). Inaccurately low HbA1c values provide a false sense of security to clinicians and patients (601). Interpretation of HbA1c in patients with ESKD requires complex statistical adjustment to better reflect ambient blood sugars. Markedly high and low adjusted HbA1c values predict poorer outcomes on dialysis (602,603). Frequent serum glucose monitoring or novel assays (glycated albumin and continuous glucose monitoring) may more accurately reflect glycemia in patients with advanced DKD.

**Summary**

Renal microvascular dysfunction, which is common in individuals with diabetes, is characterized by strong but incompletely understood genetic predisposition. Its development and progression are clearly affected by clinical variables including control of blood glucose and blood pressure. The successes with control of these variables achieved in the past several decades along with other progress with risk factor management are gratifying in that they have lessened progression to end-stage renal disease. However, the increased prevalence of diabetes
significantly offsets this progress and consequently diabetes remains a major contributor to renal failure and the associated increased mortality from cardiovascular disease seen with ESRD.

Developing a more complete understanding of the genetic/molecular factors contributing to initiation and progression of microvascular disease will hopefully lead to even more successful preventive strategies.
Chapter 6. The Microvasculature and Diabetic Neuropathy

Introduction

Diabetic neuropathies are very common and troublesome complications of diabetes that lead to morbidity and mortality and a huge economic burden for diabetes care (604,605). Distal symmetric polyneuropathy (DSPN) is the most common form of neuropathy. It is responsible for 50-75% of non-traumatic amputations (605,606). Diabetic neuropathy is a set of clinical syndromes that affect distinct regions of the nervous system, singly or combined. It may be silent and go undetected while exercising its ravages; or it may present with clinical symptoms and signs that, although nonspecific and insidious with slow progression, mimic those of other diseases. Clinicians, therefore, diagnose diabetic neuropathy by exclusion. Unfortunately, diabetic neuropathy is underdiagnosed, and even when symptomatic, less than one third of physicians recognize the cause or discuss this with their patients (607).

Epidemiology

The epidemiology and natural history of diabetic neuropathy remains poorly defined, in part, because of variable criteria for the diagnosis, failure of many physicians to recognize and diagnose the disease, and lack of standardized methodologies for the evaluation of these patients (608). It has nonetheless been estimated that 50% of patients with diabetes have diabetic neuropathy and in the U.S., 2.7 million have painful neuropathy. Out of 25% of patients attending a diabetes clinic who volunteered symptoms; 50% tested positive for neuropathy after a simple clinical test (such as the ankle jerk or vibration perception test), and almost 90% tested positive to sophisticated tests of autonomic function or peripheral sensation (609). Neurologic
complications occur in both T1DM and T2DM and in various forms of acquired diabetes (51).

The major morbidity associated with DSPN is foot ulceration, a precursor to gangrene and limb loss. DSPN increases the risk of amputation 1.7-fold, however that risk jumps to 12-fold if there are deformities (itself a consequence of neuropathy) and 36-fold, if there is a history of previous ulceration (610). Each year, 96,000 diabetic patients in the U.S. undergo amputations. It is estimated that up to 75% of these amputations are preventable (606). Diabetic neuropathy also impacts QOL by causing pain, weakness, ataxia, and incoordination (predisposing to falls and fractures) (611). For patients over the age of 65, diabetes increases falls risk 17-fold, leading to fractures and traumatic brain injury. Autonomic neuropathy likewise decreases QOL and is associated with mortality rates between 25-50% within 5-10 years (612,613).

DSPN causes a variety of syndromes for which there is no universally accepted classification. Operationally, they are subdivided into focal/multifocal neuropathies, including diabetic amyotrophy and symmetric sensorimotor polyneuropathy. The latter is the most common type, affecting about 30% of diabetic patients in hospital care and 25% of those in the community (614,615). DSPN is defined as a symmetrical, length-dependent, sensorimotor polyneuropathy attributable to metabolic and microvascular alterations resulting from chronic hyperglycemia exposure (diabetes) and cardiovascular risk covariates (616). Its onset is generally insidious. Without treatment, the course is chronic and progressive. The loss of small fiber-mediated sensation results in the loss of thermal and pain perception, whereas large fiber impairment results in loss of touch and vibration perception. Sensory fiber involvement may also
result in “positive” symptoms, such as paresthesias and pain. Nonetheless, up to 50% of neuropathic patients can be asymptomatic.

Diabetic autonomic neuropathy rarely causes severe symptoms (608,617). However, in its cardiovascular form, it is definitely associated with at least a 3-fold increased risk for mortality (618-620). More recently, studies have implicated diabetic autonomic neuropathy, or even autonomic imbalance between the sympathetic and the parasympathetic nervous systems, as a predictor of cardiovascular risk (619,620).

Neuropathic pain is defined as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system” (621). Diabetic neuropathy pain is a clinical problem that is difficult to manage. It is often associated with mood and sleep disturbances, and patients with diabetic neuropathy pain are more apt to seek medical attention than those with other types of diabetic neuropathy. Recognizing psychological problems early is critical to the management of pain, and physicians need to go beyond the management of pain if they are to achieve success. Patients may also complain of decreased physical activity and mobility, increased fatigue, and negative effects on their social lives. Providing significant pain relief markedly improves QOL measures (622,623).

Classification of Diabetic Neuropathies

Figure 5 describes the classification Thomas proposed (624), which was later modified (614,625-627). It is important to note that different forms of diabetic neuropathy often coexist in the same patient (e.g., distal polyneuropathy and carpal tunnel syndrome).
Figure 7. Modified diabetic neuropathy classification first proposed by Thomas

<table>
<thead>
<tr>
<th>Large fibre neuropathy</th>
<th>Small fibre neuropathy</th>
<th>Proximal motor neuropathy</th>
<th>Acute mono neuroptlies</th>
<th>Pressure palsies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensory loss: 0 →+++ (touch, vibration)</td>
<td>Sensory loss: 0 →+ (thermal, alldynia)</td>
<td>Sensory loss: 0 →+</td>
<td>Sensory loss: 0 →+</td>
<td>Sensory loss in nerve distribution: + →+++</td>
</tr>
<tr>
<td>Pain: + →+++</td>
<td>Pain: + →+++</td>
<td>Pain: + →+++</td>
<td>Pain: + →+++</td>
<td>Pain: + →+++</td>
</tr>
<tr>
<td>Motor deficit 0 →+++</td>
<td>Motor deficit 0 →+++</td>
<td>Motor deficit 0 →+++</td>
<td>Motor deficit 0 →+++</td>
<td>Motor deficit 0 →+++</td>
</tr>
</tbody>
</table>

Abbreviations: N, normal
Reference: Jirousek et al., 1996 (25)
The natural history of diabetic neuropathies separates them into two very distinctive entities, namely those which progress gradually with increasing duration of diabetes, and those which remit usually completely. Sensory and autonomic neuropathies generally progress, while mononeuropathies, radiculopathies, and acute painful neuropathies (although manifesting severe symptoms) are short-lived and tend to recover (628). The progression of DN is related to glycemic control in both T1DM and T2DM (198,629). It appears that the most rapid deterioration of nerve function occurs soon after the onset of T1DM. Within 2-3 years there is a slowing of the progress with a shallower slope to the curve of dysfunction. In T2DM, slowing of NCVs may be one of the earliest neuropathic abnormalities and often is present even at diagnosis (630). After diagnosis, slowing of NCV generally progresses at a steady rate of approximately 1 m/sec/year, and the level of impairment is positively correlated with the duration of diabetes. Although most studies have documented that symptomatic patients are more likely to have slower NCVs than patients without symptoms, NCVs do not correlate with the severity of symptoms. In a long-term follow-up study of T2DM patients (631), electrophysiologic abnormalities in the lower limb increased from 8% at baseline to 42% after 10 years; in particular, a decrease in sensory and motor amplitudes (indicating axonal destruction) was more pronounced than the slowing of NCVs. Using objective measures of sensory function, such as the vibration perception threshold test, researchers have reported a rate of decline of 1-2 vibration units/year. However, this rate of decline now appears to be less severe, likely due to improvements in general health and nerve nutrition. This is particularly important when doing studies on the treatment of diabetic neuropathy, which have always relied on differences between
drug treatment and placebo and have apparently been successful because of the decline in function occurring in placebo-treated patients (632). Recent studies have pointed out the changing natural history of diabetic neuropathy with the advent of therapeutic lifestyle change and the use of statins and ACEi, which have slowed the progression of diabetic neuropathy and drastically changed the requirements for placebo-controlled studies (633). It is also important to recognize that diabetic neuropathy is a disorder wherein the prevailing abnormality is loss of axons, which electrophysiologically translates to a reduction in amplitudes and not conduction velocities; therefore changes in NCV may not be an appropriate means of monitoring progression or deterioration of nerve function. Small, unmyelinated nerve fibers are affected early in diabetes and are not reflected in NCV studies. Other methods of measuring diabetic neuropathy that do not depend on conduction velocities, such as quantitative sensory testing, autonomic function testing, or skin biopsy with quantification of intraepidermal nerve fibers, are necessary to identify diabetic neuropathy patients (634-636).

Pathogenesis of Diabetic Neuropathies

Historically, there were two competing hypotheses regarding the origins of diabetic neuropathy. One school of thought held that this was largely secondary to metabolic abnormalities within the nerve and/or SCs, while others held that diabetic neuropathy was another manifestation of diabetic microvascular disease. Increasingly, researchers believe that nerve and microvascular injury both contribute to nerve dysfunction. Some of the controversy arose because of the complexity of how diabetic neuropathy presents, as well as the limited ability to study the disease and its pathogenetic mechanisms, particularly early in its course.
Research has clearly shown that with DSPN there is progressive axon degeneration of all fiber types, and this is accompanied by demyelination. However, these changes, which are the proximal cause for the nerve dysfunction, are accompanied by changes in the microvasculature; microelectrode polarography has shown sural nerve hypoxemia accompanied by diminished endoneural blood flow (637,638).

Causative factors include persistent hyperglycemia, oxidative and nitrosative stress, inflammation, and autoimmune-mediated nerve destruction (see chapter 1). These factors affect the microvasculature, SCs, and the nerves themselves. However, diabetic neuropathy is a heterogeneous group of conditions with widely varying pathology, suggesting differences in pathogenic mechanisms for the different clinical syndromes. Recognizing the clinical homologue of these pathologic processes is the first step in achieving the appropriate form of intervention. It is also clear that structural changes in the microvasculature within peripheral nerves occur early in the course of diabetes. It has been known for many years that the vessel wall within peripheral nerves becomes thickened in individuals with diabetic peripheral neuropathy. This is attributed to increases in BM thickness, which is accompanied by pericyte degeneration and endothelial cell hyperplasia. These changes are, in many ways, similar to what we see within the microvasculature in other tissues. We also see these qualitative changes in individuals with diabetes without clinical peripheral neuropathy, although the changes are quantitatively less marked. These changes are typically more marked in endoneural than in epineural vessels for reasons that are unclear.
Clinical Presentation of Diabetic Neuropathies

The spectrum of clinical neuropathic syndromes described in patients with diabetes includes dysfunction of almost every segment of the somatic peripheral and autonomic nervous system (38). We can distinguish each syndrome by its pathophysiologic, therapeutic, and prognostic features.

Focal and Multifocal Neuropathies

Focal neuropathies comprise focal-limb neuropathies and cranial neuropathies. Focal limb neuropathies are usually due to entrapment, and we must distinguish mononeuropathies from these entrapment syndromes (Table 5) (626,639). Mononeuropathies often occur in the older population; they have an acute onset, are associated with pain, and have a self-limiting course resolving in 6-8 weeks. Mononeuropathies can involve the median (5.8% of all diabetic neuropathies), ulnar (2.1%), radial (0.6%), and common peroneal nerves (640). Cranial neuropathies in diabetic patients are extremely rare (0.05%) and occur in older individuals with a long duration of diabetes (641). Entrapment syndromes start slowly, and will progress and persist without intervention. Carpal tunnel syndrome occurs 3 times as frequently in diabetics compared with healthy populations (642) and is found in up to one third of patients with diabetes. Its increased prevalence in diabetes may be related to repeated undetected trauma, metabolic changes, and/or the accumulation of fluid or edema within the confined space of the carpal tunnel (639).
Table 5. Distinguishing characteristics of mononeuropathies, entrapment syndromes and distal symmetrical polyneuropathy

<table>
<thead>
<tr>
<th>Feature</th>
<th>Mononeuropathy</th>
<th>Entrapment Syndrome</th>
<th>Distal Symmetric Neuropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Sudden</td>
<td>Gradual</td>
<td>Gradual</td>
</tr>
<tr>
<td>Pattern</td>
<td>Single nerve but may be multiple</td>
<td>Single nerve exposed to trauma</td>
<td>Distal symmetrical polyneuropathy</td>
</tr>
<tr>
<td>Nerves Involved</td>
<td>CN III, VI, VII, ulnar, median, and peroneal</td>
<td>Median, ulnar, peroneal, medial, and lateral plantar</td>
<td>Mixed, motor, sensory, and autonomic</td>
</tr>
</tbody>
</table>
Proximal Motor Neuropathy (Diabetic Amyotrophy) and Chronic Demyelinating Neuropathies

For many years clinicians thought that proximal neuropathy was a component of diabetic neuropathy. There was a poor understanding of its pathogenesis (643) and clinicians often left the condition untreated with the anticipation that the patient would eventually recover, albeit over a period of some 1-2 years and after suffering considerable pain, weakness, and disability.

Proximal neuropathy has a number of synonyms including diabetic amyotrophy and femoral neuropathy. Clinicians can identify it based on the occurrence of these common features: 1) it primarily affects elderly patients (50-60 years old) with T2DM; 2) the onset can be gradual or abrupt; 3) it presents with severe pain in the thighs, hips, and buttocks, followed by significant weakness of the proximal muscles of the lower limbs and an inability to rise from the sitting position; 4) it can start unilaterally and then spread bilaterally; 5) it often coexists with DSPN; and 6) it is characterized by muscle fasciculation, either spontaneous or provoked by percussion.

Its pathogenesis is not yet clearly understood, although immune-mediated epineurial microvasculitis occurs in some cases. Clinicians generally prescribe immunosuppressive therapy using high-dose steroids or intravenous immunoglobulin (644). We now recognize proximal neuropathy can occur secondary to a variety of conditions unrelated to diabetes, but which have a greater frequency in patients with diabetes than the general population. These conditions include chronic inflammatory demyelinating polyneuropathy, monoclonal gammopathy, circulating GM1 antibodies, and inflammatory vasculitis (641, 642, 645, 646).
In the classic form of diabetic amyotrophy, axonal loss is the predominant process (647) and electrophysiologic evaluation reveals lumbosacral plexopathy (648). In contrast, if demyelination predominates and the motor deficit affects proximal and distal muscle groups, clinicians should consider the diagnoses of chronic inflammatory demyelinating polyneuropathy, monoclonal gammopathy of unknown significance, and vasculitis (649,650). Clinicians often overlook these demyelinating conditions, although recognition is very important, because unlike diabetic neuropathy, they are sometimes treatable. Furthermore, they occur 11-times more frequently in diabetic than nondiabetic patients (651,652). A biopsy of the obturator nerve reveals deposits of immunoglobulin, demyelination, and inflammatory cell infiltrate around the vasa nervorum (645,653). Cerebrospinal fluid protein content is high and there is an increase in the lymphocyte count. Treatment options include: intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy (654), plasma exchange for monoclonal gammopathy of unknown significance, steroids and azathioprine for vasculitis and withdrawal of other drugs or agents that may have caused vasculitis. It is important to divide proximal syndromes into these two subcategories, because the chronic inflammatory demyelinating polyneuropathy variant responds dramatically to intervention (649,655), whereas proximal neuropathy amyotrophy runs its own course over months to years. Until more evidence is available, clinicians should consider these as separate syndromes.
Diabetic Truncal Radiculoneuropathy

Diabetic truncal radiculoneuropathy affects middle-aged to elderly patients and has a predilection for the male sex. Pain is the most important symptom, and it occurs in a girdle-like distribution over the lower thoracic or abdominal wall. It can be unilaterally or bilaterally distributed. Motor weakness is rare. Resolution generally occurs within 4-6 months.

Generalized Symmetric Polyneuropathy

Acute Sensory Neuropathy

Some consider acute sensory (painful) neuropathy a distinctive variant of distal symmetrical polyneuropathy. The syndrome is characterized by severe pain, cachexia, weight loss, depression and, in males, erectile dysfunction. It occurs predominantly in male patients and may appear at any time in the course of both T1DM and T2DM. It is self-limiting and invariably responds to simple symptomatic treatment. Conditions such as Fabry’s disease, amyloidosis, HIV infection, heavy metal poisoning (such as arsenic), and excess alcohol consumption should be excluded (624).

Acute sensory neuropathy is usually associated with poor glycemic control but may also appear after a sudden improvement in glycemic control and has been associated with the onset of insulin therapy (occasionally referred to as “insulin neuritis”) (656). Although the pathologic basis has not been determined, one hypothesis suggests that changes in blood glucose flux produce alterations in epineurial blood flow, leading to ischemia. A study using in vivo epineurial vessel photography and fluorescein angiography demonstrated abnormalities in epineurial vessels, including arteriovenous shunting and new-vessel proliferation in patients with
acute sensory neuropathy (657). Some relate this syndrome to diabetic lumbosacral radiculoplexus neuropathy and suggest a possible immune-mediated mechanism (636).

**Chronic Sensorimotor Neuropathy or Distal Symmetric Polyneuropathy**

DSPN is seen in both T1DM and T2DM with similar frequency, and it may be already present at the time of diagnosis of T2DM (630). A population survey reported that 30% of T1DM and 36-40% of T2DM patients experienced neuropathic symptoms (59). Several studies have also suggested that impaired glucose tolerance may lead to polyneuropathy, reporting rates of impaired glucose tolerance between 30-50% in patients with chronic idiopathic polyneuropathies (658-662). Studies using skin and nerve biopsies have shown a progressive reduction in peripheral nerve fibers from the time of the diagnosis of diabetes or even from earlier pre-diabetic stages (impaired glucose tolerance and metabolic syndrome) (635,663,664).

Sensory symptoms are more prominent than motor symptoms and usually involve the lower limbs. Mild muscle wasting may occur, but severe weakness is rare and should raise the question of a possible non-diabetic etiology of the neuropathy (51,608,616,636).

**Clinical Manifestations of Small Fiber Neuropathies**

Clinical manifestations of small fiber neuropathies (Figure 5) include: symptoms of burning, superficial or lancinating pain often accompanied by hyperalgesia, dysesthesia, and allodynia; disruption of small thinly myelinated Aδ and unmyelinated C fibers; a progression to numbness; abnormal cold and warm thermal sensations; abnormal autonomic function with
decreased sweating, dry skin, cold feet, and impaired vasomotion and skin blood flow; intact motor strength and deep tendon reflexes; negative NCV findings; loss of cutaneous nerve fibers on skin biopsies; and clinical diagnosis by reduced sensitivity to 1.0g Semmes Weinstein monofilament and prickling pain perception using the Waardenberg wheel or similar instrument.

Clinical Manifestations of Large Fiber Neuropathies

Clinical manifestations of large fiber neuropathies (Figure 5) include: disruption of large myelinated, rapidly conducting Aα/β fibers, which may involve sensory and/or motor nerves; prominent signs with sensory ataxia (waddling like a duck) and the wasting of small intrinsic muscles of feet and hands with hammertoe deformities and weakness of hands and feet; abnormal deep tendon reflexes; impaired vibration, light touch, and joint position perception; abnormal NCV findings; increased skin blood flow with hot feet; higher risk of falls, fractures, and the development of Charcot neuroarthropathy; and minimal symptoms, which may include a sensation of walking on cotton, floors feeling “strange”, inability to turn the pages of a book, inability to discriminate among coins, and (in some patients with severe distal muscle weakness) inability to stand on the toes or heels.

Most patients with DPN, however, have a “mixed” variety of neuropathy with both large and small nerve fiber damages.

Diagnosing Diabetic Peripheral Neuropathy

In 2010, The Toronto Expert Panel on Diabetic Neuropathy Classification re-defined the minimal criteria for the diagnosis of typical DPN (616).
The diagnosis of DPN should rest on the findings from a clinical and neurological examination, (i.e., the presence of neuropathic symptoms [positive and negative, sensory and motor] and signs [sensory deficit, allodynia and hyperalgesia, motor weakness, absence of reflexes]) (665).

When making a diagnosis of DPN, clinicians should consider the following:

1. Symptoms alone have poor diagnostic accuracy in predicting the presence of polyneuropathy.

2. Signs are better predictors than symptoms.

3. Multiple signs are better predictors than a single sign.

4. Relatively simple examinations are as accurate as complex scoring systems.

Thus, both symptoms and signs should be assessed.

**Conditions Mimicking Diabetic Neuropathy**

Conditions that mimic diabetic neuropathy include neuropathies caused by alcohol abuse, uremia, hypothyroidism, vitamin B12 deficiency, peripheral arterial disease, cancer, inflammatory and infectious diseases, and neurotoxic drugs (70). An atypical pattern of the presentation of symptoms or signs (i.e., the presence of relevant motor deficits, an asymmetrical or proximal distribution, or rapid progression) always requires referral for electrodiagnostic testing.
Clinical Assessment Tools for Diabetic Neuropathy

Clinical assessment should be standardized using validated scores for both symptom severity and the degree of reproducible neuropathic deficits. These would include the Michigan Neuropathy Screening Instrument (666), the Neuropathy Symptom Score for neuropathic symptoms, and the Neuropathy Disability Score or the Neuropathy impairment score for neuropathic deficits (667).

Objective Diagnosis of Diabetic Neuropathy

The neurological examination should focus on the lower extremities and include foot inspection for deformities, ulcers, fungal infection, muscle wasting, hair distribution or loss, and the presence or absence of pulses. Sensory modalities should be assessed using simple handheld devices (touch by cotton wool or soft brush; vibration by 128 Hz tuning-fork; pressure by the Semmes-Weinstein 1g and 10g monofilament; pinprick by Wardenburg wheel, Neurotip, or a pin; and temperature by cold and warm objects) (668). Finally, clinicians should test the Achilles reflexes (625,669) (Table 5).
<table>
<thead>
<tr>
<th>Sensory Modality</th>
<th>Nerve Fiber</th>
<th>Instrument</th>
<th>Associated Sensory Receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vibration</td>
<td>Aβ (large)</td>
<td>128 Hz Tuning fork</td>
<td>Ruffini corpuscle mechanoreceptors</td>
</tr>
<tr>
<td>Pain (pinprick)</td>
<td>C (small)</td>
<td>Neuro-tips</td>
<td>Nociceptors for pain and warmth</td>
</tr>
<tr>
<td>Pressure</td>
<td>Aβ, Aα (large)</td>
<td>1 g and 10 g Monofilament</td>
<td>Pacinian corpuscle</td>
</tr>
<tr>
<td>Light touch</td>
<td>Aβ, Aα (large)</td>
<td>Wisp of cotton</td>
<td>Meissner’s corpuscle</td>
</tr>
<tr>
<td>Cold</td>
<td>Aδ (small)</td>
<td>Cold tuning fork</td>
<td>Cold thermoreceptors</td>
</tr>
</tbody>
</table>
Nerve Conduction Studies

We recommend using electrophysiologic measures for both clinical practice and multicenter clinical trials (670,671). In a long-term follow-up study of T2DM patients (631), NCV abnormalities in the lower limbs increased from 8% at baseline to 42% after 10 years of disease. The Diabetes Control and Complication Trial reported a slow progression of NCV abnormalities. The sural and peroneal NCVs diminished by 2.8 and 2.7 m/s, respectively, over a 5-year period (672). Furthermore, in the same study, patients who were free of neuropathy at baseline had a 40% incidence of abnormal NCV in the conventionally treated group versus 16% in the intensive therapy treated group after 5 years. However, the neurophysiologic findings vary widely depending on the population tested and the type and distribution of the neuropathy. Patients with painful, predominantly small fiber neuropathy have normal test results. There is consistent evidence that small, unmyelinated fibers are affected early in diabetes, and routine NCV tests do not diagnose these alterations. Therefore, other methods, such as quantitative sensory testing or skin biopsy with quantification of intraepidermal nerve fibers, are needed to detect these patients (634-636). Nevertheless, electrophysiological testing plays a key role in ruling out other causes of neuropathy and is essential for the identification of focal and multifocal neuropathies (608,639).

Summary of Diagnosis of Diabetic Polyneuropathies

A detailed clinical examination is the key to diagnosing diabetic polyneuropathies. The last position statement of the American Diabetes Association recommends that clinicians should screen all patients with diabetes for diabetic neuropathies at diagnosis in T2DM and 5 years after
The diagnosis of diabetic polyneuropathies is mainly clinical and involves specific tests according to the type and severity of the neuropathy. However, depending on the clinical findings, other non-diabetic causes of neuropathy must always be excluded.

**Treatment of Diabetic Polyneuropathies**

Diabetic polyneuropathy treatment should target a number of different aspects: first, underlying pathogenic mechanisms; second, symptoms and improvement in QOL; and third, the complications of neuropathy and their progression (83). We will review very briefly here only those issues related to treating the underlying pathogenetic mechanisms. A more complete approach to clinical management of the consequences of diabetic polyneuropathies is beyond the scope of this review and can be found in other texts.

**Treatment of Specific Underlying Pathogenic Mechanisms**

**Glycemic and Metabolic Control**

Several long-term prospective studies have assessed the effects of intensive diabetes therapy on the prevention and progression of chronic diabetic complications (198,199). In the DCCT and UKPDS studies only a minority of the patients enrolled in these studies had symptomatic DSPN at entry. In the DCCT study, intensive diabetes therapy slowed but did not completely prevent the development of DSPN in T1DM patients. In the DCCT/EDIC cohort, the benefits of former intensive insulin treatment persisted for 13-14 years in T1DM patients after...
DCCT closeout and provided evidence of a durable effect of prior intensive treatment on polyneuropathy and cardiac autonomic neuropathy (“hyperglycemic memory”) (673,674).

In contrast, in T2DM patients, the results were largely negative. The UKPDS showed a lower rate of impaired vibration perception thresholds (vibration perception thresholds >25 V) after 15 years for intensive therapy versus conventional therapy (31% vs. 52%). However, the only additional time point at which vibration perception thresholds reached a significant difference was the 9-year follow-up, whereas the rates after 3, 6, and 12 years did not differ between the groups. Likewise, the rates of absent knee and ankle reflexes as well as the heart rate responses to deep breathing did not differ between the groups (199). In the ADVANCE study, which included 11,140 patients with T2DM randomly assigned to either standard glucose control or intensive glucose control, the relative risk reduction (95% CI) for new or worsening neuropathy for intensive versus standard glucose control after a median of 5 years of follow-up was -4 (-10 to 2), without a significant difference between groups (675). Likewise, in the VADT study of 1,791 military veterans (mean age, 60.4 years) who had a suboptimal response to therapy for T2DM, after a median follow-up of 5.6 years there were no differences between the intensive or standard glucose control groups for DSPN or microvascular complications (88). The ACCORD trial (197) halted intensive therapy aimed at HbA1c <6.0% before the study ended because of a higher mortality in that group, and transitioned patients to standard therapy after 3.7 years, on average. At transition, sensation to light touch was significantly improved on intensive versus standard diabetes therapy. At study end after 5 years, patients on intensive therapy had better Michigan Neuropathy Screening Instrument scores and significant improvements in
sensation to vibration and light touch versus patients on standard diabetes therapy. However, because of the premature study termination and the aggressive HbA1c goal, the neuropathy outcome in the ACCORD trial is difficult to interpret.

In the Steno 2 Study (676), intensified multifactorial risk intervention (including intensive diabetes treatment, ACE-inhibitors, antioxidants, statins, aspirin, and smoking cessation) in patients with microalbuminuria showed no effect on DSPN after 7.8 (range: 6.9-8.8) years and again at 13.3 years, after the patients were subsequently followed for a mean of 5.5 years. However, the progression of cardiac autonomic neuropathy was reduced by 57%. Thus, there is no evidence that intensive diabetes therapy or a target-driven intensified intervention aimed at multiple risk factors favorably influences the development or progression of DSPN, as opposed to cardiac autonomic neuropathy in T2DM patients. However, the Steno study used only vibration detection, which measures exclusively the changes in large fiber function.

Oxidative Stress

A number of studies have shown that hyperglycemia causes oxidative stress in tissues that are susceptible to diabetes complications, including the microvasculature and peripheral nerves. Therapies that are under investigation include ARI, ALA, γ-linolenic acid, benfotiamine, Metanx, and PKC inhibitors.

As discussed elsewhere in this review, in diabetes, excess glucose accelerates AGE generation, which leads to intra- and extracellular protein cross-linking and protein aggregation.
RAGE activation alters intracellular signaling and gene expression, releases pro-inflammatory molecules, and results in an increased production of ROS that contributes to diabetic microvascular complications. Aminoguanidine, an inhibitor of AGE formation, showed good results in animal studies, but trials in humans have been discontinued because of toxicity (677). Benfotiamine is a transketolase activator that reduces tissue AGEs. Several independent pilot studies have demonstrated its effectiveness in diabetic polyneuropathy. The BEDIP 3-week study demonstrated subjective improvements in neuropathy scores in the group that received 200 mg daily of benfotiamine tablets, with a pronounced decrease in reported pain levels (678). In a 12-week study, the use of benfotiamine plus vitamin B6/B12 significantly improved nerve conduction velocity in the peroneal nerve along with appreciable improvements in vibratory perception. An alternate combination of benfotiamine (100 mg) and pyridoxine (100 mg) has improved diabetic polyneuropathy in a small number of diabetic patients (679).

Metanx is a natural food product for managing endothelial dysfunction; it contains L-methyl-folate, pyridoxal 5’-phosphate, and methylcobalamin. Metanx counteracts endothelial NO synthase uncoupling and oxidative stress in vascular endothelium and peripheral nerves. A 24-week, double-blinded, placebo-controlled multisite study concluded that although there was no significant change in vibration perception threshold, there were significant improvements in both neuropathic symptoms and mental health (680). The NTSS-6, which includes numbness, tingling, aching, burning, lancinating pain and allodynia, improved significantly at week 16 (P=0.013 vs. placebo) and week 24 (P=0.033). Moreover, there were significant improvements on the Mental Health Component of the Short Form-36 Health Survey. In this study, metformin
use was a major predictor of a beneficial response. Metformin can cause vitamin B12 deficiency and neuropathy (681). In particular, previously established normal values have grossly underestimated the level at which the peripheral nervous system is at risk (682,683) (levels >400 pg/ml are required for neuronal integrity). These findings support the use of Metanx as a safe approach for short-term alleviation of diabetic neuropathy symptoms, although we need future studies to further define these effects and their impact on long-term outcomes.

ARIs reduce the flux of glucose through the polyol pathway, inhibiting tissue accumulation of sorbitol and fructose. A 12-month study of zenarestat, reported a dose-dependent improvement in nerve fiber density (684). A 1-year trial of fidarestat in Japanese diabetics reported an improvement of symptoms (685), and a 3-year study of epalrestat showed improved NCV as well as vibration perception (100). Studies are currently exploring newer ARIs, and some positive results have emerged (686,687). However, it is becoming clear that these newer ARI’s alone may not be sufficient, and combinations of treatments may be needed (626).

Patients have used ALA or thioctic acid, which have antioxidant and thiol-replenishing redox-modulating properties. A number of studies show a favorable influence of these agents on microcirculation and on the reversal of symptoms of neuropathy (688-690). A meta-analysis including 1,258 patients from four RCTs concluded that 600 mg of intravenous ALA daily significantly reduced symptoms of neuropathy and improved neuropathic deficits (691). The SYDNEY 2 trial showed significant improvement in neuropathic symptoms and neurologic deficits in 181 diabetic patients with three different doses of ALA compared to placebo over a 5-
The NATHAN 1 Trial examined the long-term efficacy and safety of ALA. The trial randomly assigned diabetic patients (n=460) with mild-to-moderate DSPN to oral treatment with 600 mg of ALA once daily (n = 233) or placebo (n = 227) for 4 years. The primary end point was a composite score (NIS-LL and 7 neurophysiologic tests). The study showed that 4-year treatment with ALA in mild-to-moderate DSPN did not influence the primary composite end point but resulted in a clinically meaningful improvement and prevention of progression of neuropathic impairments and was well tolerated. It is worth mentioning that the primary composite end point did not deteriorate significantly in placebo-treated subjects; therefore, secondary prevention of its progression by ALA was not feasible due to the trial design (693). We need further investigation to clarify ALA’s effect on neuropathic deficits versus nerve conduction parameters and/or quantitative sensory testing. Additionally, we need to address cost-benefit analyses, optimal treatment duration, and delineation of patients with disease characteristics most likely to benefit from ALA supplementation (694).

PKC activation is a critical step in the pathway to diabetic microvascular complications. Both hyperglycemia and disordered FA metabolism activate PKC, resulting in the increased production of vasoconstrictive, angiogenic, and chemotactic cytokines, including TGF-β, VEGF, ET-1, and intercellular adhesion molecules. A multinational, randomized, phase-2, double blind, placebo-controlled trial with RBX (a PKCβ inhibitor) failed to achieve the primary endpoints, although it reported significant changes in a number of domains (61). Nevertheless, in a subgroup of patients with less severe diabetic neuropathy at baseline (sural nerve action potential greater than 0.5 μV) and clinically significant symptoms, a statistically significant improvement
in symptoms and vibratory detection thresholds occurred in the RBX-treated groups as compared
with placebo (695). A recent, smaller, single-center study showed improvements in symptom
scores, endothelium-dependent skin blood flow measurements, and QOL scores in the RBX
treated group (632). These studies and the NATHAN studies have pointed out the change in the
natural history of diabetic neuropathy with the advent of therapeutic lifestyle change, statins, and
ACEi, which have slowed the progression of diabetic neuropathy and drastically altered the
requirements for placebo-controlled studies.

**Growth Factors**

There is increasing evidence that there is a deficiency of nerve growth factor in diabetes,
as well as the dependent neuropeptides substance P and calcitonin gene-related peptide, and that
this contributes to the clinical perturbations in small-fiber function (696). Clinical trials with
nerve growth factor have not been successful, but are subject to certain caveats with regard to
design; however, nerve growth factor still holds promise for sensory and autonomic neuropathies
(609). The pathogenesis of diabetic neuropathy includes loss of vasa nervorum, so it is likely that
the appropriate application of VEGF would reverse the dysfunction. Introducing VEGF gene into
the muscle of diabetic animal models improved nerve function (697). There are ongoing VEGF
gene studies involving the transfection of the gene into human muscle.
Immune Therapy

There are several different autoantibodies in human sera that can react with epitopes in neuronal cells and that are associated with diabetic neuropathy. One study reported a 12% incidence of a predominantly motor form of neuropathy in patients with diabetes associated with monosialoganglioside antibodies (anti GM1 antibodies) (653). Perhaps the clearest link between autoimmunity and neuropathy is the 11-fold increased likelihood of chronic inflammatory demyelinating polyneuropathy, multiple motor polyneuropathy, vasculitis, and monoclonal gammopathies in diabetes (651). New data, however, support a predictive role of the presence of antineuronal antibodies on the later development of neuropathy, suggesting that these antibodies may not be innocent bystanders but neurotoxins (611,698). There may be selected cases (particularly those with autonomic neuropathy, evidence of antineuronal autoimmunity, and chronic inflammatory demyelinating polyneuropathy) that may benefit from intravenous immunoglobulin or large dose steroids (649).

Summary

Diabetic neuropathies are some of the most common complications of diabetes that lead to significant morbidity and mortality and higher health care costs. The spectrum of clinical neuropathic syndromes described in patients with diabetes includes dysfunction of almost every segment of the somatic peripheral and autonomic nervous system. Focal neuropathies include focal-limb neuropathies due to entrapment syndromes and cranial neuropathies. Proximal muscle weakness from amyotrophy and chronic demyelinating neuropathies both occur with increased frequency in the diabetic population, but require different treatments. Distal neuropathies include
DSPN and a distinctive variant termed acute sensory neuropathy, which are diagnosed by history and clinical examination. Specific diagnostic tests, such as quantitative sensory testing, skin biopsy and intraepidermal nerve fiber density, contact heat evoked potentials, sudomotor function, and nerve conduction studies can aid in the diagnosis and treatment.

Intensive glycemic and metabolic control can significantly influence the development or progression of DSPN but not reverse established neuropathy. Therapies, including benfotiamine, ARI, Metanyx, and ALA to reduce oxidative and nitrosative stress have shown encouraging results.
Chapter 7. Conclusion

Increasingly we have learned that the microvasculature within different tissues serves multiple functions beyond being a conduit for exchange of respiratory gases, nutrients, and metabolic waste. Consequently, microvascular injury can express common and unique changes at different sites. The dynamic between microvascular injury and repair determines the manifestation of tissue-specific injury. Diabetes affects both injury and repair processes in a manner distinct from other vascular diseases. We have summarized both the general molecular processes involved in diabetic microvascular disease and many of their tissue-specific expressions. Clearly, there is much we still do not understand and consequently our ability to successfully intervene to prevent or reverse microvascular disease is quite limited. Insights gained by the use of newer tools, including genetic, proteomic, metabolomics, and other analyses will certainly add new insights in the basic functioning of microvascular cells and these insights light the way to improved therapies.
Chapter 8. References


12/8/2016


50. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54:2188-2197


Eichberg J. Protein kinase C changes in diabetes: is the concept relevant to neuropathy? Int Rev Neurobiol 2002; 50:61-82


68. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS, Chung SK. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 2006; 55:1946-1953


Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 2003; 73:1813-1824


Zhong Q, Mishra M, Kowluru RA. Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy. Invest Ophthaimol Vis Sci 2013; 54:3941-3948


166

12/8/2016


145. Lei H, Rheaume MA, Kazlauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res 2010; 90:376-381


glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000; 97:8015-8020


158. Gomes E, Papa L, Hao T, Rockwell P. The VEGFR2 and PKA pathways converge at MEK/ERK1/2 to promote survival in serum deprived neuronal cells. Mol Cell Biochem 2007; 305:179-190


170. Chen YT, Cheng BC, Ko SF, Chen CH, Tsai TH, Leu S, Chang HW, Chung SY, Chua S, Yeh KH, Chen YL, Yip HK. Value and level of circulating endothelial progenitor cells, angiogenesis factors and...


<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>218.</strong></td>
<td>Dale J, Farmer J, Jones AF, Gibson JM, Dodson PM. Diabetic ischaemic and exudative maculopathy: are their risk factors different? <em>Diab Med</em> 2000; 17:47</td>
</tr>
<tr>
<td><strong>223.</strong></td>
<td>Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. <em>Diabetes Care</em> 1999; 22 Suppl 2:B65-71</td>
</tr>
</tbody>
</table>


249. Fukuda M, Nakano S, Imaizumi N, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K. Mitochondrial DNA mutations are associated with both decreased insulin secretion and advanced


Yang B, Cross DF, Ollershaw M, Millward BA, Demaine AG. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. JDiabetes Complications 2003; 17:1-6

178


ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064-1077


290. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 2001; 177:125-134


296. Lahiri DK, Maloney B. Beyond the signaling effect role of amyloid-ss42 on the processing of APP, and its clinical implications. Exp Neurol 2010; 225:51-54

298. Westermark GT, Westermark P. Localized amyloids important in diseases outside the brain--lessons from the islets of Langerhans and the thoracic aorta. FEBS J 2011; 278:3918-3929


327. Hogstrom LJ, Westlye LT, Walhovd KB, Fjell AM. The Structure of the Cerebral Cortex Across Adult Life: Age-Related Patterns of Surface Area, Thickness, and Gyrification. Cereb Cortex 2012;


183

12/8/2016


186


Pathological Features of Alzheimer Disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 2013;


Gutierrez J, Rundek T, Ekind MS, Sacco RL, Wright CB. Perivascular Spaces Are Associated with Atherosclerosis: An Insight from the Northern Manhattan Study. AJNR Am J Neuroradiol 2013;

Doubal FN, MacLullich AM, Ferguson KJ, Dennis MS, Wardlaw JM. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 2010; 41:450-454


Herman IM, D’Amore PA. Microvascular pericytes contain muscle and nonmuscle actins. J Cell Biol 1985; 101:43-52


3941
3942  396.  Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003; 74:70-76
3943
3945
3947
3949
3951
3953
3955
3957
3959
3961
3963
3964
3965
3966
3967
3968
3969
190
12/8/2016


422. Inyard AC, Chong DG, Klibanov AL, Barrett EJ. Muscle contraction, but not insulin, increases microvascular blood volume in the presence of free fatty acid-induced insulin resistance. Diabetes 2009; 58:2457-2463


425. Eggleston EM, Jahn LA, Barrett EJ. Early Microvascular Recruitment Modulates Subsequent Insulin-Mediated Skeletal Muscle Glucose Metabolism During Lipid Infusion. Diabetes Care 2012;


433. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011; 60:2441-2449


441. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol Rev 2008; 88:1009-1086


450. Wei K, Kaul S. Recent advances in myocardial contrast echocardiography. Curr Opin Cardiol 1997; 12:539-546


197


197

12/8/2016

489. Serne EH, de Jongh RT, Eringa EC, RG IJ, Stehouwer CD. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007; 50:204-211


Britton KA, Pedley A, Massaro JM, Corsini EM, Murabito JM, Hoffmann U, Fox CS. Prevalence, distribution, and risk factor correlates of high thoracic periaortic fat in the Framingham Heart Study. J Am Heart Assoc 2012; 1:e004200


515. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010; 53:2312-2319


542. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33:438-443


555. Ma RCW. Genetic Variants of the Protein Kinase C-β 1 Gene and Development of End-Stage Renal Disease in Patients With Type 2 Diabetes. JAMA 2010; 304:881


204

12/8/2016


Hanson RL, Craig DW, Millis MP, Yeatts KA, Kobes S, Pearson JV, Lee AM, Knowler WC, Nelson RG, Wolford JK. Identification of PVT1 as a Candidate Gene for End-Stage Renal Disease in Type 2 Diabetes Using a Pooling-Based Genome-Wide Single Nucleotide Polymorphism Association Study. Diabetes 2007; 56:975-983


588. Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy. JAMA 2003; 290:2159


591. de Boer IH. Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria: An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort. Arch Intern Med 2011; 171:412


high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet 2008; 372:547-553


12/8/2016
614. Vinik A, Ullal J, Parson HK, Casellini CM. Diabetic neuropathies: clinical manifestations and
current treatment options. Nature Clinical Practice Endocrinology & Metabolism 2006; 2:269-281

615. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A Review of the Epidemiology of
Painful Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, and Less Commonly Studied
Neuropathic Pain Conditions. Pain Practice 2008; 8:45-56

616. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA,
Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic Neuropathies: Update on Definitions,
Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care 2010; 33:2285-2293

Research and Reviews 2008; 24:S52-S57


619. Vinik Al, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope?
Diabetic Medicine 2011; 28:643-651

Care 2010; 33:1688-1690

621. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R,
Nurmikko T, Serra J. Neuropathic pain: Redefinition and a grading system for clinical and
research purposes. Neurology 2007; 70:1630-1635

Validation of the Norfolk QOL-DN, a New Measure of Patients' Perception of the Effects of
Diabetes and Diabetic Neuropathy. Diabetes Technology & Therapeutics 2005; 7:497-508

623. Vinik EJ, Paulson JF, Ford-Molvik SL, Vinik Al. German-Translated Norfolk Quality of Life (QOL-
DN) Identifies the Same Factors as the English Version of the Tool and Discriminates Different

624. Thomas P. Classification, Differential Diagnosis, and Staging of Diabetic Peripheral Neuropathy.
Diabetes 1997; 46:S54-S57


212

12/8/2016


642. Perkins BA, Olaleye D, Bril V. Carpal Tunnel Syndrome in Patients With Diabetic Polyneuropathy. Diabetes Care 2002; 25:565-569


12/8/2016


4693 660. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle & Nerve 2001; 24:1225-1228


215

12/8/2016

216

12/8/2016
Sensory and Motor Peripheral Nerve Function and Incident Mobility Disability. Journal of the American Geriatrics Society 2014:n/a-n/a


Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006; 29:68-72


Ikram MK, De Jong FJ, Van Dijk EJ, Prins ND, Hofman A, Breteler MM, De Jong PT. Retinal vessel diameters and cerebral small vessel disease: the Rotterdam Scan Study. Brain 2006; 129:182-188


Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 2008; 70:1664-1671


